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ABSTRACT
Adaptation of the streptococcal collagen-like protein 1, Scl1, of group A
Streptococcus to recognize fibronectin type III repeats
Dudley H. McNitt

Background: Group A Streptococcus (GAS) is responsible more than 700 million
infections worldwide each year. Most of these infections start with initial colonization of
the throat and skin, which is augmented by surface adhesins. The streptococcal collagenlike protein 1 (Scl1) is a major adhesin expressed by GAS that contains an N-terminal
sequence-variable (V) domain, protruded away from the cell surface by the collagen
domain. The Scl-V domain is comprised of three pairs of anti-parallel α-helices
interconnected by surface-exposed loops. For attachment, GAS adhesins require a portal
of entry, such as a wound or breach in the epithelium, to enter the body. Within the wound,
host cells deposit a provisional extracellular matrix (ECM) rich in cellular fibronectin (cFn)
isoforms that contain fibronectin type III (FnIII) repeats, including unique extra domains A
(EDA) and B (EDB), that are absent in plasma fibronectin. Tenascin-C (TnC) is another
ECM component, which is substantially deposited within the wound microenvironment
and contains FnIII repeats. In addition to healing wounds, EDA/EDB-cFn and TnC are
found in tumor microenvironments. Our early work showed that the Scl1-V domain binds
to cFn via EDA. Our work here has focused on understanding this selective binding of
Scl1 to wound-associated ECM and how this interaction contributes to GAS
pathogenesis. Hypothesis: The Scl1-V domain has adapted the capability to bind to
wound-associated FnIII repeats, EDA and EDB in cFn, and in TnC. Results: First, we
discovered that surface-exposed loops of the Scl1-V domain, surrounding an acidic patch,
participate in EDA binding. Both structural characteristics were conserved among
phylogenetically distant Scl1 variants. We next discovered that Scl1 also binds to EDB in
cFn, as well as to the FnIII repeats in TnC. Using defined recombinant proteins, we show
that loop-region of the Scl1-V domain mediates Scl1 binding to EDB and to the TnC FnIII
repeats. Moreover, Scl1-FnIII binding promotes GAS attachment and biofilm formation in

vitro. We also developed a more complex heterogeneous in vitro matrix-system,
deposited by cancer-associated fibroblasts, to demonstrate the selective binding of Scl1
to EDA/EDB-cFn isoforms and to TnC FnIII repeats within this matrix. Conclusions: Scl1
binds to wound-associated FnIII repeats in both cFn and TnC. This work has implications
in GAS wound-colonization and infers Scl1-FnIII binding in modulating host woundhealing responses. This work lays a foundation for the development of strategies to target
GAS during wound infections, as well as provides a rationale for the use of Scl1 in
targeting cancerous tissues.
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GENERAL INTRODUCTION
FIBRONECTIN BINDING PROTEINS OF GAS: UNIQUE ADHERENCE OF THE SCL1
ADHESIN TO THE WOUND MICROENVIRONMENT
(Portions of the introduction have been published in a mini-review; see appendix 2)

Group A Streptococcus epidemiology
Group A Streptococcus (GAS) is a human-adapted pathogen that is responsible for over
700 million infections worldwide each year (1). Diseases linked to GAS infection range in
severity from non-invasive superficial pharyngitis and impetigo to severe and invasive
diseases like necrotizing fasciitis or streptococcal toxic shock syndrome (1). Additionally,
post-infectious autoimmune sequelae include rheumatic fever and rheumatic heart
disease, acute poststreptococcal glomerulonephritis, and pediatric autoimmune
neurologic disorder associated with streptococci, also known as PANDAS (2-4). Invasive
and autoimmune diseases account for approximately 500,000 deaths globally each year
(1). GAS can transiently colonize barrier tissue sites, such as throat mucosa and the
surface of the skin (5). When the barrier is breached, the resultant wound provides GAS
with a portal of entry into host tissues and the interstitium. Once inside the wound, GAS
adheres to exposed extracellular matrix (ECM) and cells, thus enabling colonization of
the host. These essential first steps of infection that are critical to colonization are
augmented by several GAS surface adhesins, such as a prominent GAS surface adhesin
and key virulence factor, the M protein (6). DNA sequence encoding the outermost aminoterminal end of the M protein is hypervariable and is used for GAS typing, resulting in
more than 220 emm types of GAS reported globally (7). Two other major GAS surface
proteins are the streptococcal collagen-like proteins 1 (Scl1/SclA) and 2 (Scl2/SclB),
which are ubiquitous among GAS strains (8-12).

The streptococcal collagen-like proteins
Both scl1 and scl2 genes have been identified in many epidemiologically important M
types of GAS (8-11,13). scl1 expression is positively regulated by the multiple-gene
regulator, Mga (8,9,14). Mga is a major virulence-associated transcriptional regulator
expressed in all GAS strains (15-18). It controls the expression of key GAS virulence
1

factors, including the M and M-like proteins, C5a peptidase, Sic, and Scl1 (8,9,19-21).
Elevated transcription of scl1 has been found in GAS isolates from both non-invasive and
invasive infections (13,22). Unlike Scl1, expression of full-length Scl2 protein is controlled
during polypeptide translation by phase variation, which is associated with varying
numbers of pentanucleotide CAAAA repeats located downstream of the scl2-start codon
(9-11). Like scl1, scl2 transcription has been observed during GAS infection, but protein
expression varies between strains due to the aforementioned phase variation (9,23). The
invasive M3-type GAS strains (24-26) show elevated levels of scl2 transcripts and low
levels of scl1 transcripts, compared with strains of several other M types (27).
Both Scl1 and Scl2 proteins have similar structural organization (28) (Fig. 1A). Both
are homotrimeric, with an N-terminal globular, sequence-variable (V) domain, followed by
the collagen-like (CL) domain and a C-terminal cell wall-anchoring domain. The CL
domain of both Scl1 and Scl2 is composed of varying numbers of Gly-Xaa-Yaa collagen
repeats, analogous to triple-helical mammalian collagen (29,30). Structurally, the triple
helix is a motif characterized by the association of three distinct polypeptide chains
wrapped around a common axis, where each chain assumes a polyproline-II (PPII)-type
conformation (31-34). However, the CL domain does not contain hydroxyproline, which
provides the main stabilizing contribution to triple-helix structure in mammalian collagens
(35-39). Indeed, bacteria lack the prolyl-hydroxylase, an enzyme necessary for posttranslational modification of Pro to Hyp. Despite the lack of Hyp, however, Scl1- and Scl2CL domains form triple-helix structures with a stability ranging between 35 and 40ºC,
similar to mammalian collagens (29,40-43). Instead, alternative stabilization mechanisms
are employed in bacteria that secure triple-helix stability, such as hydration networks,
electrostatic interactions between side chains, and specific stabilization repeats (30,43).
The primary sequences of V domains differ both between and within Scl1 and Scl2
variants originating from strains of different M types (28). Despite sequence differences,
secondary-structure prediction algorithms identified two conserved α-helices interspaced
by a hypervariable segment (8,44). This prediction was validated by crystallography data
of the recombinant protein, corresponding to the Scl2-V domain from an M3-type GAS
(45,46) (Fig. 1A). The crystal structure showed that the Scl2-V domain folds into a trimeric
six-helical bundle, forming a cylinder that is 30 Å in diameter and 60 Å in height, which is
2

stabilized by a hydrophobic core and salt bridges. The inner core of this bundle consists
of a parallel, trimeric structure in which helices are wrapped in a gradual left-handed
superhelix. Three further helices wrap antiparallel to the internal helices in a left-handed

Figure 1: Scl1 and Scl2 structure. A) Top, Schematic representation of the common domain
organization of Scl1 and Scl2 proteins. Domains: V, the N-terminal globular sequence-variable domain;
CL, the collagen-like domain; G+, the C-terminal cell-wall-anchor domain. Bottom insert, Cartoon
representation of Scl2-V-CL structure. This structure has been obtained by combining the crystal
structure of the Scl2-V domain, with the modeled structure of the CL domain, generated using the
structure of the collagen peptide (Pro-Pro-Gly)10 as a template; only the first 15 Gly-X-Y repeats is
shown for clarity. B), Homology model of the Scl1-V domain. Left, Side view of the Scl1-V domain,
showing the six-helix bundle fold, with three pairs of anti-parallel α-helices and connecting loop
segments. The N-terminus and C-terminus of a single presentative α-helix pair is marked. Right, Topdown view of the Scl1-V domain. The three helix-pairs are shown, wrapped in a left-handed orientation.
The homology model is based on the crystal structure of the Scl2-V domain originating from M3-type
group A Streptococcus (PDB accession code: 4nsm).
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direction around the exterior of the central trimer. The pairs of anti-parallel α-helices are
each connected with PPII-type loop segments. Structural and biophysical data suggested
that V domains of Scls display dichotomous functions by acting as triple-helix stabilization
domains through facilitating proper folding and refolding of the collagen triple-helix (47).
Consistently, recombinant collagen-domain constructs cannot refold following thermal
denaturation (29,47). In addition to facilitating trimerization of the CL-domain, the Vdomain of Scl1 mediates host-pathogen interaction (48-50).

Scl1 binds to several ligands found in tissue and blood, compared with Scl2; the
latter’s function in GAS pathogenesis is less clear (reviewed in (28)). The collagen domain
of Scl1 can bind and activate human collagen integrin receptors (48,49,51), whereas the
V domain is responsible for the majority of ligand binding (44,51-55). Interestingly, Scl1
mutants of M1-type GAS were attenuated in a mouse skin infection model, but not
following intraperitoneal inoculation (12), conceivably due to differences in the capacity
to evade innate immune defenses between wild type and mutant strains (12,56). In
contrast, Scl1 mutants of two other M types exhibited increased lesion size in mouse skin
(27). In vitro assays and animal models show that Scl1 contributes to host colonization
and biofilm formation within tissues by binding to host ECM proteins (27,52,57). Scl1
binds to wound-enriched isoforms of cellular fibronectin containing the extra domain A
(58). The ubiquitous presence of Scl1 in GAS strains across different M types and the
distinctive binding to cellular fibronectin isoforms specific to the wound microenvironment,
which enables favorable colonization of the first environment encountered by GAS during
infection.

Extracellular matrix proteins associated with the wound microenvironment
GAS utilizes a wounded portal of entry to gain access to host tissues, initiating host
colonization and subsequent infection. One of the essential measures during wound
healing is the deposition of new distinct matrices that participate in tissue remodeling and
signal pro-inflammatory responses. These complex processes engage macrophages and
neutrophils in clearing out tissue debris and keratinocytes in facilitating wound closure
4

(59,60). One of the major constituents of these matrices is fibronectin (Fn) (61-63). Fn is
a high-molecular weight glycoprotein that exists in two main forms within the body, e.g.,
as a plasma fibronectin (pFn) secreted by hepatocytes into the blood stream and as

Figure 2: Wound-associated extracellular matrix proteins that contain fibronectin type III
repeats. Schematic of fibronectin, model of EDA, EDB, and tenascin-C. A) Schematic of fibronectin,
with fibronectin type I, II, and III repeat domains denoted by squares, ovals, and hexagons, respectively.
Regular Fn domains are shown in light grey and are numbered, constitutively, whereas alternatively
spliced extra domains A, B and IIICS are shown in dark gray. Scl1-EDA binding is marked with an arrow
and binding regions for several GAS Fn-binding proteins (PrtF1, FbaA, SOF, etc.) are also indicated.
B-C) Cartoon representation of the EDA (left) and EDB (right) domains of fibronectin. Models (PDB
accession code: 1J8K) show the β-sandwich structures of each, with each β-strands marked (A, B, C,
C’, D, E, F); the C-C’ loop of EDA is shown in ball-and-stick style. D) Schematic representation of fulllength TnC. Depicted are from the N-terminus: assembly domain (triangle), epidermal growth factorlike repeats (ovals), constitutively expressed fibronectin type III repeats 1-5 and 6-8 (light hexagons),
alternatively spliced fibronectin type III repeats (dark hexagons), fibrinogen-related domain (circle).
Known integrin-binding domains are marked above the model.

5

cellular fibronectin (cFn) secreted by cells within tissues (64). Both forms of fibronectin
originate from the same gene, FN1, and are composed of three different types of
repeating domains: types I, II, and III (64,65)(Fig. 2A). cFn-mRNA can be alternatively
spliced, resulting in more than 20 different isoforms found within the body (65-67). This
alternative splicing leads to the inclusion of extra domains that are found in cFn, but not
pFn. The alternatively spliced type III domains are known as extra domain A (EDA/EIIIA)
and extra domain B (EDB/EIIIB), as well as different combinations of the type III
connecting segment (IIICS), also known as the variable domain (67).
The EDA-containing cFn isoforms (EDA/cFn) are highly expressed during
embryonic development but only at negligible levels within healthy adult tissues (68-70).
On the other hand, EDA/cFn isoforms are deposited in high quantities within inflamed and
wounded tissue environments in adults and play essential roles in wound healing (69,7173). EDA adopts the prototypical type III repeat structure, which is composed of two βsheets, forming a β-sandwich consisting of seven β-strands (i.e. A, B, C, C’, D, E, and F)
connected by loop segments (74,75)(Fig. 2B). In full-thickness excisional wounds, wound
healing was delayed in mice lacking EDA, however, others report no differences in wound
healing between normal and EDA knockout mice (72,76). These differences may be due
to differences in genetic background of the mice used in each study, in wounding method
or differences in analysis. Other studies in mice found deletion of EDA protected mice
from developing lung fibrosis during murine models of pulmonary fibrosis (77), and when
crossing EDA knockout mice to ApoE knockout mice, EDA deletion results in smaller
atherosclerotic lesions compared to control mice (78). Dysregulation of EDA splicing,
resulting in EDA overexpression, results in increased occlusive thrombi during vascular
damage compared to normal mice (79), and EDA overexpression results in differences in
behavior compared to normal mice (80).
An important role for EDA/cFn within wounded tissue is to support host cell
attachment, achieved by the interactions between the C-C’ loop of EDA and cellular
integrin receptors, α9β1 and α4β1, as well as α4β7, which binds EDA by an unknown
mechanism (81-83). Integrin α9β1 is upregulated by keratinocytes during tissue injury
(71,84). Integrins α9β1, α4β1, and α4β7 through their attachment to EDA/cFn regulate
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important repair mechanisms, such as cell migration, angiogenesis, myofibroblast
differentiation, growth factor secretion, and tissue remodeling (71,73,83,85,86).
Like EDA, EDB also adopts the prototypical type III repeat structure (Fig. 2C), and
follows the same expression pattern as EDA, highly expressed during embryogenesis
and development, but only found in wounded and inflamed adult tissues (69,87). Isoforms
of cFn that contain EDB are highly expressed in the cerebral spinal fluid of patients
suffering from bacterial meningitis, compared to non-bacterial meningitis (88). The
canonical role of EDB is its association with angiogenesis, as it is highly expressed around
growing vasculature in human tissues during fetal tissue development, in the granulation
tissue of wounds, and within the stroma around tumors, suggesting an important role for
EDB containing cFn isoforms in the growth of blood vessels (89). Despite this known
association, the role of EDB during wound healing is not as well understood as that of
EDA, as no direct cell binding sites have been identified within EDB (84). EDB knockout
mice do not exhibit noticeable differences compared to normal mice in studies examining
behavior, angiogenesis, tumorigenesis, and bone fracture healing (90-92). The lack of
noticeable changes in these systems may be due to compensation of EDA or other ECM
proteins (91). Double knockout of EDA and EDB is embryonic lethal in mouse models,
exhibiting 80% penetrance, with the surviving pups exhibiting severe cardiovascular
defects (93), suggesting that EDA and EDB may compensate for each other when one
domain is unable to be expressed. Some studies have however identified important roles
for EDB in fibronectin structure, using in vitro or ex vivo samples. Inclusion of EDB in cFn
leads to confirmation changes that expose cryptic sites that facilitate cell attachment to
cFn (94). In addition, EDB isoforms of cFn contributes to head-to-tail dimerization of cFn,
facilitating Fn fibril formation on the surface of cells, supported by the observation that
mouse embryonic fibroblasts from EDB knockout mice deposit smaller Fn fibrils than
those from normal mice (90,95). Though EDA and EDB are fibronectin type III repeats
(FnIII repeats) with highly regulated expression, other ECM proteins within the wound
microenvironment also contain FnIII repeats.
Tenascin-C (TnC) is another ECM protein that is highly expressed within the
wound microenvironment, as a component of the provisional wound matrix, and contains
FnIII repeats (96). TnC is high molecular weight glycoprotein, and is the founding member
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of the Tenascin family, that also consists of Tenascin-R, Tenascin-X, and Tenascin-W
(97). TnC is comprised of distinct regions, starting from the N-terminus, the heptad
repeats, followed by the epidermal growth factor-like repeats, the FnIII repeats, and a Cterminal fibrinogen-related domain (Fig. 2D)(98). The FnIII repeats of TnC adopt the
prototypical FnIII β-sandwich structure, as well as undergo alternative splicing, where the
first 5 and last 3 repeats are constitutively expressed, and a varying number and
combination of 9 different FnIII repeats, in humans, can be included between repeats 5
and 6 (97,99). This results in the potential for over 511 different isoforms of TnC to be
expressed in tissues, though only 100 variants have been identified in tissues (97).
Though both Fn and TnC contain FnIII repeats, they originate from different genes, FN1
and TNC, respectively (100,101). Genetic analysis of animals from different phylum
reveal that while fibronectin was discovered first, TnC appears first in evolution (100).
TnC is often co-expressed with Fn in tissues, circulating in blood plasma at low
levels, but highly expressed in blood and tissues upon inflammation, similar to EDA and
EDB isoforms of cFn (96,102). Upon inflammation and tissue damage, TnC is deposited
into the wound from blood plasma, co-localizing with fibronectin fibrils in the provisional
ECM (103,104). At the same time, TnC mRNA is upregulated within the first 24 hours of
wounded tissue cells such as keratinocytes and fibroblasts, and is deposited during this
time (105-107). TnC protein levels will grow into their peak during the beginning of tissue
building and repair phases of wound healing, deposited by activated fibroblasts, and
remain high in the tissues for several days to weeks pending the anatomical site and
nature of the injury (96). As a part of the ECM, TnC plays multiple roles, such as
supporting other proteins within the ECM, regulating cell attachment to other ECM
proteins, initiating inflammation via direct binding to TLR4, and is directly bound by cells
to facilitate wound closure (108) (109-112). The FnIII repeats of TnC are directly bound
by cells via integrin receptors, due in part to the presence of the RGD motif and an IDG
motif in the third TnC FnIII repeat, bound by αvβ1 and α9β1 respectively (TnFnIII)(Fig. 2D)
(113-115). These, and other integrin binding interactions, were found to mediate cell
motility and survival (115), and are believed to be critical for proper wound healing through
facilitating keratinocyte and fibroblast proliferation and migration and regulating
attachment to collagen type I fibers (96,107,116,117). In addition to regulating host cell
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attachment, TnC Fn III fragments also regulate ECM assembly through direct binding to
proteoglycans and play important roles in tissue remodeling through mediating
myofibroblast wound contracture (118,119).

Fibronectin-binding proteins of GAS
In addition to being a target for host cells, TnC is bound by several pathogens, including
GAS, as GAS expresses several adhesins that bind to both TnC (120,121) and Fn (122),
though, there are more examples of those that bind to Fn.
GAS expresses a number of fibronectin binding proteins, which can be broadly
divided into two types, those with fibronectin-binding repeat domains, and those without.
(122,123). The fibronectin-binding repeats are found in several fibronectin-binding
proteins of GAS, including Protein F1, Protein F2, Serum opacity factor, and fibronectinbinding protein A (124-129). The unstructured fibronectin-binding repeats of these
adhesins bind to the N-terminal FnI repeats, through a tandem β-zipper mechanism
(125,130). The FnI repeats adopt a β-hairpin, a three-stranded antiparallel β-sheet. Upon
contact with the FnI repeats, the unstructured region(s) of these fibronectin-binding
repeats fold into a β-strand structure, and this strand will accent the stacked β-strands in
the FnI repeat (125,130). Through binding to the type I repeats of Fn, these adhesins
contribute to GAS adherence to both pFn and cFn. These types of repeats have been
suggested to bind to the FnIII repeats (121), however, no data exists as of this writing that
demonstrates direct binding to the FnIII repeats by any GAS fibronectin-binding protein
that contains these unstructured repeats. Several of these adhesins have been shown to
contribute to both host colonization, as well as to intracellular entry of GAS into cells via
a bridge mechanism, where GAS adheres to the FnI repeats that are subsequently
internalized via endocytosized due to interactions between host-cell integrin receptors
(e.g. α5β1) and the FnIII repeats (131,132), consequently internalizing the attached GAS.
Deletion of several of these adhesins in GAS has shown to result in decreases in celladherence and virulence compared to WT strains (129,133,134).
Scl1 of GAS falls into the second category of adhesin, as Scl1 proteins across M
types do not contain any fibronectin-binding repeat domains (12). Adhesins in this
category are known to bind within the type I, II, and III repeats of Fn (122), however, Scl1
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is the only adhesin, as of this writing, shown to adhere to the wound-associated
alternatively spliced FnIII repeat, EDA, of cFn (58).
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CHAPTER 1
SURFACE-EXPOSED LOOPS AND AN ACIDIC PATCH IN THE SCL1 PROTEIN OF GROUP
A STREPTOCOCCUS ENABLE SCL1 BINDING TO WOUND-ASSOCIATED FIBRONECTIN
Dudley H. McNitt, Soo Jeon Choi, Douglas R. Keene, Livingston Van De Water, Flavia
Squeglia, Rita Berisio, Slawomir Lukomski
Published in The Journal of Biological Chemistry 2018 293(20): 7796-7810.

ABSTRACT
Keratinized epidermis constitutes a powerful barrier of the mucosa and skin, effectively
preventing bacterial invasion, unless it is wounded and no longer protective. Wound
healing involves deposition of distinct extracellular matrix (ECM) proteins enriched in
cellular fibronectin (cFn) isoforms containing extra domain A (EDA). The streptococcal
collagen-like protein 1 (Scl1) is a surface adhesin of group A Streptococcus (GAS), which
contains an N-terminal variable (V) domain and a C-terminally located collagen-like
domain. During wound infection, Scl1 selectively binds EDA/cFn isoforms and laminin, as
well as low-density lipoprotein (LDL), through its V domain. The trimeric V domain has a
six-helical bundle fold composed of three pairs of anti-parallel α-helices interconnected
by hypervariable loops, but the roles of these structures in EDA/cFn binding are unclear.
Here, using recombinant Scl constructs (rScl) to investigate structure–function
determinants of the Scl1–EDA/cFn interaction, we found that full-length rScl1, containing
both the globular V and the collagen domains, is necessary for EDA/cFn binding. We
established that the surface-exposed loops, inter-connecting conserved α-helices, guide
recognition and binding of Scl1-V to EDA and binding to laminin and LDL. Moreover,
electrostatic surface potential models of the Scl1 V domains pointed to a conserved,
negatively charged pocket, surrounded by positively charged and neutral regions, as a
determining factor for the binding. In light of these findings, we propose an updated model
of EDA/cFn recognition by the Scl1 adhesin from GAS, representing a significant step in
understanding the Scl1–ECM interactions within the wound microenvironment that
underlie GAS pathogenesis.
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INTRODUCTION
Group A Streptococcus (GAS) is a human adapted pathogen responsible for over 700
million disease-associated infections across the globe each year and an estimated
healthcare cost of 224-539 million dollars in the United States alone (1,2). GAS
asymptomatically colonizes the general population of adults (5-15%) and children (2030%), most of the morbidity is associated with superficial infections of the throat and skin
(3). In addition, bacterial spread may result in severe soft tissue and systemic infections,
like necrotizing fasciitis and streptococcal toxic shock syndrome (4), or may lead to postinfectious sequalae, such as acute rheumatic fever and rheumatic heart disease, poststreptococcal glomerulonephritis, and pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections (5,6). For the initial colonization of the human
host, GAS requires a portal of entry, which is constituted by a breach in the epithelial cell
lining (thenceforth as wound) that allows the pathogen to spread into deeper tissue and
blood. GAS expresses numerous surface adhesins that bind to host extracellular matrix
(ECM) (7). ECM binding facilitates initial localized colonization, during which GAS forms
tissue microcolonies embedded in glycocalyx (8). The interplay between GAS adhesins
and host’s ECM-components, stable tissue microcolony formation, and superficial versus
invasive infection are of significant clinical interest.
Among prominent GAS surface proteins are the streptococcal collagen-like (Scl)
proteins 1 and 2 (9-13). Scl1 and Scl2 are homotrimeric proteins that have similar domain
organization, which is comprised of an N-terminal globular sequence-variable (V) domain,
a collagen-like (CL) domain, and the C-terminal cell-wall anchoring domain (9,10). The
CL-domain of both Scl1 and Scl2 consists of varying numbers of Gly-Xaa-Yaa collagen
repeats that adopt a right-handed triple-helix structure, similar to mammalian collagen
(14-16); Scl1-CL domain may interact with human collagen-binding integrins, promoting
GAS internalization (17-19). The outermost-exposed V domains vary in amino acid
sequence between and within Scl1 and Scl2 variants and are typically associated with M
type antigen (9,11). Despite significant sequence variation, the V domains of Scl1 and
Scl2 were predicted to contain two conserved α-helices, spaced by hypervariable regions
(11,20). Recent reports of a first crystal structure for the Scl2-V domain validated these
secondary structure predictions (21,22). The recombinant Scl2-V globular domain forms
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a trimeric structure, which folds into a 6-helix bundle, with 3 pairs of anti-parallel α-helices
inter-connected by hypervariable loops (22). Despite both Scl1 and Scl2 having similar
structural organization, they play different roles in GAS pathogenesis (23). While the
number of Scl2 targets identified remains scanty (24), Scl1 variants from diverse GAS M
types bind several host proteins. Ligands include tissue components, cellular fibronectin
(cFn) and laminin (Lm), as well as blood components, low- and high-density lipoproteins,
and complement Factor H (CFH) and Factor H-related protein 1 (CFHR1), (20,25-28). It
is not clear how the variable sequences of the Scl1-V domain bind the same ligands, but
two mutually-exclusive binding patterns were observed. Scl1 proteins from several Mtypes bind to ECM proteins, cFn and Lm, and low-density lipoprotein (LDL), but not FH
and CFHR1; the converse is also true.
One of the major ECM targets for GAS within wounded tissue is fibronectin (Fn)
(7). Fn is a high molecular weight glycoprotein that is found throughout the human body
in two main forms, either as a soluble circulating plasma fibronectin (pFn) secreted by
hepatocytes or as an insoluble cellular fibronectin (cFn) secreted by a variety of cells
within tissues (29). All forms of Fn are transcribed from a single gene, FN1, and are
comprised of three modules of fibronectin repeats: type I, II, and III (29,30). There are
about 20 isoforms of human cFn that include combinations of the type III repeats, e.g.
extra domain A (EDA/EIIIA) and B (EDB/EIIIB), and a varied number of V repeats (30,31).
These isoforms differ by spatial-temporal distribution following injury (32,33). Specifically,
the EDA-containing isoforms are normally expressed during embryo-genesis, though,
they are found in negligible levels in most adult tissues, except in healing wounds where
EDA/cFn is highly upregulated (32,34). The EDA fold is a β-sandwich structure formed
by seven antiparallel β-strands (i.e. A, B, C, C’, D, E, and F) connected by loops (35,36).
The C-C’ loop is an important site for cell attachment, via integrin receptors α9β1 and α4β1
(37,38), and attachment to the C-C’ loop by these integrins has been shown to regulate
important tissue repair and wound healing functions (39-43).
Here, we established that surface-exposed loops within V domain structure guide
Scl1 to bind EDA/cFn, as well as two other Scl1 ligands, laminin and apolipoprotein B100
(ApoB100) of LDL. A second conserved constituent within variable Scl1-V domain is a
common topography of the electrostatic surface potential surrounding guiding loops,
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which includes a negatively-charged patch formed by collective Asp and Glu residues
contributed by all three monomeric chains. The proposed model accommodates binding
of common ligands by phylogenetically diverse Scl1 variants. This work implies the
evolutionary response of the Scl1-V domain to selective pressure, resulting in the
retention of the conserved structure and function of ligand binding. This underscores the
importance of Scl1 binding to EDA-containing fibronectins deposited at the pathogen
portal of entry.
RESULTS
The globular sequence-variable (V) domains of Scl1 and Scl2 contain conserved
helix-loop-helix structures – Two streptococcal collagen-like proteins, Scl1 and Scl2,
display a similar “lollipop-like” structural organization (Fig. 1A), which is comprised of an
N-terminal globular V-domain head and a C-terminal CL-domain stalk (14). Multiple
sequence alignments illustrate a significant variations in the V regions, both between and
within Scl1 and Scl2 families (Fig. 1B). Despite sequence variation, several secondary
structure prediction algorithms deduced that both Scl1-V and Scl2-V domains contain two
conserved α-helices inter-connected by hypervariable regions. Crystallography data
rendered for the recombinant Scl2-V construct, derived from M3-type GAS, revealed that
rScl2.3-V protein forms a homotrimer, with three pairs of conserved α-helices forming a
6-helix bundle and hypervariable regions forming surface-exposed loops (PDB accession
code: 4nsm). To examine the conservation of the helix-loop-helix motif, homology models
of two sequence-diverse Scl1- and Scl2-V domains were generated (Fig. 1C), using the
structure of Scl2.3-V domain as template. The homology model structure of Scl1.1-V
domain from M1-type GAS was based on the consensus- sequence alignment (24%
sequence identity on 65 amino acid residues), and the model of Scl2.28-V domain from
M28 GAS was obtained with the same approach (51.5% identity with Scl2.3-V sequence
on 74 residues). Homology models predict with high confidence that Scl1.1-V (E= 3.5 x
10-16) and Scl2.28-V (E= 1.8 x 10-40) domains each adopts a similar six-helical-bundle
trimeric structure, as Scl2.3-V template. The solved crystal structure and homology
models rendered here show that globular domains of Scl1.1 and Scl2.28 variants can
trimerize without the presence of the CL-domain, an observation that was also found in
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Scl2 proteins from other M-types (44). Furthermore, we hypothesized that trimeric rScl1V constructs will retain their binding function to ECM ligands.

The conserved structure of Scl1-V domain requires the collagen domain for ligand
binding – Full-length rScl1 proteins, derived from different GAS M-types, bind to host cFn
via interactions with EDA, which is mediated by Scl1-V domain (25,45). Here, we
examined whether the V-domain-alone rScl1 constructs bind to cFn and rEDA. Full-length
recombinant Scl1 constructs, derived from M1- (rScl1.1FL) and M3-type (rScl1.3FL)
strains, as well as their corresponding V-domain-only proteins (rScl1.1V and rScl1.3V)
were immobilized in wells and tested for ECM-ligand binding. Unexpectedly, neither
rScl1.1V nor rScl1.3V constructs bound rEDA and cFn, while the corresponding full-length
rScl1FL control proteins bound both ligands (Fig. 2). Thus, while the V domains of Scl1
proteins can fold independently of their CL domains, there are currently unknown
structural constraints that require the presence of continuous CL domains for EDA/cFn
recognition.

The loop region of Scl1-V domain plays a central role in ECM recognition and
binding - The binding site for the Scl1-V domain within the loop segment located between
C- and C’-β-strands of the EDA β-sandwich (45). Here, we hypothesized that EDA binds
to surface-exposed loops of Scl1.1-V domain, which we since identified in the crystal
structure and deduced in the homology models (Fig. 1C). To test this hypothesis, we
generated two full-length chimeric rScl.chi proteins: (i) we inserted the 22-amino-acid loop
sequence of the ECM-binding-positive rScl1.1 variant (residues 25-46 of the V-domain)
in place of the respective loop sequence of the ECM-binding-negative protein rScl2.28
(residues 20-45), resulting in the chimeric construct rScl.chi1FL (Fig. 3A); and (ii) the
reverse was also constructed, by inserting the 26-amino-acid-loop region of rScl2.28-V in
place of loop sequence of rScl1.1-V, resulting in rScl.chi2FL. To identify the proper site
for inserting these sequences, we considered secondary structure predictions, computed
with JPRED; resulting models were then minimized using GROMACS.
To ensure that we did not substantially alter the overall structure of the chimeric
proteins, both rScl.chi1FL and rScl.chi2FL were examined by circular dichroism (CD)
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spectroscopy and electron microscopy of rotary shadowed samples (Fig. 3B). The
wavelength scans of the original rScl1.1FL and rScl2.28FL proteins each exhibit a positive
peak of molar ellipticity at 220 nm, [θ]220 (14), which is a characteristics of the collagen
triple helix (46). The CD spectra of both chimeric proteins, rScl.chi1FL and rScl.chi2FL,
rendered at 20ºC, show peak ellipticity values at 220 nm (Fig. 3B, solid lines), thus,
demonstrating that both chimeric constructs adopt triple helix structures. These peaks
were not observed at 50ºC, indicating that each triple helix unfolded (Fig. 3B, dashed
lines). The domain organization of both chimeric rScls was further examined via rotary
shadowing and subsequent electron microscopy. This technique has been used
previously by our lab and others to investigate the structure of multi-domain collagens,
containing collagenous and non-collagenous domains (14,47). Both chimeric rScls
displayed the characteristic two-domain lollipop-like organization, with the CL domain, as
the stalk, and the globular V-domain head (Fig. 3B). Thus, swapping the loop regions
between rScl1.1FL and rScl2.28FL did not alter the overall structural organization and
triple-helices in the chimeric proteins.
We next examined the binding characteristics of both chimeric proteins to rEDA
and cFn ligands, with rScl1.1FL and rScl2.28FL serving as positive and negative controls,
respectively. Binding data show that rScl.chi1FL chimera, containing donor-loop
sequence of rScl1.1FL, binds both rEDA and cFn, while the reverse construct rScl.chi2FL
did not bind to either ligand, similar to negative control protein rScl2.28FL (Fig. 3C). These
data demonstrate the importance of the loop region in ECM binding for Scl1.1FL, and
hypothetically for other Scl1 variants.
To assess the importance of the Scl1.1-V loop in rEDA recognition in the context
of whole-GAS cells, we complemented in-trans the scl1-inactivated mutant (Δscl1) of M1type strain (9) for the expression of original Scl1.1 (Δscl1::scl1.1) or chimeric Scl.chi2
protein (Δscl1::scl.chi2), using plasmids pSL620 and pSL621 (Table 1). The M1-type wild
type (WT) and Δscl1 mutant strains were used as positive and negative controls,
respectively (Fig. 3D, left panel). Expression of surface Scl1.1 and Scl.chi2 was assessed
via western immunoblotting of the cell wall fractions. Additionally, rScl1.1FL protein was
loaded, as a positive control (rScl1.1FL is smaller on the SDS gel since it is devoid of the
cell-wall region of native Scl1.1 protein). Western blot analysis detected an
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immunoreactive band of ~55 kDa, corresponding to the Scl1.1 surface protein (9), in WT
and both complemented strains but not in Δscl1 mutant complemented with vector alone.
It should be noted that lower amounts of protein samples, prepared from complemented
strains (5 µLs versus 25 µLs of WT and Δscl1 mutant samples), were loaded on the SDS
gel to avoid an overwhelming chemiluminescent signal. This is not surprising since
Scl1.1FL and Scl.chi2FL proteins are expressed in complemented strains from multicopy
plasmids. A similar expression pattern was recorded by flow cytometry of GAS cells.
Approximately 66% of the WT cells had detectable levels of surface Scl1.1 and only 2%background level recorded for Δscl1 mutant, compared to 77% and 92% detection
recorded for trans-complemented Δscl1::scl1.1 and Δscl1::scl.chi2, respectively (not
shown).
We next investigated the rEDA binding to whole GAS cells by flow cytometry (Fig.
3D, right panel). As expected, the WT and Δscl1::scl1.1-complemented cells bind rEDA,
although, the complemented strain binds ~4 times more ligand due to overexpression of
the surface Scl1.1 protein. In contrast, neither Δscl1 mutant nor complemented GAS cells,
overexpressing the Scl.ch2 protein, bind rEDA. Thus, GAS cells that express native Scl1
adhesin bind rEDA to the cell surface but lose this capacity once cells express a mutated
variant with loop substitution from Scl2 protein, which does not bind EDA/cFn.

The C-terminus of the loop region of Scl1-V domain plays a central role in ECM
recognition and binding - We next designed additional chimeric rScl constructs to
identify the specific region of the loop involved in rEDA and cFn binding. Instead of
replacing the entire 22 amino acids, the Scl1.1-V loop was substituted into Scl2.28-V loop
in three segments (Fig. 4A). For the first construct, only the N-terminal 11 amino acids of
Scl1.1-V loop (residues 25-35) were substituted in place of the first 11 amino acids of the
corresponding Scl2.28-V sequence (residues 20-30), resulting in construct rScl.chiNFL.
Similarly, the C-terminal 11 amino acids of Scl1.1-V (residues 36-46) were substituted in
place of the C-terminal 15 amino acids of Scl2.28 (residues 31-45), resulting in construct
rScl.chiCFL. The third construct, rScl.chiIFL, contains the internal 11 amino acids of
Scl1.1-V (residues 30-40) in place of the central (residues 25-36) 11 amino acids of
Scl2.28-V.
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All three chimeric rScls, containing partial loop substitutions, were examined by
CD spectroscopy and electron microscopy to confirm the essential structural
characteristics (Fig. 4B). The CD spectra of all three chimeric proteins showed peak
ellipticity values at 220 nm at 20ºC, while these peaks were not observed at 50ºC. Rotary
shadowing images show that each chimeric rScl adopts a lollipop-like structural
organization, with both CL-domain stalks and globular V domains. Thus, like whole loop
substitutions, partial loop substitutions did not impact the structures of the chimeric rScls.
Binding data to cFn and rEDA indicated that only one of the three chimeras with partialloop-substitutions, rScl.chiCFL (C-terminal substitution), binds to cFn and rEDA, similar
to the whole-loop-substitution construct rScl.chi1FL and the loop donor protein rScl1.1FL
(Fig. 4C); the other two chimeric proteins, as well as binding-negative control protein
rScl2.28FL, do not bind to cFn and rEDA. We observed substantially lower O.D. values
recorded during rEDA binding to rScl.chi1FL and rScl.chiCFL, compared to rScl1.1FL.
This may reflect less than optimal loop conformation in chimeric proteins associated with
rScl2 backbone. Additional binding assays were carried out with increasing
concentrations (0.039 – 5.0 µM) of rEDA ligand and rScl proteins to assess binding
specificity (Fig. 4D). Concentration-dependent binding of rEDA to rScl.chi1FL,
rScl.chiCFL, and control protein rScl1.1FL plateaued between 2.5 and 5.0 µM
concentration. In contrast, neither rScl.chiNFL, rScl.chiIFL, rScl.chi2FL, nor control
rScl2.28FL showed significant binding to rEDA. Therefore, these data provide evidence
that the C-terminal 11 amino acids of rScl1.1-V loop are sufficient for conferring EDA/cFn
binding, when inserted into binding-negative rScl2.28 protein.

Distribution of the charged residues on the surface of V domain hints at a binding
mechanism for EDA/cFn - Our initial examination of the multiple sequence alignment of
Scl1- and Scl2-V domains failed to identify any reasonably conserved pattern of residues,
which could be responsible for EDA/cFn binding (Fig. 1A). Our subsequent experiments,
employing the chimeric loop sequences, highlighted a pattern of charged amino acids
(e.g., K45 (Scl1.1), E46, 47 (Scl1.1), and D48 (Scl1.1)) that were present within the uppermost portion
of the Scl1-V loops and transitioning to inner α-helices, but were absent in the respective
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regions of the ECM-binding-negative Scl2-V loops (Fig. 1B). Therefore, we sought to
investigate the surface potentials of the Scl1-, Scl2-, and the chimeric rScl.chi-V domains.
Electrostatic surface maps were computed from the homology models of the ECMbinding-positive and binding-negative proteins. Electrostatic maps computed for Scl1.1and Scl2.28-V domains reveal striking differences in the distribution of charges across
their surfaces. A uniform, negatively-charged electrostatic potential characterizes the
ECM-binding-negative Scl2.28-V on the frontal apical region of the molecule, opposite to
the triple helix attachment (Fig. 5, black ovals). These charges are due to acidic residues
located on the C-terminal part of the first outer α-helix, the loop region, and N-terminal
part of the second inner α-helix. In this same area, the electrostatic potential map of the
binding-positive Scl1.1-V domain presents a central negatively charged pocket or cleft
(Fig. 5, white arrowhead), surrounded by a neutral and basic crown surface. Although
less pronounced, the same features of electrostatic potential, with a central negativelycharged region surrounded by a neutral/basic surface are present in maps of the bindingpositive chimeric rScl.chi1 and rScl.chiC-V domains, but not binding-negative chimeric
rScl proteins. Therefore, the specific charge pattern of the V-domain head strongly
differentiates between binding-positive and binding-negative V domains. These
considerations suggest that interactions with partnering molecules occur through
electrostatic recognition of the observed charge pattern.

Scl1-V-loop is responsible for the ECM binding in phylogenetically distant Scl1
variants - Phylogenetic analysis of the amino acid sequences of the Scl1-V and Scl2-V
domains show that both Scl1 and Scl2 form two distinct clusters (Fig. 6A). Within Scl1,
there are two observed ligand-binding patterns. The first pattern is represented by Scl1
variants (Fig. 6A, black boxes) that bind host ECM proteins, cFn/EDA and Lm, (25) and
ApoB100/LDL (20). The second pattern is represented by two Scl1 variants (Fig. 6A,
black dots) that bind host complement components, CFH and CFHR1 (26,27), suggesting
the potential for a unique adaptation of Scl1 proteins in M6 and M55 GAS. In contrast, the
majority of rScl1 constructs investigated, show the former binding pattern and these Scl1
variants are distributed all over many branches of the Scl1 cluster, highlighting the
importance of ECM and LDL binding among GAS of various M types (20,25,45,48,49).
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We next investigated whether the loop region of the phylogenetically distant
Scl1.28-V variant, found in M28-type GAS, which shares 46% sequence identity with
Scl1.1-V sequence (Fig. 6A, arrows), will support EDA/cFn binding. To do this, we
substituted the loop region of Scl1.28-V (residues 25-46) in place of the loop region of
Scl2.28-V (residues 20-45), resulting in the chimeric construct rScl.chi3FL (Fig. 6B). The
CD spectra of rScl.chi3FL showed peak ellipticity at 220 nm at 20ºC, but not at 50ºC, and
rotary shadowed images shows characteristic lollipop-like domain organization (Fig. 6C).
Binding data to cFn and rEDA show that rScl.chi3FL binds both ligands (Fig. 6D). Thus,
as in Scl1.1-V, the loop region of the divergent Scl1.28-V variant confers binding to both
rEDA and cFn. Despite significant efforts, we could not generate a homology model of
Scl1.28-V domain with a satisfactory global model quality estimation, due to the low
sequence identity with the template structure of Scl2.28-V domain, close to 12%.

The same structural constraints determine recognition and binding of the Scl1-V
domain to laminin and apolipoprotein B100/LDL - Here, we sought to understand
whether the same structural constraints apply during Scl1 binding to Lm and Apo
B100/LDL (Fig. 7). Both rScl1.1FL and rScl1.3FL bound to Lm and ApoB100, while their
respective V-domain-only counterparts, rScl1.1V and rScl1.3V, demonstrated negligible
or no binding to both ligands (Fig. 7A). Chimeric constructs rScl.chi1FL, rScl.chiCFL, and
rScl.chi3FL also bind to Lm and ApoB100/LDL, whereas binding-negative control proteins
rScl2.28FL and rScl.chi2FL (reverse loop replacement to that in rScl.chi1FL) did not (Fig.
7B, C); in addition, both rScl.chiN and rScl.chiI did not bind to Lm and ApoB100/LDL (data
not shown). Collectively, our data show that: (i) full-length Scl1 protein is required for
binding to all ligands; and (ii), the C-terminal 11 amino acids of the Scl1-V loop region is
sufficient to mediate binding of Scl1 to its sequence- and structure-diverse ligands.
DISCUSSION
Adhesion to Fn is important for the pathogenesis of group A Streptococcus (7) by
promoting the development of glycocalyx-embedded tissue microcolonies (in vivo
biofilms) that are seen in clinical specimens collected from cases of pharyngitis and skin
infections (8,50). We previously reported that the streptococcal collagen-like protein 1 or
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Scl1 uniquely adheres to cFn isoforms expressed in wounded tissue, and that interactions
involve the sequence-variable (V) globular domain of Scl1 and extra domain A (EDA) of
cFn (25,45). Here, we report on the structural determinants involved in Scl1 binding to
cFn, in the context of diversity among fibronectin-binding proteins of GAS and other
bacterial pathogens. We also report that the same determinant of the Scl1 adhesin is
responsible for binding to laminin (Lm) and apolipoprotein B100/low density lipoprotein
(ApoB100/LDL) complex.
Several mammalian collagens, such as collagen type I, IV, and X, contain an Nterminal and/or C-terminal non-collagenous domain, which serves as a nucleation or
trimerization domain, thereby facilitating proper folding of the three adjacent α-chains into
a mature collagen triple helix (51). Similarly, bacterial collagen-like proteins contain noncollagenous trimerization domains, often of unknown functions (14,44). The BclA of
Bacillus anthracis endospores possess a C-terminal non-collagenous trimerization
domain, BclA-CTD, for CL-domain folding and increased thermal stability (52). Two
different recombinant BclA-CTD constructs had the same crystal structure, similar to a
non-collagenous globular domain of C1q, independent from whether these constructs
included the continuous CL domain (53,54). Likewise, the N-terminal V domains of Scl1
and Scl2 assisted in the trimerization of homologous and heterologous CL domains
(44,55), and the recombinant Scl2-V-only construct formed a trimeric 6-helical bundle
structure (22). However, here we found that the rScl1-V-only constructs, derived from the
corresponding full-length rScl1FL proteins, did not bind rEDA, cFn, Lm, and
ApoB100/LDL. We propose that the triple helix imposes a restraint on the V domain in a
way to destabilize it and make it more prone to conformational changes. We expect a
slight effect on the tertiary structure but not on the secondary structure. A reason of the
restraint may be the one residue stagger of triple helices, whereas the V domains are
perfectly aligned; these structural features likely distort the V domain slightly, to make it
more flexible.
While Scl1 is unique amongst GAS Fn-binding proteins in recognizing the EDA
type III repeat of cFn, several other bacterial adhesins may in fact recognize the EDA,
due to their selective binding to cFn but not pFn, such as FimH of pathogenic E.coli, OppA
and Msp of Treponema denticola, and Tp0155 of Treponema pallidum (56). In addition,
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numerous bacterial surface proteins bind Fn type III repeats other than EDA that are
present in both pFn and cFn, including proteins ShdA, ComE1, Pap31, and Ali, that are
associated with the outer membrane of gram-negative bacteria (57-60) and fibrillar
surface proteins Embp and PavA-B of gram-positive bacteria (61,62). Two pneumococcal
Fn-binding proteins, PavA and PavB, bind to multiple FnIII repeats via common epitopes
located on β-strands B, C, and F, as well as the AB and BC loops (62). This is, however,
different from the Scl1 binding site on EDA, mapped to C-C’ loop (45). Interestingly,
PavA/B did not bind the RGD sequence on FnIII10, which is recognized by the integrin
α5β1, nor to the synergistic sites on repeats III8 and III9 (62), whereas the Scl1 binding site
on C-C’ loop maps in the vicinity of binding site for integrins α9β1 and α4β1 (38,45). PavA
and PavB binding to the FnIII repeats was modeled to be largely due to electrostatic
interactions; however, basic amino acids were primarily responsible for binding, rather
than negatively charged residues, as modeled here for Scl1-V. Thus, Scl1 remains a
unique adhesin that targets EDA/cFn isoforms that are expressed at the pathogen portal
of entry.
Here, we identified the loop region of the Scl1-V domain, as the structural
determinant that is central to EDA/cFn recognition and binding. When the 22-amino-acid
loop sequence of the EDA-binding positive Scl1-V variant, derived from the global M1type strain, was transplanted into the corresponding region of the binding-negative Scl2
protein, the chimeric construct gained EDA-binding activity. When the reverse
transplantation was performed, ligand binding was lost both in recombinant protein and
when expressed on the surface of Scl1 mutant GAS. A similar gain-of-binding function by
the chimeric protein was achieved, when the loop-region from a phylogenetically distant
Scl1 variant from M28-type GAS was substituted into the Scl2-V loop. A novel ‘catchclamp’ Fn-binding mechanism was deciphered for the multifunctional filamentous adhesin
of S. gordonii, CshA (63). The CshA protein, which also lacks the classical Fn-binding
repeats, binds both pFn and cFn via its non-repetitive domains 1 and 2. The NR2 globular
domain has a β-sandwich structure with lectin-like fold, and likely binds glycosylated sites
on Fn. The Fn-binding site of NR2 domain is capped by a flexible ligand-gating loop,
which, upon ligand recognition, uncovers a presumed binding cleft. The Scl1-V domain is
different, because it forms a 6-helix bundle structure, not lectin-like fold, and binds non32

glycosylated recombinant EDA protein; in addition, the EDA repeat in human cFn is not
glycosylated (31). The lectin-like domain, containing ligand-gating loop capping the
ligand-binding cleft, is represented in numerous fibrillar streptococcal adhesins, including
S. mutans SpaA (64), S. gordonii SspB (65), S. agalactiae BspA (66), and M28-type S.
pyogenes AspA (67), all correlated with the extended antigen I/II protein family. While the
detailed Scl1 structure and structural organization is different from those of antigen I/II
affiliates, there are several intangible similarities, where the elongated CL domain projects
the globular ligand-binding domain away from the cell surface, with ligand-engaging loop
placed at the apex of the Scl1-V structure.
Homology modeling of the Scl1-V domain revealed that electrostatic surface
potential and distribution of charged residues likely participate in ligand recognition and
binding. A negatively charged region is formed in the center of the Scl-V trimer of ligandbinding-positive proteins modelled (Scl1.1, rScl.chi1, and rScl.chiC) that are surrounded
by neutral and positively-charged residues. In contrast, the electrostatic models of the
binding-negative Scl-V domains (Scl2.28, rScl.chi2, and rScl.chiN) display a uniform
negative surface charge throughout the crown of the Scl-V domain. The arrangement of
the surface potential observed in the Scl1-V domains was associated with a pattern of
conserved negatively-charged amino acids, primarily E46, 47(Scl1.1) and D48(Scl1.1), located at
the C-terminus of the loop sequence at the junction with the α-helices forming the inner
core of Scl1.1-V bundle. This charge distribution is reminiscent of the ligand-gating loops,
capping negatively-charged binding clefts, proposed in CshA and BspA (63,66). This
conserved pattern is observed in Scl1 variants that are evolutionarily distant on the
phylogenetic tree; for example, E48,
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of Scl1.28 from M28 GAS. Therefore,

phylogenetically distant Scl1 proteins, which have significant amino-acid sequence
variation, exhibit conservation in the arrangement of charged amino acids, and similar
ligand-binding partners.
We previously reported that Scl1-V domain bound EDA/cFn, Lm and
ApoB100/LDL, thus, supporting a dichotomous nature of Scl1-ligand binding in tissue and
blood (23). Here, we established that the same regions of the globular Scl1 domain are
critical in binding with all three ligands. It is not unusual that bacterial adhesins are multifunctional and bind several distinct ligands. Such proteins typically contain clearly defined
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functional domains; for example, the ECM-binding protein of S. epidermidis Embp,
discussed earlier, contains both the Fn-binding FIVAR domains and the G-related
albumin binding GA domains (61). The collagen domain in streptococcal surface proteins
is also found in association with additional domains; for instance, the pneumococcal
protein PclA (68), harbors both FIVAR and G5 (binds N-acetylglucosamine) domains, in
addition to the collagen domain (23). The Scl1-V domain is different in that the short
sequence-variable loop region and a conserved arrangement of the surface potential at
the apical plane of Scl1-V structure, are involved in binding of assorted ligands that do
not share substantial sequence nor structural similarities. These data, combined with
previous molecular evolutionary analysis (9,11), as well as structural and phylogenetic
analyses (20,22), indicate that retaining the conserved structure of the Scl1-V domain is
the selective constraint, which influenced sequence variation.
Our work demonstrates several critical structure-function constraints that
determine ligand binding capacity by the globular domain of a major group A
streptococcal adhesin, Scl1. Current prospects for a global GAS vaccine, based on M
protein, are problematic because more than 240 M-protein types have been reported,
especially in regions outside North America and Europe, where vaccines are acutely
needed. The EDA binding to diverse Scl1 variants could be developed into a nonconventional treatment option for GAS infections. The EDA-derived cyclic peptide bound
Scl1 with an affinity in the micromolar range (48). The ongoing research explores the
possibility of designing an improved EDA-derived peptide for targeting diverse GAS
strains. This work provides an important structural understanding of Scl1 adhesin, which
is essential during early stages of GAS infection, and lays the foundation for the
development of non-vaccine inhibitors of Scl1-ligand interactions for the prevention of
infection progression.
EXPERIMENTAL PROCEDURES
Production of recombinant streptococcal collagen-like proteins (rScls) – Gene
cloning and rScl-protein production were performed in Escherichia coli TB1 and BL-21,
respectively, grown in Luria-Bertani (LB) media (Fisher Scientific) with ampicillin (100 µg
mL-1) at 37ºC. rScl-encoding clones, which were derived from the original scl alleles, were
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generated by PCR amplification from GAS genomic DNA; primers contained flanking
sequences compatible E.coli expression vector pASK-IBA2 digested with BsaI. Clones
encoding the chimeric rScl proteins were generated using synthetic double-stranded DNA
fragments (gBlocks; Integrated DNA Technologies) flanked by PflMI and BsaI sites. All
plasmids were verified by DNA sequencing. Plasmid constructs used in this study are
described in Table 1 and gBlocks are shown in Table S1.
All rScl proteins were produced using the Strep-tag II cloning, expression, and
purifications system (IBA-GmbH, Geottingen, Germany). Proteins were expressed with a
C-terminal affinity tag and purified on Strep-Tactin sepharose, as described (14,15). The
full-length (rSclFL) and V-region-only (rSclV) constructs were made, as designated:
rScl1.1FL and rScl1.1V are derived from Scl1 protein in M1-type strain MGAS6708 (14);
rScl1.28FL and rScl2.28FL originate from M28 strains MGAS6274 (14); and rScl1.3FL
and rScl1.3V are derived from M3 strain MGAS315 (48). Both naturally-derived and
chimeric rScl proteins were expressed in E. coli BL21 periplasm following the induction
with anhydrotetracycline at 0.2 µg mL-1 for 3 hours. Cells were centrifuged and suspended
in high sucrose buffer (100mM Tris-HCl, 1 mM EDTA, pH 8.0, 500mM sucrose) or Cell
Lytic B Buffer (Sigma) for separation of the periplasmic fraction and subsequent affinity
purification. Purified proteins were analyzed by SDS-PAGE and stained with
RAPIDstainTM (G-Biosciences); proteins were dialyzed against 25 mM HEPES, pH 8.0,
and stored at -20oC. Protein concentrations were determined using Qubit fluorometric
quantitation (ThermoFisher).

Recombinant extra domain A (rEDA) Production - Recombinant EDA (Table 1) was
produced using the pQE-30 His-tag cloning, expression, and purification system (Qiagen)
in the E.coli strain JM-109 (Promega), as described (69). E. coli containing rEDAencoding plasmid was grown in LB broth supplemented with ampicillin (100 µg/ml -1).
Protein expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside for 3
hours. Cells were harvested by centrifugation, and pellets were frozen at -20oC for 2 hours
or overnight. Cells were next suspended in a lysis buffer (50 mM Tris/HCL pH 8.0, 50 mM
NaCl, 2 mM MgCl2, 2% Triton X-100, 10 mM β-mercaptoethanol, 0.2 mg/ml lysozyme, 1
EDTA-free protease inhibitor cocktail tablet [per 10 mL] (Pierce), 1 mM phenylmethane
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sulfonyl fluoride, 10 U/ml DNaseI) and incubated on ice for 20 minutes. Cell lysate was
centrifuged at high speed (16000g x 20 minutes) and supernatant was collected.
Supernatant was mixed with Ni-NTA agarose resin (Qiagen) by inversion for 1.5 hours,
and then poured into a column (Bio-Rad). Sample was washed with 50x resin bed volume
of the wash buffer (50 mM NaH2PO4, 20 mM imidazole, 500 mM NaCl), and then rEDA
protein was eluted in elution buffer (50 mM NaH2PO4, 250 mM imidazole, 300 mM NaCl).
Purified protein was dialyzed against 25 mM HEPES buffer, pH 8.0 and protein
concentration was measured with Qubit fluorometric quantitation; protein integrity and
purity were assessed by 15% SDS-PAGE. Protein was stored at -20oC until future use.
Rotary shadowing and electron microscopy – rScl proteins were rotary shadowed and
analyzed by electron microscopy, as previously described (14). Briefly, recombinant
proteins were dialyzed against 0.1 M ammonium bicarbonate. rScl samples were mixed
with glycerol to a final glycerol concentration of 70% (vol/vol) and 100 µl of each sample
was nebulized with an airbrush onto freshly cleaved mica. Samples were then dried in a
vacuum and rotary shadowed with carbon/platinum using an electron beam gun titled at
an angle of 6 degrees, relative to the mica surface, in a Balzers BAE 250 evaporator. The
replicas were backed with carbon at 90 degrees, and then were floated in distilled water
and picked up onto bare 600-mesh copper grids. Photomicrographs were taken using a
FEI G2 electron microscope operated at 120 kV with a 30-µm objective aperture.
Circular dichroism spectroscopy – Circular dichroism spectroscopy of rScl proteins
was performed as previously described (14). Briefly, protein samples were dialyzed
against 1x Dulbecco’s phosphate buffered saline, pH 7.4. CD spectra were taken with a
Jasco 810 spectropolarimeter, in a thermostatically controlled cuvette, with a path length
of 0.5 cm. Data were acquired at 10 nm per minute. Wavelength scans were performed
from 240 nm to 190 nm, at either 20ºC, or 50ºC for denaturation.
Protein binding assays – rScl proteins (0.5 µM solutions) were immobilized onto StrepTactin-coated microplate wells for 1.5 h at room temperature and blocked with Trisbuffered saline supplemented with 1% fetal bovine serum albumin (BSA) overnight at 4ºC,
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followed by incubation with ECM ligands: cellular fibronectin (cFn) (Sigma), recombinant
extra domain A (rEDA), murine laminin-111 (Lm) (Sigma), and Apolipoprotein B100
(ApoB) and low-density lipoprotein (LDL) (Sigma). The no rScl controls were performed
in BSA-coated wells for each ligand and each antibody used. Final ODs were normalized
by subtracting the BSA controls in each experimental set-up.
In regular binding assays, ECM ligands were added to the rScl-immobilized wells
at 1 µg per well and incubated at room temperature for 1 h. To assess concentrationdependent binding, rEDA was added to the wells at concentrations ranging between
0.039-5 µM. Bound ECM ligands were detected with anti-cFn polyclonal antibody
(Sigma/F3648; 1:4000), anti-His-Tag monoclonal antibody (Proteintech/66005; 1:100),
anti-Lm polyclonal antibody (Sigma/L939; 1:500), and anti-ApoB (Chemicon/AB742;
1:500); followed by goat anti-rabbit (Bio-Rad/1721019; 1:2000), anti-mouse (BioRad/1721011; 1:1000), or rabbit anti-goat (Bio-Rad/1721034; 1:1000) secondary
antibodies conjugated to horseradish peroxidase (HRP) (Bio-Rad). The HRP substrate,
2,20-azino-bis(3-ethylbenzthiazoline-6-sulphonic

acid)

(Fisher)

was

used

and

colorimetric reactions were recorded at OD415 nm.

Protein modeling - Multiple sequence alignments of protein sequences were generated
using MUSCLE and refined manually based on the results of secondary structure
predictions. Predicted α-helices represent the consensus between PSIPRED, PHD, and
SSPRO. The phylogenetic tree of Scl1-V and Scl2-V regions was inferred based on
multiple sequence alignments, using Neighbour-Joining method (adapted from (20)).
Branch lengths were scaled to the distance computed using the Gonnet250 matrix, and
bootstrap values (statistical support for given bifurcation) were calculated for all nodes.
The homology models of Scl1.1-V and Scl2.28-V domains were obtained after
consensus-based sequence alignment using HMMer, against the amino acid sequence
of Scl2.3-V domain with solved, crystal structure(22)(PDB accession code: 4nsm). The
homology models were built with MODELLER (70) and stereo-chemical quality of the
models was improved by energy minimization with GROMACS (71).
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Complementation of M1 group A Streptococcus– The E.coli shuttle plasmid pSB027
(72) (Table 1) was used for in-trans complementation. The DNA fragment encompassing
the scl1.1 coding sequence with upstream promoter was PCR-amplified using genomic
DNA from the M1-type strain MGAS5005 (WT) with primers 232Reg and 232Rev_BgIII
(Table S1). The amplified DNA was cloned into pSB027 between BglII and HindIII sites,
resulting in pSL620 (Table 1). The scl.chi2 sequence was cloned as a synthetic double
stranded DNA fragment (gBlocks: Integrated DNA Technologies: SL621 gBlock, Table
S1) between SpeI and PpuMI sites of pSL620, resulting in pSL621 (Table 1). Both pSL620
and pSL621 were electroporated into MGAS5005

scl1 mutant GAS (9) and

transformants were selected on BHI agar containing 10 µg/mL -1 chloramphenicol;
plasmids were verified by DNA sequencing.
GAS cultures were grown in Todd Hewitt broth (Becton Dickinson and Co)
supplemented with 0.2% yeast extract (THY medium) and on Brain Heart Infusion agar
(Becton Dickinson and Co) at 37ºC in an atmosphere with 5% CO 2. For antibiotic
selection, chloramphenicol (5 µg mL -1) was added to the medium.

Western blot analysis - Expression of Scl1.1 and Scl.chi2 proteins was determined by
western immunoblotting of the bacterial cell-wall protein fraction, as described previously
(9,10). Briefly, bacterial cultures were grown to an OD600 of 0.5 and cells were harvested
by centrifugation. GAS cells were next digested with 100 µg lysozyme and 5 U
mutanolysin and phenylmethylsulfonyl fluoride in a 20% sucrose buffer. 5- 25 µL of the
sample supernatants were separated by SDS-PAGE and transferred to a nitrocellulose
membrane. Detection of Scl1.1 and Scl.chi2 proteins was performed using rabbit antibody
(1:2000) specific to the Scl1.1-V domain (9). Horseradish peroxidase-conjugated goat
anti-rabbit IgG secondary antibody (Bio-Rad/1721019; 1:2000) was added to blots,
followed by addition of Clarity ECL substrate (Bio-Rad) for detection. Images were
acquired using a ChemiDoc Touch Imaging System (Bio-Rad).
Flow cytometry analysis – Determination of Scl-surface expression and rEDA binding
by GAS cells was measured by flow cytometry. Bacteria grown to an OD 600 of 0.5 were
harvested by centrifugation and washed with flow cytometry buffer (phosphate-buffered
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saline containing 10% Todd-Hewitt broth with 0.2% yeast extract). For Scl-surface
detection, the anti-Scl1.1-V antibody (9) was pre-absorbed with MGAS5005 Δscl1 cells
and then Ab (1:10 dil.) was incubated with GAS cells tested for 30 minutes on ice. Cells
were next washed and incubated with Allophycocyanin (APC)-conjugated donkey antirabbit antibody (Jackson ImmunoResearch; 1:150).
For rEDA binding, GAS cells tested were incubated with rEDA for 30 minutes at
room temperature and bound rEDA was detected with anti-His-Tag monoclonal antibody
(1:10 dil.) (Proteintech) pre-absorbed with MGAS5005 WT cells. Samples were then
incubated with goat anti-mouse polyclonal antibody conjugated with Alexa Fluor® 568
(ThermoFisher; 1:150). Cells were washed and fixed in 0.4% paraformaldehyde and
stored at 4ºC until analysis. 50,000 events were collected per sample using a BD
LSRFortessa and data were analyzed with FCS Express Flow 6 software.
Statistical analyses – Statistics was performed using the two-tailed paired Student’s ttest or Two-way ANOVA analyses. Significance was denoted at levels of *P ≤0.05, **P
≤0.01, or ***P ≤0.001. Error bars represent standard deviations with analyses based on
three independent experimental repeats (N=3), each performed in triplicate technical
replicates.
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TABLES
Table1: Plasmids used in this study.
Plasmid
Description
E. coli expression vector,
pASK-IBA2
C-terminal Strep-tag II
pASK-IBA2 encoding
pSL503
rScl1.3FL
pASK-IBA2 encoding
pSL514
rScl1.3V
pASK-IBA2 encoding
pSL144
rScl1.1FL
pASK-IBA2 encoding
pSL158
rScl1.1V
pASK-IBA2 encoding
pSL161
rScl1.28FL
pASK-IBA2 encoding
pSL163
rScl2.28FL
pASK-IBA2 encoding
pSL600
rScl.chi1FL
pASK-IBA2 encoding
pSL601
rScl.chiNFL
pASK-IBA2 encoding
pSL602
rScl.chiCFL
pASK-IBA2 encoding
pSL603
rScl.chiIFL
pASK-IBA2 encoding
pSL613
rScl.chi2FL
pASK-IBA2 encoding
pSL614
rScl.chi3FL
N-terminal His-tag E. coli
pQE-30
expression vector
pQE-EDA
pSB027
pSL620
pSL621

pQE-30 encoding rEDA
E. coli -GAS shuttle
plasmid encoding GFP
pSB027 encoding scl1.1
allele from MGAS 5005
pSL620 encoding
Scl.chi2FL
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Source
IBA, Göttingen
(73)
(48)
(14)
(14)
(15)
(14)
This study
This study
This study
This study
This study
This study
Qiagen
(69)
(72)
This study
This study

FIGURES
Figure 1

Figure 1. Conserved structure of the Scl1 and Scl2 globular domains. (A) Cartoon model of full-length
Scl proteins. Globular N-terminal sequence-variable (V) domain, central rod-shaped collagen (CL) domain,
and C-terminal cell-wall-anchor domain are shown. (B) Multiple sequence alignment of the V regions of
Scl1 and Scl2 variants. MSA was generated using MUSCLE; amino acid residues are colored according to
their physico-chemical character: red - negative (D, E), blue – positive (R, K, H), gray - hydrophobic,
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aliphatic or aromatic (I, L, V, A, M, F, Y, W), and green – polar, Gly, and Pro (S, T, Q, N, G, P). Predicted
alpha helices: N-terminal helix 1 (grey) and C-terminal helix 2 (blue) are shown below the alignments (H).
(C) Homology models of the Scl1.1-V and Scl2.28-V domains. Models were generated based on the crystal
structure of the Scl2.3-V variant (PDB accession code: 4nsm). Modeled alpha helices: N-terminal helix 1
(grey) and C-terminal helix 2 (blue) are shown.
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Figure 2

Figure 2. Full-length Scl1 proteins are required for binding to ECM ligands. Recombinant full-length
proteins (rScl1.1FL and rScl1.3FL) and their respective V-region-only constructs (rScl1.1V and rScl1.3V)
were tested for binding to cellular fibronectin (cFn) and recombinant extra domain A (rEDA). (A) ELISA
binding assay. rScl proteins were immobilized onto Strep-Tactin-coated microplate wells and incubated with
ECM ligands, cFn and rEDA. Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for
ligand detection. Graphic bars indicate the mean OD 415 nm normalized against control BSA-coated wells.
Statistical analysis was calculated using Student’s two-tailed t-test from three independent experiments,
each performed in triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines
indicate threshold OD415

nm

±2SD values recorded for experimentally validated ECM-binding-negative

control protein rScl2.28FL.
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Figure 3

Figure 3. Surface-exposed loop of the Scl1.1-V domain is central in ECM recognition and binding.
Full-length chimeric rScl proteins were generated by exchanging V-region loop sequences between ECMbinding-positive and binding-negative rScl proteins; the resulting chimeric rScl.chiFL constructs were
characterized structurally by circular dichroism spectroscopy and electron microscopy, as well as
functionally for ECM binding. (A) Amino acid sequences of the V domains of native (rScl1.1FL and
rScl2.28FL) and chimeric (rScl.chi1FL and rScl.chi2FL) proteins. rScl.chi1FL resulted from the insertion of
22-amino-acids from the ECM-binding-positive variant rScl1.1FL in place of the corresponding loop region
of the binding-negative variant rScl2.28FL, whereas rScl.chi2FL resulted from the reverse replacement;
inserted sequences are shown in italics and numbers mark residue number within V-domain. (B) Structural
characterization of the chimeric rScl.chiFL constructs. Left, CD wavelength scans of folded (20ºC, solid
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lines) or denatured (50ºC, dashed lines) rScl.chiFL proteins are shown. Right, structural organization
viewed by electron microscopy of the rotary shadowed rScl.chi1FL and rScl.chi2FL shows characteristic
two-domain organization; Bars, 50 nm. (C) ECM binding to full-length original and chimeric rScl constructs
by ELISA. rScl proteins were immobilized onto Strep-Tactin-coated microplate wells and incubated with
ECM ligands, cellular fibronectin (cFn) and recombinant extra domain A (rEDA). Primary anti-ECM Abs and
HRP-conjugated secondary Abs were used for ligand detection. Graph bars indicate the mean OD415 nm
normalized against BSA controls. Statistical analysis was calculated using Student’s two-tailed t-test, from
three independent experiments, each performed in triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001.
Statistical significance evaluates the differences between ECM binding by chimeric proteins rScl.chi1FL
and rScl.chi2FL, and the control proteins, rScl2.28FL and rScl1.1FL. Solid (rEDA) and dashed (cFn) lines
indicate threshold OD415

nm

±2SD values recorded for experimentally validated ECM-binding-negative

rScl2.28FL control protein. (D) rEDA binding to whole GAS cells. M1-type GAS wild-type (WT), isogenic
scl1 inactivated mutant (Δscl1), and mutant complemented for the expression of Scl1.1 (Δscl1::scl1.1) and
Scl.chi2 (Δscl1::scl.chi2) proteins are shown. Left, Western blot detection of Scl1 expression in cell wall
fractions. 25 µLs of cell wall samples prepared from GAS WT and Δscl1, , and 5 µLs of samples from
complemented Δscl1::scl1.1 and Δscl1::scl.chi2 cells overexpressing Scl proteins, were loaded per well.
rScl1.1FL protein was included as a control. Scl1 was detected with anti-Scl1.1-V antibody. Right, rEDA
binding to whole-GAS cells by flow cytometry. Cells were incubated with rEDA, and binding was detected
with primary anti-his-tag mAb and secondary Ab conjugated to Alexa Fluor® 568. Binding to WT cells was
set as 100%. Statistical analysis was calculated using Student’s two-tailed t-test from three independent
experiments (N= 3 ± SD); **P≤0.01.
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Figure 4

Figure 4. The C-terminal 11 amino acids of the loop segment of the Scl1.1-V domain is central in
ECM recognition and binding. Chimeric rScl proteins were generated by exchanging portions of the loop
from ECM-binding-positive rScl1.1-V with respective loop sequences of the binding-negative protein
rScl2.28FL; the resulting chimeric rScl.chi constructs were characterized structurally by circular dichroism
spectroscopy and electron microscopy, as well as functionally for ECM binding by ELISA. (A) Amino acid
sequences of the V domains of native (rScl1.1FL and rScl2.28FL) and chimeric (rScl.chiNFL, rScl.chiCFL,
rScl.chiIFL) proteins. rScl.chiNFL resulted from the insertion of the N-terminal 11 amino acids of the
rScl1.1FL-loop sequence in place of the corresponding N-terminal loop region of the rScl2.28FL, whereas
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rScl.chiCFL resulted from the replacement of the C-terminal 11 amino acids and rScl.chiIFL from the
replacement of internal 11 amino acids; inserted sequences are shown in italics and numbers mark residue
number within V-domain. (B) Structural characterization of the chimeric rScl constructs. Left, CD
wavelength scans of folded (20ºC, solid lines) or denatured (50ºC, dashed lines) rScl.chi proteins are
shown. Right, structural organization viewed by electron microscopy of the rotary shadowed rScl.chiNFL,
rScl.chiCFL, and rScl.chiIFL shows characteristic two-domain organization; Bars, 50 nm. (C) ECM binding
to chimeric rScl constructs by ELISA. rScl proteins were immobilized onto Strep-Tactin-coated microplate
wells and incubated with ECM ligands, cellular fibronectin (cFn) and recombinant extra domain A (rEDA).
Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for ligand detection. Graphic bars
indicate the mean OD415

nm

normalized against BSA controls. Statistical analysis was calculated using

Student’s two-tailed t-test, from three independent experiments, each performed in triplicate wells (N= 3 ±
SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines indicate threshold OD415 nm ±2SD values
recorded for experimentally validated binding-negative rScl2.28FL control protein. (D) Concentrationdependent binding of rEDA to rScl constructs. rScl proteins were immobilized onto Strep-Tactin-coated
microplate wells and incubated with increasing concentrations of rEDA. Wells were further developed, as
described above. Statistical analysis was calculated using two-way ANOVA, from two-independent
experiments, each performed in triplicate wells (N=2 ± SD), *P ≤0.05, **P ≤0.01, ***P ≤0.001. Statistical
significance evaluates difference between bindings of each rScl1-chimeric protein to binding-negative
control rScl2.28FL.
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Figure 5

Figure 5. Electrostatic potential surfaces of Scl1-V, Scl2-V, and Scl.chi-V domains. The positive and
negative charges are colored blue and red, respectively. Exposed loops are outlined by the black ovals in
side views. Black arrowheads point to negatively charged pockets of the D/E residues, embedded in neutral
and positively-charged environment, seen within the binding-positive Scl1.1-V and Scl.chiC-V domains.
Homology models were generated using the crystal structure of the Scl2.3 V domain (PDB accession code4nsm), as a template.

55

Figure 6

Figure 6. Conservation of ECM recognition and binding by phylogenetically distant Scl1 variant. (A)
Phylogenetic tree of Scl1-V and Scl2-V regions. Branch lengths are scaled to genetic distance and
bootstrap values are shown for all nodes. Scl1 variants with known ECM-binding capacities are boxed,
while variants known to bind complement components, Factor H and Factor H-related protein 1, are marked
with dots. ECM-binding-positive variants, Scl1.28 and Scl1.1, and binding-negative variant Scl2.28, used
for loop switching, are marked by arrows. (B) Amino acid sequences of the V-domains of native (rScl1.28FL
and rScl2.28FL) and chimeric (rScl.chi3FL) proteins. rScl.chi3FL resulted from the insertion of the 22amino-acids from the ECM-binding-positive variant rScl1.28FL in place of the corresponding loop-region of
the binding-negative variant rScl2.28FL; inserted sequence is italicized and numbers mark residues within
V-domain. (C) Structural characterization of rScl.chi3FL. Left, CD wavelength scans of folded (20ºC, solid
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line) or denatured (50ºC, dashed line) rScl.chi3FL protein are shown. Right, structural organization viewed
by electron microscopy of the rotary shadowed rScl.chi3FL shows characteristic two-domain organization;
Bar, 50 nm. (D) ECM binding to rScl.chi3FL by ELISA. rScl proteins were immobilized onto Strep-Tactincoated microplate wells and incubated with ECM ligands, cellular fibronectin (cFn) and recombinant extra
domain A (rEDA). Primary anti-ECM Abs and HRP-conjugated secondary Abs were used for ligand
detection. Graphic bars indicate the mean OD415 nm normalized against BSA controls. Statistical analysis
was calculated using Student’s two-tailed t-test, from three independent experiments, each performed in
triplicate wells (N= 3 ± SD); **P ≤0.01, ***P ≤0.001. Solid (rEDA) and dashed (cFn) lines indicate threshold
OD415

nm

±2SD values recorded for experimentally validated ECM-binding-negative rScl2.28FL control

protein.
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Figure 7

Figure 7. Conserved structural constraints and exposed loop of Scl1 proteins determine binding to
laminin and apolipoprotein B100/low-density lipoprotein. Full-length recombinant Scl1 proteins,
chimeric rScl proteins, and rScl1-V-only constructs were tested for binding to laminin (Lm), and
apolipoprotein B100 (ApoB100) and low-density lipoprotein (LDL). rScl proteins were immobilized onto
Strep-Tactin-coated microplate wells and incubated with ligands. Primary anti-Lm or anti-ApoB100 Abs and
HRP-conjugated secondary Abs were used for ligand detection. Graphic bars indicate the mean OD 415 nm
normalized against BSA-coated control wells. Statistical analysis was calculated using Student’s two-tailed
t-test from three independent experiments, each performed in triplicate wells (N= 3 ± SD); *P ≤0.05, **P
≤0.01, ***P ≤0.001. (A) Full-length Scl1 proteins are required for binding to Lm and ApoB100. Statistical
significance evaluates the differences between binding by the full-length proteins, rScl1.1FL and rScl1.3FL,
and their respective V-region only constructs, rScl1.1V and rScl1.3V. Dashed line (ApoB) and solid line
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(Lm) indicate threshold OD415

nm

±2SD values recorded for experimentally validated binding-negative

control protein rScl2.28FL. (B, C) Surface-exposed loop of the Scl1-V domain is central in Lm (B) and
ApoB100/LDL (C) recognition and binding. Dashed (LDL) and solid lines (B – Lm, C – ApoB) indicate
threshold OD415 nm ±2SD values recorded for experimentally validated binding-negative rScl2.28FL control
protein.
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ABSTRACT
The human-adapted pathogen group A Streptococcus (GAS) utilizes wounds as a portal
of entry into host tissues, wherein surface adhesins interact with the extracellular matrix,
enabling bacterial colonization. The streptococcal collagen-like protein 1 (Scl1) is a major
adhesin of GAS, which selectively binds to fibronectin type III (FnIII) repeats, extra
domains A and B in cellular fibronectin and to several FnIII repeats within tenascin-C.
Binding to FnIII repeats occurred through a conserved mechanism, involving the Scl1
globular domain, and facilitated GAS adherence and biofilm formation. Numerous
extracellular matrix proteins can be targeted by group A streptococcal adhesins to enter
the human host. The extra domains A and B are unique in that they are alternatively
spliced in cellular fibronectin and appear transiently in the wound extracellular matrix. This
Scl1-FnIII binding is therefore a remarkable example of GAS adaptation to this transient
environment that is initially encountered within the host. Cellular fibronectin isoforms and
tenascin-C are also present in the tumor microenvironment, and here, we found that Scl1
mediated GAS attachment and biofilm formation on the extracellular matrices deposited
by cancer-associated fibroblasts and osteosarcoma cells. These data lay the groundwork
for the assessment of Scl1 as a cancer-targeting biomolecule.

INTRODUCTION
Group A Streptococcus (GAS or Streptococcus pyogenes) is an obligate human pathogen
that is responsible for over 700 million infections worldwide each year (1). Infection by
GAS can result in diseases that range in severity, from highly prevalent superficial
infections to fatal conditions (1). GAS infection can also lead to the development of postinfectious autoimmune sequelae (2-4). Invasive infections and rheumatic heart diseases
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results in over 500,000 deaths globally each year (1,5), which places GAS among the top
ten most lethal infectious disease-causing organisms (5). Nevertheless, superficial GAS
infections account for the vast majority (~95.5%) of the 700 million infections, mostly
affecting children; GAS also asymptomatically colonizes the throat and skin of 5-25% of
children of the general population (6). GAS isolates are subtyped based on the 5’hypervariable end of the emm gene, encoding the N-terminus of the M-protein, a major
surface adhesin and virulence factor of GAS (7). There have been over 220 different emm
types of GAS identified and there is a non-random correlation between certain M-types
and infection-associated diseases (8).
In addition to protein M, GAS express numerous adhesins that contribute to host
colonization (9). Two ubiquitous surface-associated proteins are the streptococcal
collagen-like protein 1 (Scl1/SclA) and 2 (Scl2/SclB) (10-14). Scl1 and Scl2 share a
unique structure that is distinct from other GAS adhesins; both are homotrimeric and have
similar “lollipop-like” structural organization (15,16). The N-terminal sequence-variable
(V) globular domain is followed by the collagen-like (CL) domain, and with a LPATG cellwall anchoring motif at the C-terminus (11,12). The V-domain of the Scl2 protein from M3type GAS has been crystalized (17). It forms a six-helix bundle, where two antiparallel αhelices in each monomer are joined by surface-exposed loops. (18,19). Regardless of the
conserved structure, the amino-acid sequences of the V-domains diverge between Scl1
and Scl2 proteins and also differ among Scl1 and Scl2 variants from strains of different
M-types (20). The Scl1-V domain binds selected isoforms of cellular fibronectin (cFn) that
are expressed within wounded tissue (21,22), via the surface-exposed loops of the Vdomain (19).
cFn is a high molecular weight glycoprotein encoded by the FN1 gene that contains
three different types of repeating domains (I, II, and III) (23,24). Type I and II repeats
interact with fibrin, fibronectin and collagen, while the type III repeats contain numerous
cell-binding sites via integrins and other receptors (25). There are over 20 different
isoforms of cFn in humans due to alternative splicing of FN1-mRNA, which can lead to
the inclusion of extra domains. These extra domains are both fibronectin type III (FnIII)
repeats, known as extra domain A (EDA/EIIIA) and extra domain B (EDB/EIIIB) (26). The
EDA and EDB repeats vary in sequence but retain the conserved prototypical FnIII-repeat
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β-sandwich structure (27,28). Spatial and temporal inclusion of EDA and EDB domains
in cFn is tightly regulated; both are expressed during embryogenesis but are not readily
detectable in healthy adult tissue (29,30). Conversely, isoforms of cFn that contain EDA
and/or EDB are expressed in pathological adult tissues, such as within wound beds and
around tumors (31-33). EDA has been shown to play important roles in wound healing
(34,35). The role of EDB in the wound microenvironment is not well understood, but it is
known to be highly expressed during angiogenesis of healing tissues and of tumors (3638). Tenascin-C (TnC) is another ECM protein that contains canonical FnIII repeats (39).
Like EDA and EDB of cFn, TnC is predominately expressed during fetal development and
is found at negligible levels within normal adult soft tissue (40-42); though, it is highly
deposited in wound and within tumor stroma (39,43).
We previously reported that Scl1 binds to the wound-associated fibronectin type
III repeat, EDA, and this binding contributes to GAS colonization and biofilm formation on
matrices deposited by normal human dermal fibroblasts (22). In this report, we show that
Scl1 binds to recombinant EDB and to some FnIII repeats within TnC. Binding was
conserved across phylogenetically distant Scl1 variants, originating from strains of
epidemiologically relevant M types. Recognition of both ligands was mediated through
the Scl1-V-domain loop-region, the same binding mechanism as for the EDA segment
within cFn (19). Scl1 facilitates GAS biofilm formation on rEDB coatings. In addition, ECM
deposited by cancer-associated fibroblasts and osteosarcoma cells contains cFn
isoforms with EDA and/or EDB, and TnC, capable of binding Scl1-expressing GAS to
facilitate biofilm formation. This work identifies novel wound–associated ECM targets for
Scl1 that are expressed at the portal of entry for GAS and facilitate host colonization at
wound sites. The unique binding of Scl1 to EDA, EDB and TnC and may present
alternative opportunities to target tumors or other disease regions that selectively express
these ECM variants.

RESULTS
Scl1 binds to EDB of cFn via surface exposed loops – Previously, we established that
Scl1 binds to cFn, but not plasma fibronectin (pFn) (21), via the C-C’ loop of EDA (22). In
addition to EDA, cFn can include another extra domain, EDB, which is also upregulated
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within wounded tissue (31). EDA and EDB both adopt a typical fibronectin type III repeat
structure (27,28), comprised of 7 β-strands (A, B, C, C’, E, F, G) that form 2 β-sheets,
with strands connected by flexible loops (27,28), including the C-C’ loop that mediates
Scl1 binding to EDA (Fig. 1A). Interestingly, we determined that the commercial cFn
preparations we used in binding assays contained cFns that included the EDB segment
(data not shown). Therefore, we hypothesized that Scl1 may also bind to EDB by a similar
mechanism, involving the surface-exposed loops of Scl1-V domain (19).
To test our hypothesis, we devised a panel of chimeric rScl constructs to be used
in binding assays with rEDB protein (Fig. 1B). A chimeric rScl construct was devised,
wherein we replaced the loop region (22 amino acids) of the EDA-binding-negative
rScl2.28-V domain, originating from Scl2 of M28-type strain, with that originating from
EDA-binding-positive rScl1.1 (Scl1 of M1 strain), resulting in rScl.chimera1 (rScl.chi1).
We correspondingly did the reverse, replacing the loop-region from rScl1.1-V domain with
the loop from rScl2.28-V domain, resulting in rScl.chi2. We also devised the rScl.chiC
construct, with a partial loop substitution (11 amino acids) from Scl1.1 that replaced an
analogous loop sequence of rScl2.28; this loop fragment was responsible for EDA
recognition. To assess whether this EDB-binding mechanism is true for a different Scl1
variant, we similarly replaced the whole loop (22 aa) with another EDA-binding-positive
sequence from a phylogenetically distant Scl1.28 protein, resulting in rScl.chi3. This panel
of devised rScl constructs was next tested for rEDB binding and compared to our
previously reported binding data with rEDA (19).
Both naturally-derived rScl1.1, rScl1.3, rScl1.28 and rScl1.41, as well as the
chimeric proteins rScl.chi1-3 and rScl.chiC were tested for binding to rEDB by ELISA;
binding was compared to that of rEDA-binding-negative rScl2.28 control. As it was
previously established for rEDA binding, all rScl1 proteins, derived from Scl1 variants
originating from several GAS M-types (M1, M3, M28 and M41), bind rEDB to varying
degrees, while control rScl2.28 protein did not bind (Fig. 1C). We furthermore
demonstrate that the Scl1-V loop mediates rEDB binding, as evidenced by rEDB binding
to the chimeric constructs rScl.chi1, rScl.chi3, and rScl.chiC, and a loss of binding to
rScl.chi2, harboring a reverse loop substitution. These data reveal that the Scl1 adhesin
binds to both the EDA and EDB segments that are found within cFn, expressed in the
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wounded portal of entry, and signify the importance of the Scl1-V loop in EDB/EDA
recognition and binding.
Scl1 mediates GAS-EDB binding and promotes biofilm formation – We next
investigated if Scl1 expressed on GAS cells mediates EDB binding, using flow cytometry
(Fig. 1D). Deposition of rEDB onto the surface of M1 and M41 strains was assessed after
30-minute incubation. M1 GAS is isolated across the globe and is responsible for both
superficial and invasive infections, while M41 is historically associated with superficial
skin infections (5,44) The rEDB binding to GAS WT cells was compared to that measured
for the corresponding isogenic Scl1-deficient mutant cells, M1Δscl1 and M41Δscl1. We
also tested rEDB binding to the M1Δscl1 mutant cells complemented in trans for the
expression of either the original Scl1.1 protein (Δscl1::scl1.1) or the chimeric Scl.chi2
variant (Δscl1::scl.chi2). There was a significant reduction in rEDB deposition on the
surface of both isogenic M1Δscl1 and M41Δscl1 mutants, compared to their respective
WT strains. In addition, restoration of Scl1.1 or Scl.chi2 expression on the surface of the
M1Δscl1 mutant restored rEDB binding (Fig. 1D). Thus, just like with rScl1-rEDB binding
above, our data demonstrate for the first time that GAS can bind to EDB containing cFn
isoforms through surface Scl1.
Because wounds, which contain isoforms of cFn that contain either EDA and/or
EDB fibronectin, can serve as a portal of entry for GAS to gain access to host tissues, we
sought to understand if the GAS-EDB interaction facilitates GAS biofilm formation in vitro,
which could influence the course of GAS infection. We used rEDB-coated surfaces and
analyzed biofilm formation by GAS isogenic strains spectrophotometrically, using crystal
violet staining to assess biomass (Fig. 1E), as well as microscopically, with GFPexpressing M41 GAS, to examine biofilm morphology and thickness (Fig. 1F). After 24
hours, there was significantly more stained biomass of WT strains grown on rEDB,
compared to amounts of biomass of the isogenic M1Δscl1 and M41Δscl1 mutants (Fig.
1E). These results were further supported through confocal laser scanning microscopy,
demonstrating that M41 WT biofilm had an average thickness of approximately 18 µm,
while the M41Δscl1 mutant had an average thickness of approximately 8 µm, a 40%
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decrease (Fig. 1F, bottom images). Altogether, our data validate GAS capacity for binding
to the fibronectin type III repeat, EDB, which facilitates GAS biofilm formation.
Scl1 binds tenascin C via surface-exposed loops of the Scl1-V domain – TnC is a
multi-domain glycoprotein with a central region made of fibronectin type III repeats (Fig.
2A) (45). Similar to EDA- and EDB-fibronectins, TnC is abundantly deposited within
wounded tissue (39,46). Here, we hypothesized that Scl1 could bind to TnC. We first
investigated TnC binding to our panel of rScl1 and rScl2 constructs that we characterized
previously for binding to cFn (21) and rEDB above (Fig. 1B-C). ELISA binding data
demonstrate that constructs rScl1.1, rScl1.2, rScl1.12, rScl1.28 and rScl1.41, derived
from diverse Scl1 variants expressed by M1-, M2-, M12, M28 and M41 GAS, all bind to
TnC. In contrast, rScl2.4 (Scl2 of M4) and rScl2.28 (Scl2 of M28) constructs demonstrate
minimal levels of TnC binding (Fig. 2B) and were considered binding-negative controls,
reminiscent of their lack of binding to cFn, rEDA and rEDB. Based on these results we
asked if TnC binding occurs via the loop-region of the Scl1-V domain, utilizing the same
panel of chimeric rScl proteins described above. ELISA binding data demonstrate TnC
binding to rScl.chi1, rScl.chiC and rScl.chi3, whereas constructs rScl.chi2 and rScl2.28
are binding-negative (Fig. 2C). Hence, our results establish the same binding pattern
documented earlier for EDA of cFn and EDB of cFn, pointing towards one conserved Scl1
binding mechanism to cFn and TnC, which is mediated by the surface-exposed loops
present in the structure of Scl1-V domain (18,19).
Scl1 binds to the type III repeats of tenascin C – We next tested whether Scl1 binds
to FnIII repeats within TnC. EDA in cFn interacts with Scl1 (22) and with the α9β1 integrin
receptor (47), which also binds to the TnFn3 repeat in TnC (48). Therefore, we
hypothesized that Scl1 specifically binds to the TnFn3 repeat within the TnC molecule
(Fig. 2D). To test this hypothesis, we produced recombinant fragments of the TnFnIII
repeats, encompassing repeats 1-5 (rTnFn1-5), repeat number 3 (rTnFn3), and repeats
6-8 (rTnFn6-8), the later to be used as a binding-negative control. We first tested the
rTnFnIII constructs for binding to our panel of naturally-derived and chimeric rScl
constructs (Fig. 2E). Binding to rTnFn1-5 was significantly higher for all naturally-derived
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rScl1.1, rScl1.28 and rScl1.41 proteins and the chimeric EDA/EDB/TnC-binding-positive
proteins rScl.chi1, rScl.chiC, and rScl.chi3, as compared to ECM-binding-negative
rScl2.28 and rScl.chi2 controls. However, binding between rTnFn3 and rScl constructs
that bind the larger rTnFn1-5 fragment was negligible and inconsistent. Unexpectedly, we
also recorded a significant binding between control rTnFn6-8 fragment and rScl
constructs positive for rTnFn1-5 binding (48).In summary, we have demonstrated for the
first-time direct binding between Scl1 and TnFnIII repeats using recombinant proteins.
The α9β1 and α4β1 integrins were historically referred to as “acidic” integrin
receptors that recognized LDV or similar tripeptide sequences (49), like an IDG sequence
located in the B-C loop of TnFn3 (Fig. 2D). We reasoned that the Scl1 binding site in TnC
may overlap with similar LDV-like sequences, particularly located within the exposed
loops of the rTnFn1-5 (outside Fn3 repeat) and rTnFn6-8 fragments, and the homology
models of the TnFn1-5 and TnFn6-8 fragments (48) identified several candidate
sequences within both TnFn1-5 and TnFn6-8 regions (Fig. 2Fi-ii). Specifically, the VDG
triplet was identified in the C’-E loop of TnFn6, the LDG sequence in the connecting
segment between repeats TnFn6 and 7, and the LDS sequence in the connecting
segment between TnFn7 and 8, and VDG sequence in the B-C loop of TnFn8 (Fig. 2Fi).
Most of these share a DG-dipeptide with C-C’ loop in EDA that is critical for integrin α9β1
binding (47). We similarly identified several LDV-like tripeptides within TnFn1-5 fragment
e.g., PEG, LDA, IDS, VDV, LDT, and LEP triplets (Fig. 2Fii). We propose that Scl1 may
recognize the TnFnIII repeats 1-5 and 6-8 via LDV/IDG-like motifs, similar to some the
α9β1binding sequence (50).

Identification of Scl1 targets within the ECM deposited by cancer-associated
fibroblasts – Tumors have many similarities to healing wounds, including extensive ECM
remodeling (51). ECM deposition and remodeling is due in part to the surrounding stromal
cancer-associated fibroblasts (CAFs) (38,52,53) that deposit EDA/EDB-fibronectins and
TnC (52,54-57). Here, we characterized the extracellular matrix deposited by primary
CAFs as an in vitro model for Scl1 targeting to the tumor microenvironment, expressing
significant amounts of cFn isoforms that contain EDA and/or EDB, and TnC. CAFs were
grown to confluency and were subsequently removed non-proteolytically from deposited
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matrices by EGTA treatment. Matrices were initially visualized using Ponceau S staining,
showing good overall integrity of a complex fibrillary network, without obvious signs of
degradation (Fig. 3A). The composition of the matrices was then assayed by ELISA for
the presence of cFn, EDA, EDB, and TnC, using specific mAbs (Fig. 3B). ELISA data
shows that CAFs deposit ECM that contains 2-7 fold higher levels of cFn with EDA, EDB,
as well as TnC, relative to control BSA background. Matrices were also visualized using
immunofluorescent staining of the specific distribution of ECM components with the same
mAbs, used in the ELISA. Immunofluorescence imaging revealed a significant presence
of cFn isoforms that contain EDA and EDB, as well as the presence of TnC within CAFdeposited ECM (Fig. 3C). We conclude that we developed a suitable in vitro model to test
Scl1 binding to complex extracellular matrices potentially akin to those generated by
fibroblasts in wounds and the tumor microenvironment.
Scl1 mediates GAS targeting to cancer-associated fibroblast-derived ECM – We first
visualized and quantified the GFP-expressing WT and isogenic M1Δscl1 and M41Δscl1
mutant cells adherence to glass coverslips, containing CAF-deposited matrices, after 1hour incubation (Fig. 4A). More fluorescent M1- and M41-WT GAS were seen adhered to
the CAF-derived ECM on coverslips than their respective M1Δscl1 and M41Δscl1 mutants
(Fig. 4A, left). The quantification of attached cells revealed that significantly fewer of the
M1Δscl1 mutant cells, by ~70%, bound the matrices, compared to the WT strain; similarly,
the M41Δscl1 mutant bound the matrices ~80% less than the WT strain (Fig. 4A, right).
Therefore, our results show that GAS adheres to the ECM deposited by CAFs, and this
attachment is mediated through Scl1.
We next investigated if Scl1 expression facilitates GAS biofilm formation on the
CAF-deposited matrix, using crystal violet staining and confocal fluorescence microscopy
(Fig. 4B-C). Crystal violet staining of 24-hour bacterial biomass formed on CAF-derived
ECM detected significantly more of both M1 and M41 WT GAS, compared to their
respective M1Δscl1 and M41Δscl1 mutants (Fig. 4B). In addition, we compared biofilm
thicknesses formed on CAF-derived ECM by GAS M41 WT and M41Δscl1 mutant strains
(Fig. 4C). As expected, the M41 WT GAS formed biofilms that averaged 20 µm in
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thickness, while M41Δscl1 mutant strain had a 40% decrease in thickness, averaging 12
µm.
Scl1 mediates GAS colonization of matrix deposited by osteosarcoma cells – In
1891, Dr. William B. Coley injected inoperable osteosarcomas with live group A
streptococci and observed tumor shrinkage and increased survival in some patients (minireview by (58)). While the likely success of Coley’s treatment was principally due to the
stimulation of immune responses by GAS within tumors (59,60), it is possible that Scl1
indirectly, although relevantly, contributed to treatment success by promoting GAS to
colonize the microenvironment of osteosarcomas. Here, we applied the same in vitro
model as above, but using Saos-2 osteosarcoma cell line (61). Saos-2 cells were grown
to confluency; cells were removed from the matrices that were visualized by Ponceau S
staining (Fig. 5A) and characterized for ECM composition by ELISA (Fig. 5B). As before,
Ponceau S staining showed the formation fibrillary matrix characteristic of Fn and TnC
(Fig. 5A), and ELISA data demonstrated that Saos-2 cells deposited some EDAcontaining cFn, as well as considerable amounts of EDB-rich cFn isoforms and TnC (Fig.
5B), relative to BSA background.
To assess if Scl1 promotes GAS attachment and colonization of Saos-2-deposited
matrices, we performed a 1-hour whole-cell attachment assay, using GFP-expressing M1
and M41 isogenic GAS strains (Fig. 5C). There were more fluorescent M1 and M41 WT
GAS on the Saos-2-deposited matrices than the M1Δscl1mutant and M41Δscl1 mutant
cells (Fig. 5C, top panels). Quantification revealed significant differences in the
attachment between isogenic strain pairs; there was ~80% reduction in the attachment of
the M1Δscl1 mutant and ~90% reduction by the M41Δscl1 GAS (Fig. 5C, bottom graph).
In addition to facilitating GAS attachment, Scl1 contributes to biofilm formation on Saos2-deposited matrices (Fig. 5D). Crystal violet staining after 24 hours showed significantly
larger bacterial biomass grown by both WT strains on Saos-2 matrices, compared with
their respective Δscl1 mutant counterparts (Fig. 5D). In summary, our data demonstrates
that Scl1 targets GAS to colonize the complex ECM deposited by cancer-associated
fibroblasts and osteosarcoma cells.
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DISCUSSION
GAS infections typically start within the wounded portal of entry, which is characterized
by a microenvironment rich in cFn isoforms that contain either EDA and/or EDB, as well
as TnC. Here we report that Scl1 of GAS binds multiple wound-associated ECM targets
that contain FnIII-type repeats and includes EDA and EDB of cFn, as well as FnIII repeats
in TnC (Fig. 6). These interactions occurred through the same conserved binding
mechanism mediated by the Scl1-V domain and facilitated GAS adherence and biofilm
formation.
Group A streptococcal strains may express numerous Fn-binding proteins on the
cell surface and at least 11 distinct Fn adhesins have been reported (reviewed in (62)).
The most common mechanism of Fn binding is via the classical Fn-binding repeats which
are found in several Fn-binding proteins of GAS, such as protein F1/SfbI and F2/PFBP,
serum opacity factor SOF/SfbII, FbaA and FbaB, SfbX, and Fbp54 (63-68). During the
binding process, the Fn-binding repeats of those adhesins, interact with the N-terminal
fibronectin type I repeats (FnI) through a tandem β-zipper mechanism and contribute an
additional anti-parallel β-strand within the

-sheet structure of the FnI repeats (64,69).

Scl1, however, lacks the classical Fn-binding repeats and binds, instead, to the FnIII
repeat EDA, via its globular V domain (22). Scl1-EDA binding mechanism was mediated
by the C-C’ loop of EDA and surface-exposed loops of the Scl1-V domain (19). Here, we
determined that several rScl1 variants, with diverse V-domain sequences, bind to FnIIIderived rEDB polypeptide. Using a series of engineered rScl constructs, we furthermore
showed that Scl1-EDB binding engaged, like EDA binding, the Scl1-V-domain loops and
suggests the same conserved binding mechanism. Homology modeling of EDB and
analysis of the predicted loop sequences imply that the C-C’ loop of EDB is a potential
Scl1-binding target. To our knowledge, Scl1 is the first bacterial adhesin that directly binds
the FnIII-EDB of cFn.
In addition, we show that the Scl1-EDB interaction facilitates GAS biofilm formation
in vitro on rEDB-coated surfaces. The role of EDB in bacterial infections is beginning to
be appreciated. Recently, cFns that include the EDB segment were shown to be
upregulated in the cerebral spinal fluid and serum of patients suffering from
Staphylococcus aureus meningitis (70). EDB-containing cFns in these patients were
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released by immune cells during phagocytosis of S. aureus and enhanced bacterial
removal by phagocytic cells. Phagocytosis of S. aureus in vitro was augmented by the
addition of exogenous EDB/cFn, which activated the αvβ3 integrin on phagocytic cells.
However, it was not shown if S. aureus adhered directly to EDB (70). Similarly, EDA/cFn
isoforms were shown to be elevated in a post-surgical bacteremia model in sheep;
however, the role of EDA/cFn in facilitating phagocytosis was not investigated (71).
Other bacterial adhesins may also bind to EDA and/or EDB, like Tp0155 of
Treponema pallidum and YadA of Yersinia spp. (72). The outer envelope protein Tp0155
of T. pallidum displayed a selective binding to cFn (referred to in text as insoluble matrix
fibronectin), but not plasma pFn, which contributed to T. pallidum host-cell adhesion (73).
YadA of Y. pseudotuberculosis and Y. enterocolitica also demonstrated preferential
binding to cFn, promoting bacterial cell entry (74,75). Further investigations are needed
to assess EDA/cFn and/or EDB/cFn binding by these adhesins.
Two streptococcal proteins have been reported to bind to the FnIII repeats of TnC
(TnFnIII): protein H (76) and protein F2 (77). The M-like protein H binds factor H and IgG,
as well as the neural cell adhesion molecule (N-CAM), which contains FnIII repeats (78).
Protein H binding to N-CAM was competitively inhibited with pFn fragments
encompassing the FnIII repeat region, as well as with two different FnIII-containing
recombinant proteins derived from TnC (76). Protein F2 contains the prototypical
fibronectin-binding repeats, that bind to the N-terminal type I and II repeats of Fn (66,79).
To our knowledge, direct binding to the FnIII repeats in either fibronectin or TnC by F2
protein has not been reported. A recent study showed that a protein F2-deficient mutant
of an M3-GAS strain bound significantly less TnC compared with the wild-type parental
organism, which was restored by in-trans complementation (77). It should be noted that
the M3 strain used in this study, MGAS315, does not express Scl1 adhesin (80). Here we
used defined recombinant TnFnIII fragments, rTnFn1-5 and rTnFn6-8, and show for the
first time that Scl1 binds directly to TnFnIII repeats of TnC.
Cellular fibronectin isoforms and tenascin-C are also present in the tumor
microenvironment. In cancerous tissues, cancer cells activate the surrounding stromal
fibroblasts, known as cancer-associated fibroblasts (CAFs) (38,81,82). Here, we show
that cultured CAFs, isolated from a stage IV laryngeal primary tumor, deposit cFn
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isoforms that contains EDA and/or EDB, as well as TnC in vitro; and that Scl1 facilitates
GAS adherence to and biofilm formation on CAF-deposited ECM preparations. GAS has
a known connection to cancer, as an original and major component of Coley’s toxin
(succinctly reviewed in (58)). Developed by Dr. William Coley, a bone sarcoma surgeon
(1862-1936), Coley’s toxin was the first use of a cancer immunotherapy in medicine
(58,83). Coley and colleagues injected live and killed streptococci to treat patients afflicted
with soft-tissue and bone tumors with relative success (84). Interestingly, we now know
that osteosarcoma cells upregulate cFn isoforms that contain EDA and/or EDB, and TnC
expression (85-87). Here we used model osteosarcoma Saos-2 cells to produce matrices
containing the cFn isoforms that contain EDA and/or EDB, as well as TnC. Scl1 promoted
GAS colonization and biofilm formation on osteosarcoma-derived matrices. This work
adds a new dimension to the history of Coley’s toxin, through the capacity of the Scl1
adhesin to target ECM proteins that are present within the tumor microenvironment; this
provides a previously unrealized feature in the utilization of GAS in the potential treatment
of cancer (59,60).
Understanding of the GAS-fibronectin interaction has evolved since our finding that
the GAS adhesin, Scl1, selectively binds to cFn, but not pFn, (21) via unique mechanism
involving the cFn type III repeat, EDA (19,22). Here, we demonstrate that Scl1 also binds
to EDB in isoforms of cFn, as well as to the FnIII repeats within TnC. All three ECM ligands
are expressed within wounded tissue, which is typically the first site GAS encounters
within the host. In each case, surface-exposed loops of the globular sequence-variable
but structurally-conserved V-domain of Scl1 were responsible for ligand recognition and
binding. The Scl1 adhesin improves GAS adherence and biofilm formation on
extracellular matrices rich in cFn isoforms that contain EDA and/or EDB, and TnC.
Interestingly, the aforementioned ECM components are also constituents of tumor
microenvironments and our initial experiments suggest Scl1 has the capacity for targeting
tumors. In summary, the Scl1-V domain has evolved within the wound microenvironment,
driven by selection for binding to multiple ECM components containing FnIII repeats.
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EXPERIMENTAL PROCEDURES
Bacterial strains and growth – Group A Streptococcus (GAS) strains MGAS5005-M1
and MGAS6183-M41, as well as their scl1-inactivated isogenic mutants were used in this
study (88,89);Lukomski, 2000 #119973;Han, 2006 #119967}. Briefly, both mutants were
generated by allelic replacement with nonpolar resistance cassettes, encoding
spectinomycin (MGAS5005 Δscl1) and erythromycin (MGAS6183 Δscl1) resistance. GAS
cultures were grown at 37ºC, with 5% CO2 in Todd-Hewitt broth supplemented with 0.2%
yeast extract, and on Brain Heart Infusion (BHI) agar. For GAS antibiotic selection,
erythromycin (4 µg ml-1), chloramphenicol (5-10 µg ml-1), and spectinomycin (100 µg ml1)

were added to the medium.

Complementation of M1 group A Streptococcus – To complement MGAS5005 Δscl1
with either scl1.1 or scl.chi2 in-trans, the E.coli shuttle vector pSB207 was used (90).
Briefly, a DNA fragment, encompassing the scl1.1 coding sequence with upstream
promoter, was PCR-amplified from genomic DNA and cloned into pSB207, generating
plasmid pSL620 (19). A synthetic double-stranded DNA fragment (gBlocks; Integrated
DNA Technologies) encoding the scl.chi2 coding sequence was cloned into pSB620,
generating pSL621 (19). Clones were verified by sequencing and were then introduced
into MGAS5005 Δscl1 mutant; transformants were selected on BHI agar containing 10 µg
ml-1 chloramphenicol and GAS cultures were routinely grown in THY broth with 10 µg ml1

chloramphenicol.

Recombinant protein production – Production of recombinant streptococcal collagenlike proteins (rScls). Gene cloning and rScl-protein production were performed in
Escherichia coli DH5a, TB1 and BL-21 strains grown in Luria-Bertani (LB) media with
ampicillin (100 µg ml-1) at 37ºC. rScl-encoding clones, which were derived from the
original scl alleles, were generated by PCR amplification from GAS genomic DNA and
cloned into the E.coli expression vector pASK-IBA2(15) (16). Clones encoding the
chimeric rScl proteins were generated using synthetic double-stranded DNA fragments
(gBlocks; Integrated DNA Technologies), as described previously (19). All plasmids were
verified by DNA sequencing.
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All rScl proteins were generated using the Strep-tag II cloning, expression, and
purification system (IBA-GmbH). Proteins were expressed with a C-terminal affinity tag
and purified on Strep-Tactin sepharose, as described (15,16). The rScl1.1 protein is
derived from Scl1 protein in M1-type strain MGAS6708 (15); rScl1.28 originates from M28
strain MGAS6274 (15), rScl1.41 is derived from M41 strain MGAS6183 (91), rScl1.3 is
derived from M3 strain MGAS315 (80), rScl1.12 is derived from an M12 strain MGAS6139
(16), rScl1.2 is derived from an M2 strain MGAS3803 (92), and rScl2.4 is derived from
M4 strain MGAS321 (16). Both naturally-derived and chimeric rScl proteins were
expressed in E. coli BL21 periplasm following induction with anhydrotetracycline at 0.2
µg mL-1 for 3 hours. Cells were centrifuged and suspended either in high sucrose buffer
(100mM Tris-HCl, 1 mM EDTA, pH 8.0, 500mM sucrose) or Cell Lytic B Buffer (Sigma),
for separation of the periplasmic fraction and subsequent affinity purification. Purified
proteins were analyzed by SDS-PAGE and stained with RAPIDstainTM; proteins were
dialyzed against 25 mM HEPES, pH 8.0, and stored at -20oC. Protein concentrations were
determined using Qubit fluorometric quantitation.
Recombinant extra domain B (rEDB) production – rEDB was produced using the pQE30 His-tag cloning, expression, and purification system in the E. coli strain JM-109, as
described elsewhere (93). EDB-encoding segment was amplified by PCR from rat cDNA
and cloned into pQE-30; the resulting construct was a gift from Dr. John Peters. Protein
expression was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside for 3 hours.
Cells were harvested by centrifugation, and pellets were frozen at -20oC for 2 hours or
overnight. Cells were next suspended in a bacterial lysis buffer (50 mM Tris/HCL pH 8.0,
50 mM NaCl, 2 mM MgCl2, 2% Triton X-100, 10 mM β-mercaptoethanol, 0.2 mg/ml
lysozyme, 1 EDTA-free protease inhibitor cocktail tablet [per 10 mL], 1 mM
phenylmethane sulfonyl fluoride, 10 U ml DNaseI) and incubated on ice for 20 minutes.
Cell lysate was centrifuged at high speed (16000g x 20 minutes) and supernatant was
collected. Supernatant was mixed 1:1 volumetrically with wash buffer (50 mM NaH 2PO4,
10 mM imidazole, 300 mM NaCl), added to 1 ml of cobalt-agarose resin, and then poured
into a column. Sample was washed 10x resin bed volume with wash buffer, and then
rEDB protein was eluted in elution buffer (50 mM NaH2PO4, 150 mM imidazole, 300 mM
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NaCl). Purified protein was dialyzed against 25 mM HEPES buffer, pH 8.0 and stored at
-20oC until future use. Protein integrity and purity were assessed by 18% SDS-PAGE and
concentration was measured with Qubit fluorometric quantitation.
Recombinant tenascin-C fibronectin type III fragments (rTnFnIII) – Recombinant
tenascin-C fibronectin type III (FnIII) fragments: repeats 1-5, (rTnFn1-5), repeats 6-8,
(rTnFn6-8), or repeat 3 (rTnFn3) were produced after recloning into pQE-30 His-tag
vector in the E. coli strain XL1-blue. Sequences for each fragment were PCR-amplified
from the original constructs cloned in pET15b (rTnFn1-5 and rTnFn6-8) or pET11b
(rTnFn3) expression vectors (provided by Dr. Harold P. Erickson)(94). Recombinant
proteins were expressed, purified, and stored as described above with rEDB.
Homology modeling of, EDA, EDB, and TnFnIII domains – The homology models of
tenascin-C domains from 1 to 5 (TnFn1-5) and from 6 to 8 (TnFn6-8) were obtained after
consensus-based sequence alignment using the profile hidden Markov models (profile
HMMs) implemented in the program HHpred (95). For TnFn1-5, best template model was
identified as the structure of the recombinant four-domain fragment FnIII 7B89 (PDB code
3t1w, seqid 27.7% with repeats 1-3 and 25.2% with repeats 2-5). In the case of TnFn6-8,
best template was the structure of human fibronectin domains 12-14 (PDB code 3r8q,
seqid 34.9%). Once the best templates were identified, homology models were built with
MODELLER (95). Stereo chemical quality of predicted models was improved by energy
minimization using GROMACS (96). Validation of the structural quality of predicted
models was carried out using the PDBsum database at PROCHECK server
(http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/).
Protein binding assays – rScl proteins (0.5 µM solutions) were immobilized onto StrepTactin-coated microplate wells for 1.5 h at room temperature and blocked with 1xTBS (25
mM Tris, 150 mM sodium chloride, pH 7.4) supplemented with 1% fetal bovine serum
albumin overnight at 4ºC, followed by incubation with ECM ligands: rEDB, tenascin-C
(TnC) purified from glioblastoma cells (Sigma), rTnFn1-5, rTnFn6-8, and rTnFn3. The no
rScl controls were performed in BSA-coated wells for each ligand and each antibody
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used. Final OD values were normalized by subtracting the BSA controls in each
experimental set-up. ECM ligands were added to the rScl-immobilized wells at 1 µg per
well (except for TnC, incubated at 0.5 µg per well) and incubated at room temperature for
1 hour. Bound rECM ligands were detected with monoclonal antibodies (mAbs): anti-Histag for rEDA and rEDB (Proteintech; 1:1000), anti-TnC BC-24, specific for the epidermal
growth factor-like repeats, (ThermoFisher; 1:1000), followed by goat anti-mouse
secondary

antibody

conjugated

to

horseradish

peroxidase

(HRP)

(Jackson

ImmunoResearch; 1:1000). The HRP substrate, 2,20-azino-bis(3-ethylbenzthiazoline-6sulphonic acid) (ThermoFisher; ABTS) was used and colorimetric reactions were
recorded at OD415 nm.

Eukaryotic cell assays
Isolation of cancer-associated fibroblasts (CAFs) – CAFs were isolated from a stage
IV laryngeal cancer resection obtained from the West Virginia University Pathology
Laboratory for Translational Medicine in compliance with approved Institutional Review
Board protocol #1310105737A033 as described previously (97). Briefly, tissue was
submerged in DMEM/10% FBS containing 1% penicillin-streptomycin-amphotericin B (PS-A) (Millipore, 51610420ML) and mechanically digested. Tissue pieces <2 mm were
placed into a 24-well plate, allowed to adhere for 2-3 min, then covered with media and
placed in a humidified 37°C incubator with 5% CO2. Emanating CAFs were cultured in
DMEM supplemented with 10% FBS/1% P-S-A, passaged 2-3 times with Accumax
(Millipore, SCR006) until acclimated, then passaged with 0.25% trypsin and grown in
DMEM/10% FBS. CAFs were passaged 5 times before being cryopreserved. Thawed
CAFs were passaged 2 times prior to use.
Preparation of cancer-cell-derived extracellular matrices – Cancer-associated
fibroblasts (CAFs) and the osteosarcoma cell line Saos-2 (ATCC® HTB-85) were used to
produce cell-derived extracellular matrices. Matrices were prepared, as described
previously (22), Briefly, CAFs and Saos-2 cells were cultured in high-glucose Dulbecco’s
Modified Eagle Medium with 10% fetal bovine serum and 1% penicillin and streptomycin
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at 37ºC in an atmosphere of 5% CO2 throughout the experiment. To produce the
extracellular matrix for specific tests, cells were grown as follows: (i) for matrix
characterization via immunofluorescence or for GFP expressing GAS (GFP-GAS)
attachment assays, cells were grown on 15-mm glass coverslips inserted into wells of
(24-well) tissue culture plates, and (ii) for crystal violet biofilm assay, matrix
characterization by ELISA or by Ponceau S staining, cells were growth in plastic wells
without glass coverslips. Cells were seeded at 50,000 cells per well, grown until confluent,
and then removed through treatment with 5 mM ethylene glycol tetraacetic acid (EGTA).
Samples were washed gently with PBS and wells or coverslips were subsequently used
for assessment.

Cell-derived ECM matrix characterization
Ponceau S staining – To visualize the matrices deposited by CAFs and Saos-2 cells,
Ponceau S solution (0.1% in 5% acetic acid solution) was added to the wells for 20
minutes. Stain was then removed, and wells were examined microscopically using a Zeiss
Axiovert 40 CFL microscope with a 20x objective. Image acquisition was done using the
Zeiss AxioCam Mrc5 camera and images analyzed with Zeiss AxioVision 4.8 software.
Matrix characterization by ELISA – CAFs- and Saos-2-derived matrices were prepared,
as above, and wells were blocked overnight with 1% bovine serum albumin in 1X TBS.
The next day, the following mAbs were added to wells for 1 hour at room temperature:
anti-fibronectin, specific for the fourth fibronectin type III repeat of fibronectin, (Sigma;
IST4, 1:1000), anti-EDA (Santa Cruz Biotechnology; IST9, 1:1000), anti-EDB containing
cFn (Sirius Biotechnology; C6, 1:500), or BC-24, (1:1000); a goat anti-mouse secondary
antibody conjugated with HRP (1:2000) was added for 1 hour, washed, and then
developed with ABTS substrate. Each antibody was used in triplicate wells, over 3
different experiments. Wells with secondary antibody only were used for background
correction.
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Matrix characterization by immunofluorescence microscopy – To visualize the
matrices deposited on glass coverslips, wells were denuded of cells and blocked
overnight at 4ºC with 1% BSA/TBS. Anti-ECM antibodies: IST4 (1:100), IST9 (1:200), C6
(1:100) and BC-24 (1:1000) were added to wells for 1 hour at room temperature, washed
with TBS, followed by addition of goat anti-mouse secondary Ab conjugated with Alexa
Fluor 568® (Thermofisher, 1:300). Coverslips were then washed and mounted in ProLong
Gold (Invitrogen). Matrices were visualized using a Nikon A1R confocal microscope
equipped with a 60x objective. Images were processed using Nikon NIS-Elements
Software.

GAS attachment and biofilm assays
Scl1 surface expression and rEDB binding by flow cytometry – Determination of Sclsurface expression by GAS cells, as well as rEDB binding to whole-GAS cells were
measured by flow cytometry. Bacteria were grown to an OD600 of 0.5, harvested by
centrifugation and washed with flow cytometry buffer (phosphate-buffered saline
containing 10% Todd-Hewitt broth with 0.2% yeast extract). For Scl-surface detection, the
anti-Scl1.1-V antibody (11), pre-absorbed with MGAS5005 Δscl1 cells, was incubated
with GAS cells for 30 minutes on ice. Cells were next washed and incubated with
Allophycocyanin

(APC)-conjugated

donkey

anti-rabbit

antibody

(Jackson

ImmunoResearch; 1:150). For ligand binding, GAS cells tested were incubated with rEDB
for 30 minutes at room temperature. GAS cells were then centrifuged and washed 2x with
flow cytometry buffer. Bound protein was detected with anti-His-tag mAb (1:750), followed
by a goat anti-mouse secondary pAb conjugated with Alexa Fluor® 568 (1:150). Cells
were washed, fixed in 0.4% paraformaldehyde and analyzed. 50,000 events were
collected per sample using a BD LSRFortessa flow cytometer and data were analyzed
with FCS Express Flow 6 software.
GAS whole-cell attachment assay – GFP-GAS adherence was studied on glass
coverslips with rEDB coating and on cancer-cell-derived matrices, as described (21). 1
ml of GFP-GAS cultures, prepared as above, were seeded into wells and incubated for 1
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hour at 37ºC, washed with PBS, fixed with 3% paraformaldehyde for 30 minutes, and then
mounted in ProLong Gold overnight. The total number of GAS cells were counted in 10
arbitrary fields and the numbers of WT M1 or M41 GAS cells were set as 100%. The
differences between WT and isogenic

scl1 mutants were evaluated statistically.

Crystal violet staining of GAS biofilms – GAS biofilm formation was tested on rEDBcoated surfaces and on cancer-cell-derived matrices. Wild-type and isogenic scl1 mutant
GAS strains were grown to an OD600 of 0.5 and 1-ml aliquots were seeded into 24-well
culture plates coated either with rEDB (2 µg/well) or in wells containing CAF- or Saos-2derived extracellular matrices, prepared as above. GAS biofilms were grown for 24 hours,
washed with PBS, and stained with 1% (v/v) crystal violet solution (Becton Dickinson) for
30 minutes at room temperature. Biomass staining was solubilized with 0.5 ml of 90%
ethanol and assessed spectrophotometrically at OD600nm.
Confocal laser scanning microscopy of GAS biofilms – GAS biofilms were also
visualized on glass coverslips coated with rEDB (2 µg) or on cancer-cell-derived matrices,
using isogenic GFP-GAS (21,98). 24-hour biofilms were grown as above, fixed in 3%
paraformaldehyde for 30 minutes, and mounted in ProLong Gold overnight. Biofilms were
imaged using a Nikon A1R confocal microscope, with a 100x objective. Images were
analyzed and deconvoluted using NIS-Elements Software. Conversion to threedimensional images was performed with conventional Z-stacks, deconvoluted stepwise
and transformed using NIS-Elements Software.
Statistical analyses – Statistics were performed using the two-tailed paired Student’s ttest. Significance was denoted at levels of *P ≤0.05, **P ≤0.01, or ***P ≤0.001. Error bars
represent standard deviations with analyses based on three independent experimental
repeats (N=3), each performed in triplicate technical replicates.
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Figure 1. Scl1-EDB binding mediates GAS adherence and biofilm formation. Recombinant fibronectin type
III repeat, extra domain B (rEDB) was tested for binding to recombinant streptococcal collagen-like proteins
(rScl) , as well to whole-GAS cell. Scl1-mediated biofilm formation was studied on rEDB coatings. (A)
Cartoon representations of the EDB and EDA domains of fibronectin. Structures of EDB (grey – adapted
from PDB accession code: 5n48), and EDA (blue – adapted from PDB accession code: 1j8k) are shown in
forward (left) and side (right) views. Left, front view of superimposed β-sandwich structures of EDA and
EDB, with each β-strand marked (A, B, C, C’, E, F, G) and C-C’ loops shown in stick representation. Right,
side view of EDB structure, depicting the C-C’ loop in ball and stick representation. The N- and C-terminal
ends are labeled in both models. (B) Schematic representation of the variable (V) domains in recombinant
Scl constructs used. Homotrimeric rScl1.1-, rScl1.28 (gray box), and rScl2.28-V domains (white box) consist
of three conserved pairs of anti-parallel α-helices, with connecting loops (19). Chimeric proteins were
generated by replacing either the entire (rScl.chi1-3) or partial (rScl.chiC) loop sequences between different
constructs. (C) rEDB binding to naturally-derived and chimeric rScl constructs. rScl proteins were
immobilized onto Strep-Tactin coated microplate wells and incubated with rEDB. Primary anti-His-tag mAb
and HRP-conjugated secondary Ab were used for ligand detection by ELISA. Graph bars indicate the mean
OD415nm normalized against BSA controls. Statistical analysis was calculated using Student’s two-tailed ttest from three independent experiments, each performed in triplicate wells (N=3±SD); *P≤0.05, **P≤0.01.
Statistical significance evaluates the differences in rEDB binding by naturally-derived rScl1 (left 4) and
chimeric proteins (right 4), as compared to ECM-binding-negative rScl2.28 control protein; rEDB binding by
rScl.chi2 was compared to that of rScl1.1. Dashed line indicate threshold OD 415nm +2SD values recorded
for binding-negative rScl2.28 control protein. (D) rEDB binding to whole GAS cells. Isogenic M1- and M41type GAS strains were used, as well as the M1 isogenic Δscl1 mutant complemented for the expression of
Scl1.1 (Δscl1::scl1.1) and Scl.chi2 (Δscl1::scl.chi2) proteins. rEDB binding to whole GAS cells was detected
by flow cytometry with primary anti-His-tag mAb; binding to GAS WT cells was set as 100%. Statistical
analysis was calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD);
*P≤0.05. (E) Assessment of biofilm formation on rEDB-coated surfaces. Isogenic M1- and M41-type GAS
strains were compared. Biofilm formation was evaluated spectrophotometrically following crystal violet
staining. Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was
calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); *P≤0.05. (F)
Microscopy imaging of GAS biofilms formed on rEDB coating. GFP-expressing M1 WT and Δscl1.1 mutant
strains were grown on rEDB-coated glass coverslips for 24 h. Two-dimensional orthogonal views of GAS
biofilms are representative of Z stacks from 10 fields within a single experiment. Average vertical thickness
is indicated in micrometers below two-dimensional orthogonal views, taken from 10 arbitrary fields per
experiment.
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Figure 2

Figure 2. Scl1 of GAS binds to the fibronectin type III repeats in tenascin C (TnC). For ligand binding by
ELISA, rScl proteins were immobilized onto Strep-Tactin coated microplate wells and incubated with fulllength TnC (B-C) or recombinant TnC fragments (E) comprising of the fibronectin type III repeats (rTnFnIII).
Primary anti-ECM mAb and HRP-conjugated secondary Ab were used for ligand detection. Graph bars
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indicate the mean OD415nm normalized against BSA controls. Statistical analysis was calculated using
Student’s two-tailed t-test from three independent experiments, each performed in triplicate wells
(N=3±SD); *P≤0.05, **P≤0.01, ***P≤0.001. Statistical significance evaluates the differences in TnC and
rTnFn binding by rScl1 and chimeric proteins, as compared to ECM-binding-negative rScl2.28 control
protein; TnC and rTnFn binding by rScl.chi2 was compared to that of rScl1.1. Dashed line indicate threshold
OD415nm +2SD values recorded for binding-negative rScl2.28 control protein. (A) Schematic representation
of full-length TnC. Depicted are from the N-terminus: assembly domain (triangle), epidermal growth factorlike repeats (ovals), constitutively expressed fibronectin type III repeats 1-5 and 6-8 (light hexagons),
alternatively spliced fibronectin type III repeats (dark hexagons), fibrinogen-related domain (circle). Known
integrin-binding domains are marked above the model. (B) TnC binding to recombinant Scl1- and Scl2derived constructs. rScl panel represents diverse Scl1 and Scl2 variants originating from strains of several
M-types. (C) TnC binding to rScl chimeric proteins. rScl panel represents constructs shown in Fig. 1B-C
and described (19). (D) Cartoon representation of the third fibronectin type III repeat of TnC PDB accession
code: 1TEN). β-strands of the EDB β-sandwich are labelled (A, B, C, C’, D, E, F, G); the B-C loop with LDV
motif and the F-G loop harboring the RGD sequence is shown in dark gray. (E) rScl binding to recombinant
fibronectin type III fragments within TnC. rScl panel represents constructs shown in Fig. 1B-C above and
previously described (19). (F) Cartoon representations of the homology models of the fibronectin type III
repeats 1-5 (orange) and 6-8 (gray) of TnC. Models of (i) TnFn6-8 repeats, and (ii) TnFn1-5 repeats.
Segments harboring the potential LDV-like Scl1-binding motifs are shown in light blue ball and stick
representation. Model of TnFn1-5 based on PDB accession code 3t1w; model of TnFn6-8 based on PDB
accession code 3r8q.
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Figure 3

Figure 3. Characterization of extracellular matrices deposited by cancer-associated fibroblasts (CAFs).
CAFs were isolated from a stage IV laryngeal primary tumor and grown to confluency; matrices were
prepared after the removal of cells by treatment with EGTA. Matrices were evaluated for the presence of
EDA- and EDB-containing fibronectins and TnC. (A) Visualization of the overall structure of ECM deposited
by CAFs. Ponceau S staining reveals complex fibrillary network of the matrices used in this study. (B)
Characterization of the ECM deposited by CAFs by ELISA. The presence of total cFn, EDA/cFn, EDB/cFn,
and TnC was assessed with specific mAbs and secondary HRP-conjugated antibody. Graph bars indicate
the mean OD415nm. Three independent experiments were performed, each with triplicate wells (N=3±SD).
Dashed line indicate threshold OD415nm +2SD values recorded for BSA control wells. (C) Immunofluorescent
visualization of the ECM deposited by CAFs. CAFs were grown on glass coverslips, then cells were
removed from matrices and incubated with primary mAbs specific for cFn, EDA/cFn, EDB/cFn, and TnC,
followed by secondary Ab conjugated with Alexa Fluor® 568. Images were taken using confocal microscope
with 60x objective; representative images are shown from 2 independent experiments, imaging 10 arbitrary
fields per coverslip.
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Figure 4

Figure 4. Scl1-mediated GAS attachment to and biofilm formation on ECM deposited by cancer-derived
fibroblasts. Wild type (WT) GAS strains M1 and M41, and their isogenic Δscl1 mutants were compared for
attachment and biofilm formation. (A) GAS adherence to CAF-derived ECM. Isogenic GFP-GAS strains
were inoculated onto CAF-derived ECM coatings, allowed to attach for 1 hour, and imaged using
fluorescent confocal microscope with 100x objective. Left, representative images of attached GAS were
taken in 10 fields, over three independent experiments. Right, quantification of GAS attachment with WT
binding set as a 100%; bacteria were counted in 10 fields, and the average from all 10-fields was calculated.
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Statistical significance was calculated using Student’s two-tailed t-test from three independent experiments,
each performed in duplicate wells (N=3±SD); **P≤0.01, ***P≤0.001. Statistical analysis evaluates the
difference between adherence to CAF-derived matrices by the WT and their respective isogenic Δscl1
mutants. (B) Assessment of biofilm formation on CAF matrices. Isogenic M1- and M41-type GAS strains
were compared. Biofilm formation was evaluated spectrophotometrically following crystal violet staining.
Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was
calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); *P≤0.05. (C)
Microscopy imaging of GAS biofilms formed on CAF matrices. GFP-expressing M1 WT and Δscl1.1 mutant
strains were grown for 24 h on CAF matrices coated glass coverslips. Two-dimensional orthogonal views
of GAS biofilms are representative of Z stacks from 10 fields within a single experiment. Average vertical
thickness is indicated in micrometers below two-dimensional orthogonal views, taken from 10 arbitrary fields
per experiment.
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Figure 5

Figure 5. Scl1-mediated GAS attachment to and biofilm formation on ECM deposited by bone
osteosarcoma cells. Wild type (WT) GAS strains M1 and M41, and their isogenic Δscl1 mutants were
compared for attachment and biofilm formation on the ECM produced by osteosarcoma Saos-2 cells. (A)
Representative image of Ponceau S staining of ECM network deposited by Saos-2 cells. (B)
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Characterization of the ECM deposited by Saos-2 cells by ELISA. The presence of total cFn, EDA/cFn,
EDB/cFn, and TnC was assessed with specific mAbs and secondary HRP-conjugated antibody. Graph bars
indicate the mean OD415nm. Three independent experiments were performed, each with triplicate wells
(N=3±SD). Dashed line indicate threshold OD415nm +2SD values recorded for BSA control wells. (C) GAS
attachment on Saos-2-derived ECM. Isogenic GFP-GAS strains were inoculated onto Saos-2-derived
matrices, allowed to attach for 1 hour, and imaged using fluorescent confocal microscope with 100x
objective. Top, representative images of attached GAS were taken in 10 fields, over three independent
experiments. Bottom, quantification of GAS attachment with WT binding set as a 100%; bacteria were
counted in 10 fields, and the average from all 10-fields was calculated. Statistical analysis was calculated
using Student’s two-tailed t-test from three independent experiments, each performed in duplicate wells
(N=3±SD); **P≤0.01, ***P≤0.001. Statistical significance evaluates the difference between adherence to
Saos-2-derived matrices by the WT and their respective isogenic Δscl1 mutants. (D) GAS biofilm formation
on Saos-2-derived ECM. Isogenic GAS strains were inoculated onto Saos-2-derived matrices and grown
for 24 hours. Bacterial biomass was evaluated spectrophotometrically following crystal violet staining.
Graphic bars indicate the mean OD600nm normalized against BSA controls. Statistical analysis was
calculated using Student’s two-tailed t-test from three independent experiments (N=3±SD); ***P≤0.001.
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Figure 6

Figure 6. Model of GAS colonization of wound and tumor microenvironments. The wound and tumor
microenvironments are enriched in isoforms of cellular fibronectin (cFn) that contain extra domain A (EDA)
and extra domain B (EDB), as well as monomer of tenascin-C (TnC). Left, GAS gains access to the host
via portal of entry, such as through a breach in keratinized squamous epithelium (SE), into a tissue
environment that contains keratinocytes (KC), basal lamina (BL) ECM, and dermal fibroblasts (DF). Within
wound, cells such as DFs deposit cFn isoforms that contain EDA and EDB, as well as TnC. GAS-Scl1
adhesin binds EDA and EDB of cFn, and TnC within the wound, promoting wound colonization. Right,
Cancer cells (CC) are surrounded by cancer-associated fibroblasts (CAF), which deposit cFn isoforms that
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contain EDA and/or EDB, and TnC, recognized by GAS-Scl1. Enlarged insert, close-up view of the woundand tumor-associated ECM
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DISCUSSION AND PROSPECTS

Our work sought to investigate the interactions between the Scl1 adhesin of GAS and
wound-associated ECM, and the contribution of these interactions to GAS adherence and
host colonization. The work presented in detail within preceding chapters elaborates on
important structural determinants and mechanisms of binding for Scl1 and identifies FnIII
repeats that are associated with the wound microenvironment, as Scl1 targets. In this
chapter, we will selectively discuss our research in the context of important implications,
resulting from Scl1-FnIII binding, in GAS wound colonization and pathogenesis, GAS
targeting, and application to cancer therapies.

Scl1 is a unique Fn-binding adhesin of GAS that adapted to colonize wound
microenvironment
Classical fibronectin-binding proteins of GAS, such as proteins F1 and F2, contain a block
of fibronectin-binding repeats that recognize and bind to Fn type I repeats present in both
pFn and cFn (1). These classical Fn-binding adhesins of GAS bind FnI repeats via a βzipper mechanism, wherein the Fn-binding repeats adopt a β-strand conformation and
then align parallel to the outer most β-strand within the FnI structure (2). Scl1 lacks these
canonical Fn-binding repeats and binds FnIII repeats through a different mechanism. Scl1
interacts with EDA, EDB, and TnFnIII via surface-exposed guiding loops of the Scl1-V
domain that surround a negatively-charged cleft bordered by a crown of positive and
neutral surface charges present in binding-positive Scl1 proteins but not in bindingnegative Scl2 proteins (3). In this regard, Scl1 is similar to streptococcal adhesins, CshA
of S. gordonii and BspA of S. agalactiae, that exploit a “catch-clamp” Fn-binding
mechanism (4,5). In “catch-clamp” binding model, a surface-exposed loop caps the
binding cleft, and guides Fn recognition towards binding cleft. The “catch-clamp” adhesins
and Scl1-V domain share similar electrostatic surface charge distributions. Future
crystallization of Scl1 in complex with FnIII ligand will aim to verify binding mechanism.
Scl1 variants from several different M-types of GAS were shown to selectively bind
cFn, but not pFn (6), and our initial work showed that Scl1 binds EDA (7). Here, I identified
that Scl1 also binds to EDB of cFn, as well as to FnIII repeats of TnC. Two other GAS
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proteins have been reported to bind to the FnIII repeats of TnC and Fn: the protein H, and
protein F2. The M-like protein H binds factor H and IgG, as well as the neural cell adhesion
molecule (N-CAM), which contains FnIII repeats (8). Protein H binding to N-CAM was
competitively inhibited with pFn fragments encompassing the FnIII repeat region, as well
as with two different FnIII-containing recombinant proteins derived from TnC (9). Protein
F2 contains the prototypical Fn-binding repeats (10,11). To our knowledge, direct binding
to the FnIII repeats in either Fn or TnC by F2 protein has not been reported. We, on the
contrary, showed direct binding between rScl1 and rFnIII. Scl1 is, therefore, the only GAS
adhesin with demonstrated binding to EDA, EDB, and to the TnFnIII repeats, which
promotes GAS attachment and biofilm development within the wound. Additional bacterial
adhesins may also bind to EDA and/or EDB, like Tp0155 of Treponema pallidum and
YadA of Yersinia spp. (12). The outer envelope protein Tp0155 of T. pallidum displayed
a selective binding to cFn (referred to in text as insoluble matrix fibronectin), but not
plasma pFn, which contributed to T. pallidum host-cell adhesion (13). YadA of Y.
pseudotuberculosis and Y. enterocolitica also demonstrated preferential binding to cFn,
promoting bacterial cell entry (14,15). Further investigations are needed to assess
EDA/cFn and/or EDB/cFn binding by these adhesins.

EDA/EDB cFn isoforms and TnC are expressed during wound healing and are
accessible to Scl1
Immediately after the initial wounding (portal of entry), platelets deposit EDA and/or EDB
containing cFn isoforms within the wound, as a component of the initial clot and first
provisional matrix during wound healing. These isoforms of cFn are released from
granules that are formed during the development of platelets from megakaryocytes (16).
In addition, TnC circulates at low levels in human blood, and is deposited within the
initial matrix formed during clotting (17,18). Several hours after wounding, fibroblasts
and endothelial cells begin to deposit large amounts of EDA- and/or EDB-containing
cFn isoforms, and TnC, within the wound bed as a transitional provisional matrix,
contributing to proper wound healing (19); macrophages have also been shown to
release EDA containing cFn within the wound bed to signal pro-inflammatory cytokine
release (20). These isoforms of cFn are present within healing tissue for up to 2 weeks
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after wound is healed (19). As we have shown previously (7), and outlined above, Scl1
binds to EDA and EDB isoforms of cFn, and to all splice-variants of TnC via the
constitutively-expressed FnIII repeats of TnC. This may enable GAS to colonize the
immediate wound area (Fig. 1), rather than become invasive and disseminate to other
tissues. As an example, the M3-type GAS strains that are associated with invasive
infections (21,22) lack surface Scl1, due to a null mutation within collagen domain, which
prevents cellular attachment (23). Restoring Scl1-surface expression enables Scl1mediated ECM binding in these strains, enhances biofilm formation on ECM coated
surfaces (24), and decreases overall virulence (25). Therefore, the capacity of Scl1 to
recognize multiple targets within wound microenvironment augments GAS colonization,
while decreasing invasive spread and avoiding killing the host. In addition to adhesion,
we have shown that the Scl1-EDA and -EDB interaction contributes to GAS biofilm
formation in vitro ((7), current work). GAS biofilms are found in both non-invasive and
invasive infections (26,27), and are thought to play an immune evasive role and offer
protection from antibiotics (28,29). Therefore, the Scl1 capacity to recognize and bind
EDA/ and EDB/cFn, and TnC within the wound facilitates enhanced tissue-microcolony
formation (Fig. 1), thus, contributing to the pathogenesis of GAS infections. To examine
the importance of EDA/cFn, EDB/cFn, and TnC in GAS wound-colonization, both in vitro
and in vivo studies can be conducted. Using cell-derived matrices or organotypic
cultures with EDA, EDB, TnC, or combinations of the three, could be used to assess
changes in GAS colonization without these components. Inasmuch as double
EDA/EDB-knockouts are embryonic-lethal, single knockout mouse lines exist for both
EDA and EDB, as well as whole TnC knockout animals (30-32), enabling the study of
EDA, EDB, and TnC during GAS wound infections, assessing differences in wound
colonization.

Scl1 alters human-cell integrin binding to EDA/cFn
EDA and EDB are highly included in cFn isoforms expressed within wound beds and
perform important functions in wound healing (33-36). Inasmuch as, the role of EDA in
wound healing is well defined, limited knowledge exist for EDB. Multiple cells have been
shown to bind to EDA via integrin receptors α9β1, α4β1, and α4β7. EDB, on the contrary, is
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Figure 1: Modulation of host responses by GAS Scl1 during wound colonization. In this model, GAS
gains access to the host via the portal of entry, shown here as a breach in protective epidermis (i.e. skin
and throat mucosa). The wound microenvironment ECM is enriched with extra domains A (EDA) and B
(EDB) containing cellular fibronectin (cFn) isoforms, as well as tenascin-C (TnC). Scl1 binds to EDA/cFn,
EDB/cFn, and TnC within the wound, mediating GAS wound-colonization and biofilm formation. The
globular V-domain of Scl1 binds to the C-C’ loop of EDA. Neutrophils (NT) and keratinocytes (KC) bind to
the C-C’ loop of EDA via integrin receptor α9β1, regulating important wound-healing functions. EDA/cFn
also activates TLR4 on monocytes (MC) and dermal fibroblasts (DF) to stimulate the production of proinflammatory cytokines, TNFα and IL-8, through the NF-κB signaling cascade. The Scl1-EDA/cFn
interaction may alter several important wound-healing functions.

not known to interact with integrin receptors. Both α9β1 and α4β1 bind directly to the C-C’
loop of EDA, and this binding regulates important wound-healing functions. Scl1 binding
102

to EDA was also mapped to the C-C’ loop (7), at or near the binding site of host cell
integrin receptor α9β1 (37). Since Scl1 and integrin α9β1 bind to the same peptide region
of the EDA segment, Scl1 may compete with α9β1 binding to EDA, impacting functions of
cells, such as keratinocytes. To this extent, our preliminary unpublished data suggests
that rScl1 competes in vitro with α9β1 binding to EDA and impedes cell attachment and
spreading. By competing with the host’s integrins, Scl1 binding to EDA/cFn could lead to
alterations of the dynamic wound-healing processes, such as changes in angiogenesis,
dysregulation of α3β1 function, and neutrophil migration to the wound (Fig. 1).
Wound keratinocytes express α9β1, which exerts a “trans-dominant” inhibitory
effect on α3β1 during angiogenesis in healing wounds (36). On keratinocytes, α3β1 binds
to laminin-332, and this binding mediates endothelial cell migration and angiogenesis
through the secretion of growth factors (38,39). Binding of α9β1 to EDA/cFn controls α3β1mediated angiogenesis by modulating growth factor secretion, thereby reducing
endothelial cell migration and leading to increases in endothelial cell apoptosis during the
regression of growing blood vessels (36). Inhibition of α3β1 by α9β1 occurs through
changes in Src-mediated phosphorylation of focal adhesion kinase (36). The temporal
expression of EDA/cFn, during wound healing, suggests that the α 9β1-to-α3β1 integrin
cross-talk is important for controlling the level of angiogenesis. Therefore, Scl1 binding to
EDA/cFn, within the α9β1 binding site, may disrupt this inhibition, leading to dysregulated
α3β1 function (Fig. 1). This could result in: altered angiogenesis, increased keratinocyte
activation and the development of hypertrophic scars (40), or aberrant tissue remodeling
due to ECM production and increased MMP9 secretion (36,41). Future in vitro and in vivo
experiments are needed to test if Scl1 mediates such effects.
In addition to keratinocytes, the β1 integrin receptors on neutrophils play important
roles in inflammation and wound healing. Neutrophils are one of the first immune cells to
enter into infected tissues. Neutrophils have multiple effector functions, such as the
production of reactive-oxygen species, proteases, antimicrobial peptides and cytokines,
as well as killing the pathogens by phagocytosis and via neutrophil extracellular traps
(42). During infection, GAS causes the release of chemoattractants from the site of
infection, into the blood stream that lead to the extravasation of neutrophils from the blood
stream into the interstitial tissue, where they migrate through the ECM to the site of the
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infection (43). The α9β1 expression is upregulated on activated neutrophils, and plays an
essential role during neutrophil extravasation and in interstitial tissue migration (44,45).
The α9β1 integrin acts in concert with β2 integrins during the trans-endothelial movement
of neutrophils from the bloodstream into the interstitial space (46). In vitro studies
demonstrated that the α9β1 integrin receptor significantly contributes to the passage of
neutrophils through human-dermal fibroblast-derived matrices, implicating α9β1 in the
movement of neutrophils through dermal tissue (44). EDA/cFn is highly upregulated in
damaged tissues (33), as well as increased in the blood in a post-surgical bacteria model
in sheep (47); in vitro studies have demonstrated co-localization of fibronectin and α9β1 in
areas of tissue damage in human patients (48). It is possible that the α9β1 integrin receptor
adheres to EDA/cFn during migration through infected tissue, and Scl1 may disrupt this
interaction to block neutrophil migration into damaged tissues (Fig. 1).Experiments
examining neutrophil migration in the presence of Scl1, on ECM coated surfaces could
address this potential impact of Scl1 on neutrophils.

Perturbation of EDB/cFn and TnC function by Scl1 binding
The role of EDB in the wound microenvironment is not well understood, as no integrinbinding sites have been identified directly within EDB. EDB/cFn isoforms are associated
with angiogenesis during fetal development and within healing tissues (49,50). Inclusion
of EDB into cFn has been shown in vitro to contribute to head-to-tail dimerization of Fn,
leading to fibril formation (51). It is possible that Scl1 binding to EDB may block important
sites necessary for head-to-tail dimerization and prevent or delay fibril formation on the
surface of cells. Moreover, EDB inclusion into cFn is known to expose cryptic sites that
are necessary for EDB/cFn attachment to cells (52). Scl1 binding to EDB may alter the
structural conformation of cFn, preventing full-exposure of those cryptic sites in EDB/cFn
isoforms. Other bacterial adhesins that bind to the FnIII repeats of Fn have been shown
to have a such effect on Fn structure (53,54). These potential impacts of Scl1 binding to
EDB/cFn isoforms require further investigations.
Similar to affecting EDA/EDB containing cFn isoforms, TnC plays important
functions in wound healing (outlined in the General Introduction). Scl1 binds within the
FnIII repeats of TnC. The TnFnIII repeats of TnC have been implicated in facilitating
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fibroblast proliferation, fibronectin fibril formation, proteoglycan binding and assembly,
and regulating myofibroblast contracture of wounded tissues (55-58). It is possible that
Scl1 binding to TnFnIII repeats leads to alterations in fibroblast function, proper matrix
assembly, fibrotic tissue development, and wound closure. It is important to note that the
exact motif within the TnFnIII repeat(s) that confers these effects on host cells is not
known. Specifically, the TnFn3 repeat is suggested to be bound by α9β1 receptor on
neutrophils during neutrophil migration to damaged tissue (43). Though our data does not
support rScl1 binding to rTnFn3, it is possible that this lack of rScl1 binding to the
individual rTnFn3 construct is due to structural differences between the individual repeat
and when it is embedded within neighboring TnFnIII repeats (e.g. FnIII repeats 1-5 of
TnC, see Chapter 2). Since the exact binding site(s) within the TnFnIII repeats for Scl1
have not been identified, these concepts require experimental testing.

Scl1-EDA binding inhibits TLR4
TLR4 is a member of the pattern recognition receptors that recognize host- and pathogenassociated molecules linked with damaged and infected tissue, and induce the release of
pro-inflammatory cytokines (59,60). TLR4 is expressed by immune cells such as
monocytes, dendritic cells, as well as endothelial cells and fibroblasts within tissues (60).
On the surface of cells, TLR4 is expressed in complex with two other surface proteins,
CD14 and MD2, which facilitate proper receptor activation and ligand specificity,
respectively (61,62). The major agonist for TLR4 is bacterial LPS; however, several hostderived molecules have also been shown to activate TLR4, including EDA/cFn fragments
(63-65).
During wound healing, one of the critical steps is tissue remodeling, fostered by
matrix metalloproteinases that are secreted by both resident tissue cells and infiltrating
immune cells (66,67). EDA/cFn fragments, generated by this proteolysis, have been
shown to activate TLR4 on dermal fibroblasts, as well as monocytes and dendritic cells
(65,67,68). This interaction induces the NF-κB signaling cascade, promoting proinflammatory responses, such as production of cytokines IL-8 and TNFα (65). In addition
to cytokines, EDA activation of TLR4 on neutrophils and monocytes was shown to
facilitate release of leukotriene B4, a chemoattractant for leukocytes, resulting in
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increased leukocyte migration, both in vitro and in vivo (69). EDA-mediated activation of
TLR4 is dependent on the TLR4-co-receptor, MD-2, and evidence suggests that
activation of TLR4 is enhanced by synergy from neighboring Fn domains (65,67,70).
It is currently not known, whether Scl1 binding to EDA/cFn fragments affects TLR4
function. In such a scenario, Scl1 may inhibit TLR4 activation, leading to a subsequent
reduction in pro-inflammatory cytokines and a reduction of neutrophil infiltration to the site
of infection (Fig. 1). This could serve as a novel Scl1-based mechanism for GAS immune
evasion. To advance this project, I cloned an rFnIII11-EDA fragment, that was previously
shown to stimulate TLR4 in vitro (67), into pET21a expression vector in the ClearColi E.
coli strain, which produces a modified LPS that does not stimulate TLR4 (71). Having an
LPS-free system, will facilitate our laboratory to study whether Scl1 blocks EDA/cFn
mediated TLR4 activation, using an in vitro HEK-blue cell system (67). In vivo animal
experiments, using WT and Scl1 mutant GAS strains could also be performed, looking
for differences in tissue NF-κB activation and differences in cytokines and leukocyte
recruitment in tissues.
Therefore, the Scl1 interaction between EDA and EDB/cFn isoforms, as well as
TnC, raises an exciting prospect that not only does Scl1 facilitate GAS wound
colonization, but colonization of GAS via Scl1 may alter wound healing responses via
competition between Scl1 and host cell receptors.

Utilization of wound-associated ECM proteins to target GAS via Scl1
Currently, GAS infections are treated either with penicillin or erythromycin in patients with
a penicillin allergy (72). Alarmingly, several studies documented penicillin treatment
failure, with up to 30% of pharyngitis patients showing persistence of GAS following
treatment (73-76). These observations underscore the need for new alternative strategies
to treat GAS infection. Considerable efforts have been undertaken by research
laboratories in search of vaccine targets to prevent GAS infections and the development
of a universal GAS vaccine. The immunogenic surface M protein serves as the basis for
most GAS vaccine candidates, as it confers M type-specific immunity (77). Historically,
cross-reactive antibody concerns between M protein and cardiac tissue impeded
development of GAS vaccines for years; however, current methods utilize peptides
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corresponding to the N-terminal hypervariable region, thereby avoiding cross-reactive
portions (78,79). A 26-valent vaccine, which is composed of N-terminal hypervariable
region peptides derived from 26 different M-protein types, has completed stage I/II clinical
trials in the United States (80). Still, other challenges exist, such as the high number of M
protein types, the lack of vaccine protection from throat infections, and differences in Mtype distribution across the globe (81,82). Antibodies against the Scl1 antigen were
produced by humans and in experimental animals (83). In general, anti-Scl1 antibodies
could be opsonic or may well block the interactions between Scl1 and EDA/cFn, thus,
preventing GAS colonization. Although infection with GAS can lead to the production of
anti-Scl1 antibodies, others have found that recombinant Scl-based collagen proteins are
non-immunogenic (84). Variability of the amino acid sequence of the Scl1 V-domain
would face challenges similar to those concerning the M protein-based vaccine.
Therefore, alternative targeting strategies utilizing Scl1 recognition by EDA, EDB, or
TnFnIII fragments could overcome the aforementioned hurdles.

EDA-derived peptides for GAS targeting
Of the known Scl1 ligands, the C-C’ loop of EDA is the best studied peptide sequence
and can potentially serve as a targeting strategy for Scl1. Inasmuch as utilizing peptides
derived from the C-C’ loop of EDA is a rational premise for treating GAS infections, there
are significant challenges that need to be overcome. First, the binding affinities between
C-C’-loop circular peptide and two different recombinant Scl1 variants, originating from
M1- and M3-type GAS, were in a range of 40–60 µM KD, as estimated through surface
plasmon resonance and tryptophan fluorescence binding assays ((24,85) appendix 2 and
3). This binding is relatively weak, especially when compared with the binding affinity of
an antibody, typically in the nM range, and mutagenesis approach may improve the
binding affinity. Second, off-target binding effects of the C-C’ loop peptide directly to host
cell integrin receptor α9β1 could lead to dysregulation of the dynamic wound-healing
processes, such as dysregulation in tissue angiogenesis (Fig. 1). Alternatively, peptides
derived from EDB could be used in targeting Scl1 on GAS. Third, although all strains carry
the scl1 gene, a small subset of strains do not express Scl1, such as M3-type GAS (24).
In these strains, however, Scl2 protein would serve as an alternative target. Fourth, the
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C-C’ loop-peptide could increase bacterial spread via microcolony dispersion.
Nevertheless, sessile GAS cells will be susceptible to drugs or C-C’ loop-derived peptide
conjugated to an antimicrobial peptide, like LL-37 (86,87). A similar strategy, utilizing
peptides derived from EDB and/or TnFnIII repeats to target Scl1 would be feasible.

Anti-Scl1 FnIII-based monobodies for GAS targeting
Alternatively to the utilization of EDA-derived peptides, the whole EDA or a modified FnIII
repeat, known as a monobody (88), could be used in targeting Scl1. Monobodies are
protein constructs that utilize FnIII scaffolds to achieve specific protein binding, as they
share structural homology to the antigen recognition region of antibodies (Fig. 2), and
serve as an alternative to antibodies (89,90). While commonly used in medicine,
monoclonal antibodies are large in size (~150 kDa) limiting their tissue distribution;
Moreover, monoclonal antibodies are complex to produce (91). Monobodies, however,
are much smaller (~10-20 kDa) enabling effective tissue distribution, are less complex to
produce, and can exhibit nM and pM affinities to their designed targets, similar to
monoclonal antibodies (91-93). The surface exposed loops within the monobody (Fig. 2)
serve as the ligand-recognition site and can be engineered to bind a multitude of epitopes
(90). Monobodies serve as diagnostic and therapeutic tools, often via the conjugation of
markers or drugs (94). Originally, monobodies were developed using the FnIII repeat
number 10 from fibronectin (95), however, monobodies derived from other fibronectin
FnIII repeats of both Fn and TnC are currently undergoing clinical trials (94). The EDB of
cFn could serve as a monobody to target GAS via Scl1, as it offers the benefit of reduced
off-target binding, compared to EDA, which has the potential to bind to cells expressing
integrin receptors α4β1, α4β7, α9β1, as well as stimulate TLR4. Conversely, EDA may serve
as the preferential monobody, as the Scl1-binding site and potential binding affinities have
been delineated (7,24). The EDA or EDB-derived monobody can be conjugated directly
to antimicrobial peptides or anti-microbials to treat GAS infection, localizing antibiotics to
the site of GAS infection, reducing impacts on the microbiome.
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Figure 2: Monobodies to target GAS via Scl1-. A) Cartoon representation of the fibronectin
type III (FnIII) repeat, extra domain B (EDB), from cellular fibronectin (PDB accession code:
2GEE); showing the fibronectin-type III repeat β-sandwich structure, with each β-strands
marked (A, B, C, C’, D, E, F). Loops of EDB that share similar orientation to the antigenbinding domain of single-chain antibodies are highlighted in blue B) Cartoon representation
of the antigen-binding domain of a camelid heavy-chain antibody (VHH; PDB accession code:
1ZVY); showing that both EDB and the antigen-binding domain of antibodies consist of a
FnIII repeat structure. The antigen-recognition sites are highlighted in blue. C) Schematic,
depicting the rationale behind monobody targeting of group A Streptococcus (GAS) via the
streptococcal collagen-like 1 (Scl1) surface adhesin. Due to shared structures, FnIII repeats
can be engineered to as antibody mimics. Scl1 binds to isoforms of cellular fibronectin that
contain EDA, EDB, as well as tenascin-C (TnC), which are associated-with the wound
microenvironment. During host wound colonization, EDB-derived monobodies that are
conjugated to anti-microbial peptides (e.g. LL-37,in red) can be administered to wound to
target and kill GAS.

Implications of Scl1 in cancer targeting
Isoforms of cFn that contain EDA and/or EDB, as well as TnC, are expressed in different
types of cancer, such as prostate cancer, colorectal cancer, head and neck squamous
cell carcinoma, cervical cancer, and lung cancer (96-101). Expression and deposition of
EDA/EDB cFn isoforms, and TnC, is predominantly done by the surrounding stromal cells,
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primarily by cancer-associated fibroblasts (CAFs)/myofibroblasts, but also by endothelial
cells during neovascularization of growing tumors (102,103). Some cancer cells will
directly produce EDA/EDB cFn, but TnC has been shown to be directly deposited on the
invasive edge of malignant cancer cells and is found to be deposited in newly localized
metastatic cancers (104,105). Current research supports a model where cancer
progression is driven by the surrounding cancer microenvironment, rather than intrinsic
cancer cell factors (106), as expression of these ECM proteins by CAFs is linked to
several important pathological mechanisms of cancer, such as the epithelial to
mesenchymal transition, cell proliferation, and metastasis (107,108). Epidemiological
studies have found that patients with elevated deposition of EDA/EDB cFn isoforms or
TnC within their tumors have lower survival rates compared to patients with lower levels
of EDA and EDB cFn isoforms and TnC (109,110). Thus, these ECM substrates are
unique targets for the delivery of diagnostics and therapeutics to the tumor sites. Several
research groups and companies across the world have developed monoclonal antibodydrug conjugates, peptides and aptamers to target EDA/EDB cFn isoforms and to TnC for
such purposes (111,112). We have shown that Scl1 specifically targets EDA/EDB, and
the FnIII repeats of TnC within the matrices deposited by CAFs (Fig. 3). Thus, Scl1 offers
similar potential as a biomolecule for the selective recognition and targeting of GAS or
Scl1-functionalized nanomaterials to cancerous tissue.

GAS infection in cancer immunotherapy
GAS has a historical connection with cancers, particularly sarcomas, as it was noted since
the early 1800s that patients who develop erysipelas, commonly caused by GAS,
demonstrated shrinkage of their tumors (113). Currently, there is interest in using
microbes in the treatment of cancer. Microbes offer advantages to traditional
chemotherapies, as they can be engineered to favorably colonize the tumor
microenvironment and lead to the death of cancer cells either directly through toxin
production or indirectly via immune stimulation (113). While there is renewed interest in
the utilization of GAS as a cancer-therapy, showing promise in the treatment of pancreatic
cancer in a murine model (114,115), there are still fears of the development of
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Figure 3. Specificity of Scl1-mediated GAS attachment to cancer-associated fibroblast
matrices. Wild type (WT) M41 was pre-incubated with recombinant ECM ligands prior to attachment
to CAF-derived ECM. GFP-WT M41 GAS were pre-incubated with recombinantly expressed extra
domain A, extra domain B, and fibronectin type III repeats of tenascin-C, for 30 minutes prior to
inoculation onto CAF-derived ECM coatings. GAS were allowed to attach for 1 hour and then
subsequently imaged using fluorescent confocal microscope with 100x objective. Images were taken
in 10 random fields over three experiments. Top, representative images Bottom, quantification of GAS
attachment with WT binding set as 100%; bacteria were counted in 30 fields, and the average from all
30-fields was calculated. Percentage based on the average number of counted bacteria for the parental
WT strain. Statistical significance was calculated using a one-way ANOVA from three independent
experiments, each performed in duplicate wells (N=3±SD); **P≤0.01, ***P≤0.001. Statistical analysis
evaluates the difference in adherence between WT GAS and WT GAS pre-incubated with ECM. Each
symbol represents one image.

autoimmune sequalae, such as rheumatic fever, in patients treated with GAS. Other
candidate bacteria do not share this concern, such as a Salmonella typhimurium and
Clostridium novyi, and treatments are under development or in clinical trials to evaluate
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their efficacy (116,117). Yet, significant challenges remain in the utilization of these
candidate bacteria in the treatment of cancer, such as the improved bacterial colonization
and retention within the cancer tissues and the development of multi-tissue specific
bacteria that can target metastatic cancers (113).

rScl1-functionalized nanoparticles for cancer diagnostics and treatment
Another approach is the use of rScl1 proteins as targeting biomolecules on the surface of
nanoparticles for targeted drug delivery to cancer tissues. Nanomaterials offer unique
advantages, due to their size, durability, surface area, and composition, relative to

Figure 4: Hybrid rScl protein in nanoparticle delivery to tumors.
Schematic of the design and intended use of recombinant hybrid streptococcal
collagen-like protein 1 (rScl.hyb1) in the delivery of nanoparticles to tumors
via recognition of tumor-associated extracellular matrix proteins, isoforms of
cellular fibronectin (cFn) that contain extra domains A (EDA) and/or B (EDB),
and tenascin-C (TnC), as well as integrin receptors α2β1 and α11β1 expressed
around and on tumor cells.
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bacteria. Moreover, nanoparticles do not pose the same off-target infection risks as
bacterial-based cancer immunotherapies. Nanoparticles can be loaded with drugs (e.g.
doxorubicin) or biologicals (e.g. siRNA) for delivery to cancer cells (118,119). However,
one of the major challenges to nanoparticle cancer therapy is the lack of localization and
retention of particles within the cancer microenvironment. This is due in part to the lack
of targets unique to the cancer microenvironment, not present healthy tissue (106).
Targeting EDA/EDB cFn isoforms and TnC, using rScl-based proteins may solve this
problem. Other groups have developed aptamers and antibodies that target these ECM
proteins with the same goal in mind, some of which have been conjugated to
nanomaterials (111,119,120). Scl-derived proteins may have superior features, like 1)
Scl1 proteins bind multiple cancer-associated ligands, thereby reducing the number of
different biomolecules needed to be conjugated to a nanomaterial, and 2) the potential to
target integrin receptors on tumor cells through incorporation of the α2β1 and α11β1
recognition motif (e.g. GLPGER) into the CL-domain of Scl proteins (121). As a part of
my IGERT research, I helped engineer a hybrid rScl protein (rScl.hybrid1; Fig. 4) that
possess both the EDA/EDB and TnC binding site in the V-domain, as well as integrin
recognition sequences within the CL-domain. This hybrid protein rScl.hybrid1 offers the
potential to target TnC, as well as EDA/cFn and EDB/cFn isoforms, highly expressed
within and around tumor/cancerous tissues, as well as promote internalization via integrin
receptors α2β1 and α11β1 (Fig. 4)(122,123).

Overall Conclusions
My work identified important structural determinants that facilitate Scl1 ligand-binding,
highlighting a binding mechanism that is unique relative to the other Fn-binding proteins
of GAS. In addition, I discovered that Scl1 binds to the FnIII repeats, EDB of cFn, as well
as to the FnIII repeats within TnC, increasing the number of known targets for Scl1 that
are associated with the wound microenvironment. My work adds new evidence in support
that Scl1 is a wound-adapted adhesin for GAS.
As GAS is a human-obligate pathogen, it has co-evolved with us over time, evident
through the plethora of virulence factors that GAS employs during pathogenesis to
facilitate host colonization (124). Scl1 is a major GAS adhesin, and is under the regulation
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of one of the major transcriptional regulators, Mga, which controls the expression of
several other key GAS virulence factors (23,125-129). Scl1 is expressed by almost every
M type studied (23), and as a surface protein, Scl1 is under selective pressure which
results in sequence variation within the Scl1-V domain across different M-types of GAS
(23). Yet, despite this sequence variation, Scl1 proteins from across different M-types
maintain the capacity to bind to EDA, EDB, and TnC, underscoring both the evolution of
this adhesin for host adaptation and the importance of these ligands for GAS. The first
environment GAS will typically encounter within our bodies is wounded tissue. This
selective binding of Scl1 to FnIII repeats that are highly associated with wounded tissue,
in addition to the conservation of this interactions across phylogenetically-diverse M
types, serves as strong evidence that Scl1 has adapted to the wound microenvironment,
contributing to GAS wound colonization.
The work presented here lays the foundation for several future directions to take
research pertaining to Scl1, having implications in the development of strategies to target
GAS using FnIII monobody, or the use of Scl1 proteins in targeting cancers for drug
delivery. Ultimately, the strongest implications of this research are in the roles the Scl1EDA/EDB/TnC interactions play in GAS pathogenesis, altering host wound healing and
in mediating GAS wound colonization.
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APPENDIX 1: SUPPLEMENTARY MATERIAL FOR CHAPTER 1
SURFACE-EXPOSED LOOPS AND AN ACIDIC PATCH IN THE SCL1 PROTEIN OF
GROUP A STREPTOCOCCUS ENABLE SCL1 BINDING TO WOUND-ASSOCIATED
FIBRONECTIN
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Table S1: Synthetic double stranded DNA blocks (gBlocks) and primer nucleotide
sequences used in this study.

gBlock - pSL600 [rScl.chi1]
ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGATGAACAAGAAGAG
AAAGCTAAAGTTAGAACTGAATTAATTCAAGAGTTAGCTCAGAAATATCCAGAAG
TGTCCAATGAGAAATTTTGGGAAAGAAAGTGGTATGGAACCTATTTTAAAGAATT
AACATACCTACAGGAACGAGAACAAGCTGAGAATAGTTGGCGAAAAAGACTACT
AAAGGGTATACAAGATCATGCCCTTGATGGTCTCGCTGGTAAA
gBlock - pSL613 [rScl.chi2]
ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGAGGTTTCTTCTACGA
CTATGACGTCGAGTCAAAGAGAGTCAAAAATAAAAGAGATCGAAGAAAGTCTTAA
AGGACTAGGGGGTATTGAGAAAAAAAATTTTCCAACTCTAGGTGATGAAGATTTA
GATCATACTTATATGACAAAGCTAGAAGATTTTCAAAAGGAGCTAAAAGATTTTAC
TGAGAAGAGGCTTAAGGAGATTCTAGATTTAATTGGTAAATCTGGAATCAAGGGA
GACCGCGG
gBlock - pSL614 [rScl.chi3]
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ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGATGAACAAGAAGAG
AAAGCTAAAGTTAGAACTGAATTAATTCAAGAGTTAGCTCAGAAAGAATATCCAAA
AGCGTCTGAGGAAAAATTTTGGGAGAGTAGCTTTTGGGGAAGAAGGTACTTTAAT
GAATTAACATACCTACAGGAACGAGAACAAGCTGAGAATAGTTGGCGAAAAAGA
CTACTAAAGGGTATACAAGATCATGCCCTTGATGGTCTCGCTGGTAAA
gBlock - pSL601 [rScl.chiN]
ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGATGAACAAGAAGAG
AAAGCTAAAGTTAGAACTGAATTAATTCAAGAGTTAGCTCAGAAATATCCAGAAG
TGTCCAATGAGAAATTTTGGACTCTAGGTGATGAAGATTTAGATCATACTTATTTA
ACATACCTACAGGAACGAGAACAAGCTGAGAATAGTTGGCGAAAAAGACTACTA
AAGGGTATACAAGATCATGCCCTTGATGGTCTCGCTGGTAAA
gBlock - pSL602 [rScl.chiC]
ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGATGAACAAGAAGAG
AAAGCTAAAGTTAGAACTGAATTAATTCAAGAGTTAGCTCAGGGACTAGGGGGTA
TTGAGAAAAAAAATTTTCCAGAAAGAAAGTGGTATGGAACCTATTTTAAAGAATTA
ACATACCTACAGGAACGAGAACAAGCTGAGAATAGTTGGCGAAAAAGACTACTA
AAGGGTATACAAGATCATGCCCTTGATGGTCTCGCTGGTAAA
gBlock - pSL603 [rScl.chiI]
ACACCATCGAATGGCCAGATGATTAATTCCTAATTTTTGTTGACACTCTATCATTG
ATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAATGAATAGTTC
GACAAAAATCTAGATAACGAGGGCAAAAAATGAAAAAGACAGCTATCGCGATTG
CAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCGATGAACAAGAAGAG
AAAGCTAAAGTTAGAACTGAATTAATTCAAGAGTTAGCTCAGGGACTAGGGGGTA
TTTCCAATGAGAAATTTTGGGAAAGAAAGTGGTATTTAGATCATACTTATATGTTA
ACATACCTACAGGAACGAGAACAAGCTGAGAATAGTTGGCGAAAAAGACTACTA
AAGGGTATACAAGATCATGCCCTTGATGGTCTCGCTGGTAAA
gBlock – pSL621 [Trans-complementation Scl.chi2]
CTCACCTTTTTCACCAGCTTTACCTTGGATTCCTTGCTCACCGCGGTCACCTTTA
GGACCTTGGGCGCCCCTCTCACCAGTTTTACCTTGTGGTCCGGCTGGGCCAGC
AGGACCAGTCTCACCACGGTCTCCCTTGATTCCAGATTTACCAATTAAATCTAGA
ATCTCCTTAAGCCTCTTCTCAGTAAAATCTTTTAGCTCCTTTTGAAAATCTTCTAG
CTTTGTCATATAAGTATGATCTAAATCTTCATCACCTAGAGTTGGAAAATTTTTTTT
CTCAATACCCCCTAGTCCTTTAAGACTTTCTTCGATCTCTTTTATTTTTGACTCTCT
TTGACTCGACGTCATAGTCGTAGAAGAAACCTCAGCCTTAACGCTGCTTGCCCC
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GCCTCCAAAGGcTAGAAGGACGGCAGCGGCTGAGGTTAGCCCGTAGCGCCAGA
CTAGTTTGTTGAGATTATGGTGCTTTGATGTC

Primer – pSL600_insert_1F
ACACCATCGAATGGCCAGATG
Primer – pSL600_insert_1R
TTTACCAGCGAGACCATCAAGG
Primer – pSL609_2R
CCGCGGTCTCCCTTGATTCCA
(rScl.chi): recombinant chimeric streptococcal collagen-like protein.
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APPENDIX 2: MINI-REVIEW
STREPTOCOCCAL COLLAGEN-LIKE PROTEIN 1 BINDS WOUND FIBRONECTIN:
IMPLICATIONS IN PATHOGEN TARGETING
McNitt DH, Van De Water L, Marasco D, Berisio R, Lukomski S
Published in Current Medicinal Chemistry 2018: Epub ahead of print

(Publication was part of invited review on biomarkers of disease. I wrote on the merits of utilizing the
streptococcal collagen-like proteins 1 and 2 as biomarkers for group A Streptococcus infections)

ABSTRACT
Group A Streptococcus (GAS) infections are responsible for significant morbidity and
mortality worldwide. The outlook for an effective global vaccine is reduced because of
significant antigenic variation among GAS strains worldwide. Other challenges in GAS
therapy include the lack of common access to antibiotics in developing countries, as well
as allergy to and treatment failures with penicillin and increasing erythromycin resistance
in the industrialized world. At the portal of entry, GAS binds to newly deposited
extracellular matrix, which is rich in cellular fibronectin isoforms with extra domain A (EDA,
also termed EIIIA) via the surface adhesin, the streptococcal collagen-like protein 1
(Scl1). Recombinant Scl1 constructs, derived from diverse GAS strains, bind the EDA
loop segment situated between the C and C’ β-strands. Despite the sequence diversity
in Scl1 proteins, multiple sequence alignments and secondary structure predictions of
Scl1 variants, as well as crystallography and homology modeling studies, point to a
conserved mechanism of Scl1-EDA binding. We propose that targeting this interaction
may prevent the progression of infection. A synthetic cyclic peptide, derived from the EDA
C-C’ loop, binds to recombinant Scl1 with a micromolar dissociation constant. This review
highlights the current concept of EDA binding to Scl1 and provides incentives to exploit
this binding to treat GAS infections and wound colonization.
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1. INTRODUCTION
“A biomarker is any measurement reflecting an interaction between a biological system
and a potential hazard, which may be chemical, physical, or biological. The measured
response may be functional and physiological, biochemical at the cellular level, or a
molecular interaction.” (1). In the case of pathogens, typical biomarkers are genes or
surface proteins/components that are expressed during the infection. Biomarker
identification and characterization aid in the understanding of pathogenesis and can be
used for diagnosis or treatment (2), e.g., the surface adhesin HBHA of Mycobacterium
tuberculosis, as biomarker to distinguish between latent and active tuberculosis infections
(3). The identification of novel biomarkers is a compelling need for many bacterial
pathogens, including highly virulent bioterrorism threat pathogens, such as Francisella
tularensis and Burkholderia spp. (4,5), or pathogens with antibiotic resistance concerns,
such as Staphylococcus aureus and group A Streptococcus (6).
Group A Streptococcus (GAS) is a human-adapted pathogen that is responsible
for over 700 million infections worldwide each year (7). Diseases linked to GAS infection
range in severity from non-invasive superficial pharyngitis and impetigo to severe and
invasive diseases like necrotizing fasciitis or streptococcal toxic shock syndrome (7).
Additionally, post-infectious autoimmune sequelae include rheumatic fever and rheumatic
heart disease, acute poststreptococcal glomerulonephritis, and pediatric autoimmune
neurologic disorder associated with streptococci, also known as PANDAS (8-10). Invasive
and autoimmune diseases account for approximately 500,000 deaths globally each year
(7). GAS can transiently colonize barrier tissue sites, such as throat mucosa and the
surface of the skin (11). When the barrier is breached, the resultant wound provides GAS
with a portal of entry into host tissues and the interstitium. Once inside the wound, GAS
adheres to exposed extracellular matrix (ECM) and cells, thus enabling colonization of
the host. These essential first steps of infection that are critical to colonization are
augmented by several GAS surface adhesins, such as a prominent GAS surface adhesin
and key virulence factor, the M protein (12). DNA sequence encoding the outermost
amino-terminal end of the M protein is hypervariable and is used for GAS typing, resulting
in more than 220 emm types of GAS reported globally (13). Two other major GAS surface
proteins are the streptococcal collagen-like proteins 1 (Scl1/SclA) and 2 (Scl2/SclB),
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which are ubiquitous among GAS strains (14-18). In vitro assays and animal model
experiments show that Scl1 contributes to host colonization and biofilm formation within
tissues by binding to host extracellular matrix proteins, cellular fibronectin (cFn), and
laminin (19,20). Scl1 binds to wound-enriched isoforms of cFn, containing the extra
domain A (EDA, also termed EIIIA), which is a unique target and distinct from other GAS
fibronectin adhesins (21). The ubiquitous presence of Scl1 in GAS strains across different
M types and the distinctive binding to the EDA/cFn isoforms within the wound
microenvironment make Scl1 a potential biomarker for GAS infections.
GAS infections are initially identified in physician’s offices, using a Rapid Antigen
Detecting Test based on the original Lancefield’s concept to detect group A carbohydrate
surface antigen (22). More recent methods target nucleic acids, such as GASDirect
hybridization test, which identifies rRNA sequences specific to S. pyogenes in tissue
swabs (23), and a PCR-based method was developed to detect GAS within clinical
isolates (24); more information can be found elsewhere (25). In this review, we will discuss
the merit of Scl1 and Scl2 proteins as potential GAS biomarkers, their unique functions in
GAS pathogenesis, and strategies to utilize the Scl1-EDA interaction to target diverse
and epidemiologically important GAS M types. The long-term goal is to disrupt wound
colonization and prevent the spread of infection.

2. SCL1 AND SCL2 AS BIOMARKERS OF GAS INFECTION
A hallmark of a pathogen biomarkers is that it is expressed by all strains of the organism
and during critical stages of infection. Both scl1 and scl2 genes have been identified in
many epidemiologically important M types of GAS (14-17,26). scl1 expression is
positively regulated by the multiple-gene regulator, Mga (14,15,27). Mga is a major
virulence-associated transcriptional regulator expressed in all GAS strains (28-31). It
controls the expression of key GAS virulence factors, including the M and M-like proteins,
C5a peptidase, Sic, and Scl1 (14,15,32-34). Elevated transcription of scl1 has been found
in GAS isolates from both non-invasive and invasive infections (26,35), underscoring the
premise of Scl1 as a biomarker. Unlike Scl1, expression of full-length Scl2 protein is
controlled during polypeptide translation by phase variation, which is associated with
varying numbers of pentanucleotide CAAAA repeats located downstream of the scl2-start
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codon (15-17). Like scl1, scl2 transcription has been observed during GAS infection, but
protein expression varies between strains due to the aforementioned phase variation
(15,36). The invasive M3-type GAS strains (37-39) show elevated levels of scl2
transcripts and low levels of scl1 transcripts, compared with strains of several other M
types (40). Therefore, Scl2 protein is a better biomarker in M3 organisms.
Detection of specific antibodies elicited during infection is commonly used in
diagnostic assays. Host seroconversion to Scl1 and Scl2 antigens has been documented
in humans and experimental murine models. Convalescent and acute-phase sera were
positive for anti-Scl1 and anti-Scl2 antibodies following infections with M1-type and M28type strains. M1 GAS is a global pandemic M type, linked with both noninvasive and
invasive infections across the globe (41,42). M28 GAS strains have historically been
associated with puerperal sepsis and neonatal infections (43-45), but also with current
cases of pharyngitis and invasive infections worldwide (46-49). Retrospective
examination of sera from patients with known previous infection by M1 GAS strains
detected anti-Scl1 antibodies in 64% of samples (50). Examination of acute and
convalescent sera from pediatric patients with non-invasive M1 and M28 GAS infections
identified broad presence of anti-Scl1 antibodies, whereas anti-Scl2 antibodies
associated with M28 infections were detected with lower frequency; the Scl2 antigen is
not expressed in M1 GAS strains due to an off-phase effect associated with CAAAA
repeats (15,40). Others have reported the presence of both anti-Scl1 and anti-Scl2
antibodies in patient sera infected by GAS strains of various M types that were collected
from cases of pharyngitis and impetigo, as well as acute rheumatic fever (51)1.
Interestingly, antibody levels against Scl1 and Scl2 antigens in patients suffering from
severe and invasive infections (toxic shock and necrotizing fasciitis) with M1, M3, and
M28 GAS were significantly lower than in patients with non-severe bacteremia,
suggesting that humoral adaptive immunity plays an important role in the protection
against severe invasive diseases (52). In murine models of pharyngitis and impetigo, mice
administered intranasally and subcutaneously, respectively, with M1 and M28 strains
seroconverted to Scl1

1

antigen,

apparently expressed

SL unpublished data
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during infections

(50).

Comparatively, there was moderate seroconversion for Scl2 antigen in mice infected with
M28 GAS. Altogether, utilization of anti-Scl1 and anti-Scl2 antibodies as biomarkers
depends on the type of GAS infection (e.g., throat versus skin infection and superficial
versus invasive infection). Furthermore, variation in the primary Scl1 and Scl2 sequences
across GAS strains pose additional diagnostic challenge. Alternative approaches, utilizing
ligands that target Scl1 and Scl2 variants in multiple M types could circumvent these
challenges.
2.1. SCL1 AND SCL2 STRUCTURE
Both Scl1 and Scl2 proteins have similar structural organization (53) (Figure 1A). Both
are homotrimeric, with an N-terminal globular, sequence-variable (V) domain, followed by
the collagen-like (CL) domain and a C-terminal cell wall-anchoring domain. The CL
domain of both Scl1 and Scl2 is composed of varying numbers of Gly-Xaa-Yaa collagen
repeats, analogous to triple-helical mammalian collagen (54,55). Structurally, the triple
helix is a motif characterized by the association of three distinct polypeptide chains
wrapped around a common axis, where each chain assumes a polyproline-II (PPII)-type
conformation (56-59). However, the CL domain does not contain hydroxyproline, which
provides the main stabilizing contribution to triple-helix structure in mammalian collagens
(60-64). Indeed, bacteria lack the prolyl-hydroxylase, an enzyme necessary for posttranslational modification of Pro to Hyp. Despite the lack of Hyp, however, Scl1- and Scl2CL domains form triple-helix structures with a stability ranging between 35 and 40ºC,
similar to mammalian collagens (54,65-68). Instead, alternative stabilization mechanisms
are employed in bacteria that secure triple-helix stability, such as hydration networks,
electrostatic interactions between side chains, and specific stabilization repeats (55,68).
The primary sequences of V domains differ both between and within Scl1 and Scl2
variants originating from strains of different M types (53). Despite sequence differences,
secondary-structure prediction algorithms identified two conserved α-helices interspaced
by a hypervariable segment (14,69). This prediction was validated by crystallography data
of the recombinant protein, corresponding to the Scl2-V domain from an M3-type GAS
(70,71) (Figure 1A). The crystal structure showed that the Scl2-V domain folds into a
trimeric six-helical bundle, forming a cylinder that is 30 Å in diameter and 60 Å in height,
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which is stabilized by a hydrophobic core and salt bridges. The inner core of this bundle
consists of a parallel, trimeric structure in which helices are wrapped in a gradual lefthanded superhelix. Three further helices wrap antiparallel to the internal helices in a lefthanded direction around the exterior of the central trimer. The pairs of anti-parallel αhelices are each connected with PPII-type loop segments. Structural and biophysical data
suggested that V domains of Scls display dichotomous functions by first acting as triplehelix stabilization domains through facilitating proper folding and refolding of the collagen
triple-helix (72) and second, by mediating host-pathogen interaction (73-75).
Consistently, recombinant collagen-domain constructs cannot refold following thermal
denaturation (54,72).
This crystal structure served as the basis for homology models of sequencediverse Scl1- and Scl2-V domains (76) (Figure 1B). Homology models predicted with
confidence that both the Scl1- and Scl2-V domains adopt similar six-helical bundle
structures, where a flexible loop segment connects each α-helix pair. Crystal structure
and homology models revealed two important features found in Scl1- and Scl2-V domains
that are essential for EDA-fibronectin binding. First, the electrostatic potential surface of
ligand-binding-positive Scl1 protein displays a negatively charged region in the center of
the Scl1-V trimer, which is surrounded by neutral and positively charged residues. In
contrast, the electrostatic surface of the binding-negative Scl2 protein displays a uniform
negative surface charge throughout the crown of the Scl2-V domain (76). The
arrangement of the electrostatic surface potential observed in the Scl1-V domains was
associated with a pattern of conserved negatively charged amino acids, primarily E46,
47(Scl1.1)

and D48(Scl1.1), located at the C-terminus of the loop sequence at the junction with

the α-helices forming the inner core of the Scl1.1-V bundle. Second, productive ligand
binding is further due to the surface-exposed loops of the Scl1-V domain. Surfaceexposed loops and a characteristic distribution of charged residues are proposed as the
key molecular determinants that generate the long-range interactions needed for ligand
recognition and binding.
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2.2. FIBRONECTIN WITHIN THE WOUND MICROENVIRONMENT
Scl1 binds to several ligands found in tissue and blood, compared with Scl2; the latter’s
function in GAS pathogenesis is less clear (reviewed in (53)). The collagen domain of
Scl1 can bind and activate human collagen integrin receptors (73,74,77), whereas the V
domain is responsible for the majority of ligand binding (19,69,77-80). Interestingly, Scl1
mutants of M1-type GAS were attenuated in a mouse skin infection model, but not
following intraperitoneal inoculation(18), conceivably due to differences in the capacity to
evade innate immune defenses between wild type and mutant strains (18,81). In contrast,
Scl1 mutants of two other M types exhibited increased lesion size in mouse skin (40).
Here we focus on the interaction between Scl1 protein and the human ECM protein,
cellular fibronectin (19,21).
GAS utilizes a wounded portal of entry to gain access to host tissues, initiating host
colonization and subsequent infection. One of the essential measures during wound
healing is the deposition of new distinct matrices that participate in tissue remodeling and
signal pro-inflammatory responses. These complex processes engage macrophages and
neutrophils in clearing out tissue debris and keratinocytes in facilitating wound closure
(82,83). One of the major constituents of these matrices is fibronectin (Fn) (84-86). Fn is
a high-molecular weight glycoprotein that exists in two main forms within the body, e.g.,
as a plasma fibronectin (pFn) secreted by hepatocytes into the blood stream and as a
cellular fibronectin (cFn) secreted by cells within tissues (87). Both forms of fibronectin
originate from the same gene, FN1, and are composed of three different types of
repeating domains: types I, II, and III (87,88)(Figure 2A). cFn-mRNA can be alternatively
spliced, resulting in more than 20 different isoforms found within the body (88-90). This
alternative splicing leads to the inclusion of extra domains that are found in cFn, but not
pFn. The alternatively spliced type III domains are known as extra domain A (EDA/EIIIA)
and extra domain B (EDB/EIIIB), as well as different combinations of the type III
connecting segment (IIICS), also known as the variable domain (90). The EDA-containing
cFn isoforms (EDA/cFn) are highly expressed during embryonic development but only at
negligible levels within healthy adult tissues (91-93). On the other hand, EDA/cFn
isoforms are deposited in high quantities within inflamed and wounded tissue
environments in adults and play essential roles in wound healing (92,94-96). EDA adopts
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the prototypical type III repeat structure, which is composed of two β-sheets, forming a βsandwich consisting of seven β-strands (i.e. A, B, C, C’, D, E, and F) connected by loop
segments (97,98)(Figure 2B). An important role for EDA/cFn within wounded tissue is to
support host cell attachment, achieved by the interactions between the C-C’ loop of EDA
and cellular integrin receptors, α9β1 and α4β1, as well as α4β7, which binds EDA by an
unknown mechanism (99-101). Integrin α9β1 is upregulated by keratinocytes during tissue
injury (94,102). Integrins α9β1, α4β1, and α4β7 through their attachment to EDA/cFn
regulate important repair mechanisms, such as cell migration, angiogenesis,
myofibroblast

differentiation,

growth

factor

secretion,

and

tissue

remodeling

(94,96,101,103,104).
Wound keratinocytes express α9β1, which exerts a “trans-dominant” inhibitory
effect on α3β1 during angiogenesis in healing wounds (96). On keratinocytes, α3β1 binds
to laminin-332, and this binding mediates endothelial cell migration and angiogenesis
through the secretion of growth factors (105,106). Binding of α9β1 to EDA/cFn controls
α3β1-mediated angiogenesis by modulating growth factor secretion, thereby reducing
endothelial cell migration and survival during angiogenesis (96). Inhibition of α3β1 by α9β1
occurs through changes in Src-mediated phosphorylation of focal adhesion kinase (96).
The temporal expression of EDA/cFn, during wound healing, suggests that the α9β1-toα3β1 integrin cross-talk is important for controlling the level of angiogenesis. Given that
Scl1 and integrin α9β1 bind to the same peptide region of the EDA segment, these findings
suggest that α3β1-mediated effects in keratinocytes could be perturbed by Scl1-mediated
streptococcal adhesion.
One of the critical steps of wound healing is tissue remodeling, which is fostered
by matrix metalloproteinases, which are secreted by both resident tissue cells and
infiltrating immune cells (86,107). EDA/cFn fragments generated by this proteolysis
activate toll-like receptor 4 (TLR4) on dermal fibroblasts, as well as monocytes and
dendritic cells (101,107,108). This interaction induces the NF-κB signaling cascade,
promoting pro-inflammatory responses, such as production of cytokines IL-8 and TNFα
(108). EDA-mediated activation of TLR4 is dependent on the TLR4-co-receptor, MD-2,
and evidence suggests that activation of TLR4 is enhanced by synergy from neighboring
Fn domains (107-109).
135

2.3. SCL1 BINDING TO WOUND FIBRONECTIN
The Scl1 proteins of several different M types of GAS bind to the C-C’ loop of EDA,
promoting GAS wound-specific recognition and tissue microcolony (in vivo biofilm)
formation (21). The Scl1-EDA interaction is different from other fibronectin-binding
proteins of GAS, such as PrtF1 and F2, Fba, FBp54, etc. These proteins bind to the Nterminal fibronectin module composed of type I repeats, which is found in both pFn and
cFn (110-113) (Figure 2A). Adherence to the N-terminal type I repeats occurs through a
β-zipper mechanism, where the adhesin contributes an additional β-strand to one of the
β-sheets of the type I Fn repeat (112). In contrast, Scl1 binding to the type III repeat of
cFn, the EDA, engages the surface-exposed loops and negatively charged cleft of the
Scl1-V domain (76).
Although not demonstrated experimentally, the Scl1-EDA/cFn interaction may alter
normal wound-healing responses. First, Scl1 binding to EDA was mapped to the C-C’
loop (21) at or near the binding site of interaction with host cell integrin receptor α 9β1 (99).
By competing with the host’s integrins, Scl1 binding to EDA/cFn could lead to alterations
of the dynamic wound-healing process, such as changes in angiogenesis (Figure 3). In
addition, Scl1 could prevent or delay the formation of fibrosis by blocking α 4β1-mediated
attachment to EDA/cFn. It is currently not known, whether Scl1 binding to EDA affects
TLR4 function. In such a scenario, Scl1 action could reduce the production of proinflammatory cytokines and infiltration of neutrophils to the site of infection, thereby
adding a new immune evasion strategy to the GAS repertoire (Figure 3). Ongoing
experiments will test this hypothesis. Altogether, Scl1 plays essential roles in the
pathogenesis of GAS and has the potential to alter host functions during infection.

3. DIFFERENT STRATEGIES FOR TARGETING GAS INFECTIONS
Currently, GAS infections are treated either with penicillin or erythromycin in patients with
a penicillin allergy (114). Alarmingly, several studies documented penicillin treatment
failure, with up to 30% of pharyngitis patients showing persistence of GAS following
treatment (115-117). Additionally, there is an increasing frequency of erythromycin
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resistance among GAS strains circulating in the industrialized world (118,119), again
underscoring the need for new alternative strategies to treat GAS infection.
Considerable efforts have been undertaken by research laboratories in search of
vaccine targets to prevent GAS infections and the development of a universal GAS
vaccine. The immunogenic surface M protein serves as the basis for most GAS vaccine
candidates, as it confers M type-specific immunity (120). Historically, cross-reactive
antibody concerns between M protein and cardiac tissue impeded development of GAS
vaccines for years; however, current methods utilize peptides corresponding to the Nterminal hypervariable region, thereby avoiding autoreactive portions (121,122). A 26valent vaccine, which is composed of N-terminal hypervariable region peptides derived
from 26 different M-protein types, has completed stage I/II clinical trials in the United
States (123). Still, other challenges exist, such as the high number of M protein types,
the lack of vaccine protection from throat infections, and differences in M-type distribution
across the globe (124,125).
Antibodies against the Scl1 antigen may possibly be developed as a strategy to
treat GAS infections. In general, anti-Scl1 antibodies could be opsonic or may well block
the interactions between Scl1 and EDA/cFn, thus, preventing GAS colonization. Although
infection with GAS can lead to the production of anti-Scl1 cross-reactive autoantibodies
(outlined in section 2), others have found that recombinant Scl1-based collagen proteins
are non-immunogenic (126). Variability of the amino acid sequence of the Scl1 V-domain
would face challenges similar to those concerning the M protein-based vaccine.
Therefore, targeting GAS with C-C’ loop-derived peptides could hypothetically overcome
this hurdle.
3.1. POTENTIAL PROBLEMS AND SOLUTIONS
Inasmuch as utilizing peptides derived from the C-C’ loop of EDA is a rational premise for
treating GAS infections, there are significant challenges that need to be overcome.

3.1.1. BINDING AFFINITIES
First, the binding affinities between C-C’-loop circular peptide and two different
recombinant Scl1 variants, originating from M1- and M3-type GAS, were in a range of
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40–60 µM KD, as estimated through surface plasmon resonance and tryptophan
fluorescence binding assays (Fig. 2 C) (40). This binding is relatively weak, especially
when compared with the binding affinity of an antibody. EDA-derived peptides can be
improved for Scl1 binding by first systematically determining the minimum amino acids
involved in the critical binding, using alanine scanning mutagenesis. After the minimum
pharmacophore is found, then synthetic modifications of peptidomimetics can be
generated and tested for binding; these compounds will incorporate natural and unnatural
amino acids (e.g., D-amino acid, α-α-disubstituted amino acids, macrocycles, etc.) (127129).

3.1.2. OFF-TARGET BINDING EFFCTS
Second, off-target binding effects of the C-C’ loop peptide directly to host cell integrin
receptor α9β1 could lead to dysregulation of the dynamic wound-healing processes, such
as dysregulation in tissue angiogenesis (Figure 3). To address these challenges, the
optimized C-C’ loop peptide must be tested for the potential recognition by host cell
integrins and other receptors.

3.1.3. STRAINS THAT DO NOT EXPRESS SCL1
Third, although all strains carry the scl1 gene, a small subset of strains do not express
Scl1, such as M3-type GAS (40). In these strains, however, Scl2 protein would serve as
an alternative target.

3.1.4. INCREASED INVASIVENESS
Fourth, the C-C’ loop-peptide could increase bacterial spread via microcolony dispersion.
Nevertheless, sessile GAS cells will be susceptible to drugs or C-C’ loop-derived peptide
conjugated to an antimicrobial peptide, like LL-37 (130,131).

4. CONCLUSIONS
 The scl1 and scl2 genes are found in every strain of GAS, and both Scl1 and Scl2
proteins elicit humoral immunity during infection. These factors make Scl1 and Scl2
promising biomarkers of GAS infection.
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 The Scl1-V domain structure is conserved among diverse GAS M types, and several
rScl1 constructs bind to the C-C’ loop of EDA through the same mechanism. The
conserved Scl1 structure and function in strains of epidemiologically important M types
serve as the foundation for effective targeting of GAS.
 EDA/cFn is highly upregulated within wounded tissues and plays important healing
roles. Scl1 binds to the C-C’ loop of EDA, and this interaction stimulates wound-specific
colonization of GAS, by facilitating pathogen adherence and tissue microcolony
formation. Scl1 binding probably impedes the important wound-healing functions that are
normally executed by EDA/cFn isoforms
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FIGURES
Figure 1

Figure 1: Scl1 and Scl2 structure. (A) Top, Schematic representation of the common domain organization
of Scl1 and Scl2 proteins. Domains: V, the N-terminal globular sequence-variable domain; CL, the collagenlike domain; G+, the C-terminal cell-wall-anchor domain. Bottom insert, Cartoon representation of Scl2-VCL structure. This structure has been obtained by combining the crystal structure of the Scl2-V domain,
with the modeled structure of the CL domain, generated using the structure of the collagen peptide (ProPro-Gly)10 as a template; only the first 15 Gly-X-Y repeats is shown for clarity. (B), Homology model of the
Scl1-V domain. Left, Side view of the Scl1-V domain, showing the six-helix bundle fold, with three pairs of
anti-parallel α-helices and connecting loop segments. The N-terminus and C-terminus of a single
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representative α-helix pair is marked. Right, Top-down view of the Scl1-V domain. The three helix-pairs are
shown, wrapped in a left-handed orientation. Negatively-charged amino acids, and their positions within the
Scl1-V domain, are marked. These residues are conserved in EDA-binding-positive Scl1 proteins. The
homology model is based on the crystal structure of the Scl2-V domain originating from M3-type group A
Streptococcus (PDB accession code: 4nsm).
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Figure 2

Figure 2: Scl1 binds to cellular fibronectin that contains extra domain A. Schematic of fibronectin,
model of EDA, and fluorescence binding data between C-C’ loop peptide and recombinant Scl1 (rScl1)
proteins. (A) Schematic of fibronectin, with fibronectin type I, II, and III repeat domains denoted by squares,
ovals, and hexagons, respectively. Regular Fn domains are shown in light grey and are numbered,
constitutively, whereas alternatively spliced extra domains A, B and IIICS are shown in dark gray. Scl1EDA binding is marked with an arrow and binding regions for several GAS Fn-binding proteins (PrtF1,
FbaA, SOF, etc.) are also indicated. (B) Cartoon representation of the EDA domain of fibronectin. Model
(PDB accession code: 1J8K) shows the β-sandwich structure, with each β-strand marked (A, B, C, C’, D,
E, F); the C-C’ loop is shown in ball-and-stick style and the corresponding amino acid sequence is shown
below. (C) Binding assay based on tryptophan fluorescence for the Scl1-EDA interaction. Binding was
assessed between a synthetic C-C’ loop-derived cyclic peptide and recombinant Scl1 forms derived from
M1 (Scl1.1V) and M3-type (Scl1.3V) GAS. Tryptophan fluorescence quenching analysis shows the doseresponse curve of the fluorescence values for both Scl1.1V and Scl1.3V at 333 nm versus the concentration
of C-C’ cyclic peptide.
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Figure 3: Modulation of host responses by GAS Scl1 during wound colonization. In this model, GAS
gains access to the host via the portal of entry, shown here as a breach in protective epidermis (i.e. skin
and throat mucosa). The wound microenvironment ECM is enriched with EDA/cFn isoforms. The globular
V domain of Scl1 binds to the C-C’ loop of EDA, facilitating GAS biofilm formation and wound colonization.
Neutrophils (NT) and keratinocytes (KC) bind to the C-C’ loop of EDA via integrin receptor α9β1, regulating
important wound-healing functions. EDA/cFn also activates TLR4 on monocytes (MC) and dermal
fibroblasts (DF) to stimulate the production of pro-inflammatory cytokines, TNFα and IL-8, through the NFκB signaling cascade. The Scl1-EDA/cFn interaction may alter several important wound-healing functions.
Designed C-C’ loop-derived peptides could prevent GAS wound colonization and reverse potentially
adverse effects of the Scl1-EDA/cFn interaction.
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(Publication demonstrated that the lack of surface expression of Scl1 from M3 serotype of group A
Streptococcus contributes to the invasiveness of this M type. I constructed and assisted in the
construction of two plasmids used in this study - pSl503, pSL514)

ABSTRACT
The streptococcal collagen-like proteins 1 and 2 (Scl1 and Scl2) are major surface
adhesins that are ubiquitous among group A Streptococcus (GAS). Invasive M3-type
strains, however, have evolved two unique conserved features in the scl1 locus: (i) an
IS1548 element insertion in the scl1 promoter region and (ii) a nonsense mutation within
the scl1 coding sequence. The scl1 transcript is drastically reduced in M3-type GAS,
contrasting with a high transcription level of scl1 allele in invasive M1-type GAS. This
leads to a lack of Scl1 expression in M3 strains. In contrast, while scl2 transcription and
Scl2 production are elevated in M3 strains, M1 GAS lack Scl2 surface expression. M3type strains were shown to have reduced biofilm formation on inanimate surfaces coated
with cellular fibronectin and laminin, and in human skin equivalents. Repair of the
nonsense mutation and restoration of Scl1 expression on M3-GAS cells, restores biofilm
formation on cellular fibronectin and laminin coatings. Inactivation of scl1 in biofilmcapable M28 and M41 strains results in larger skin lesions in a mouse model, indicating
that lack of Scl1 adhesin promotes bacterial spread over localized infection. These
studies suggest the uniquely evolved scl1 locus in the M3-type strains, which prevents
surface expression of the major Scl1 adhesin, contributed to the emergence of the
invasive M3-type strains. Furthermore these studies provide insight into the molecular
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mechanisms mediating colonization, biofilm formation, and pathogenesis of group A
streptococci.

INTRODUCTION
Group A Streptococcus (GAS) or Streptococcus pyogenes is a human-specific Grampositive pathogen responsible for significant morbidity and mortality worldwide (1,2). The
clinical outcomes resulting from GAS infection range from superficial pharyngitis and
impetigo to severe life-threatening diseases, such as streptococcal toxic shock syndrome
and necrotizing fasciitis, as well as post-infectious sequelae, including rheumatic fever,
rheumatic heart disease, and post-streptococcal glomerulonephritis (3). Historically, GAS
has been a significant cause of puerperal sepsis, scarlet fever, erysipelas, and pharyngitis
(4). GAS strains are epidemiologically subtyped based on nucleotide sequence variation
at the 5’-end of the emm gene, reflecting differences in the hypervariable N-terminal
region of the anti-phagocytic surface protein M. Over 240 M-types have been identified
(http://www.cdc.gov/abcs/index.html), and certain M-types have been shown to have
nonrandom associations with specific disease outcomes (3,5). Since the 1980’s there has
been resurgence in invasive GAS diseases in the U.S. and other parts of the world.
Numerous epidemiology studies conducted in the U.S. (6-11), Canada (12-15), and
Europe (16-19) have found associations between infections with M1- and M3-type strains
and invasive diseases. Specifically, M3-type strains have been associated with severe
invasive disease (6,19) and fatal outcomes (14,16,17).
These epidemiological observations have spurred significant whole genome
sequencing efforts aimed at identification of the underlying genetic basis for virulence in
M3-type GAS. The complete annotated genomes of invasive M3 strains MGAS315 and
SSI-1 have been reported (20,21). These studies have revealed that differing phage
elements, insertion sequences, and the large-scale chromosomal inversion identified in
SSI-1, contributed to much of the genetic variation between M3 and other M-types.
Acquisition of prophages and SNP’s drive the expansion of different M3 subclones during
epidemic waves of infection (22,23). Additionally, strains causing pharyngitis and those
causing invasive infections are derived from the same pool of M3 strains (24). In addition,
155

genetic variation in virulence regulators, including RopB and CovRS, which are “hotspots” for the accumulation of mutations, also contributes to the hypervirulence of M3
strains (23-28). The cause of the hyper-invasive phenotype of M3 strains is multifactorial
and involves multiple virulence factors controlled by complex regulatory networks that
continually undergo remodeling.
The streptococcal collagen-like proteins 1 and 2, or Scl1 and Scl2 (also known as
SclA and SclB), are major GAS surface adhesins known to contribute to pathogenesis.
Both Scl proteins contain an N-terminal variable region, followed by a collagen-like region
containing Gly-X-Y repeats and a cell-wall-anchored C-terminal region (29-33).
Transcription of scl1 is positively regulated by the multiple gene regulator Mga (30,32,34).
Scl1 binds cellular fibronectin and laminin (35), and contributes to the formation of biofilm
by strains of multiple M-types (36,37). GAS adherence and biofilm formation is enhanced
on extracellular matrix (ECM) coatings and on fibroblast-deposited ECM network (37,38),
supporting a role for Scl1 in tissue-microcolony formation described during GAS skin
infection (39). While the scl1 gene has been found in every GAS strain tested (29,32), the
scl1.3-allele in M3-type strains harbors a null mutation within the coding sequence (29).
A rare natural reversion of this polymorphism was identified in a small subset of M3 carrier
strains (40).
Scl2-protein expression is regulated during translation by varying numbers of short
CAAAA repeats downstream of the start codon that determine whether the protein-coding
sequence is in-frame or translation will be prematurely terminated (30,31); genome
sequencing indicates majority of the M3-type strain contain in-frame scl2.3 alleles (18,22).
Scl2 has been shown in some strains to bind the human thrombin-activatable fibrinolysis
inhibitor (41) and contribute to adherence to fibroblasts (31), although its role in GAS
pathogenesis is less understood. Recently, the crystal structure of the Scl2.3 globular
domain, which is structurally conserved between Scl1 and Scl2, has been reported
(42,43) providing insight into the potential binding interactions with host ligands.
In this study, we show that invasive M3-type GAS harbor two unique conserved
features of the scl1 locus including the IS1548 insertion in the promoter region and the
null mutation in the coding sequence, which results in a secreted instead of cell-attached
Scl1 protein. We demonstrate significantly different expression patterns of scl1 and scl2
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in M3-type GAS compared to representative strains of M1-, M28- and M41-types. We
demonstrate that the expression of the Scl1 adhesin is deficient in serotype M3 strains,
as opposed to M1-, M28-, and M41-type strains. However, the Scl2 protein is upregulated
in M3 strains compared to M1, M28, and M41 GAS. The M3 strains lacked significant
biofilms on cellular fibronectin and laminin coatings, compared to M41-type GAS, and did
not form tissue microcolonies in a wounded pseudo-organ skin equivalent model of
infection. Recombinant Scl1.3 specifically bound cellular fibronectin and laminin, and
restoration of surface expression of Scl1.3 conferred significant biofilm formation by M3
strains. Inactivation of Scl1 expression in biofilm-capable M28- and M41-type GAS
resulted in larger skin lesions produced by the mutants in a mouse model of subcutaneous
infection, supporting a role for Scl1 in maintaining a localized infection. Our model
advocates that the lack of surface-associated Scl1 adhesin in M3-type strains causes
decreased tissue adherence and decreased capacity for stable microcolony formation,
thus, promoting bacterial spread over localized nidus of infection.
EXPERIMENTAL PROCEDURES
1. Bacterial strains and growth – MGAS315 and MGAS10870 are fully sequenced
invasive M3-type strains (20,23). MGAS315 was isolated from a patient with streptococcal
toxic syndrome in the 1980’s (6) and MGAS10870 was isolated from a patient with soft
tissue infection in Ontario in 2002 (23). Additional strains from epidemiologically diverse
M-types were used for comparison: MGAS6183 (M41), MGAS5005 (M1), and MGAS6143
(M28). The MGAS6143∆scl1-, MGAS6183∆scl1-, and MGAS10870∆scl1-inactivated
mutant strains have been previously described (40,44,45). Group A Streptococcus
cultures were grown in Todd-Hewitt broth (Becton Dickinson and Co.) supplemented with
0.2% yeast extract (THY medium) and on Brain Heart Infusion agar (Becton Dickinson
and Co.) at 37°C in an atmosphere with 5% CO2. For antibiotic selection, erythromycin (5
µg mL-1), chloramphenicol (10 µg mL-1), kanamycin (200 µg mL-1), and spectinomycin
(100 µg mL-1) were added to the medium.
Cloning experiments were performed in XL-1 Blue and TB1 E. coli cells, while
protein expression experiments were performed in BL21 and TB1 E. coli cells grown in
Luria-Bertani

media

(Difco

Laboratories)
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at

37°C.

For

antibiotic

selection,

chloramphenicol (10 µg mL-1), kanamycin (50 µg mL-1), spectinomycin (100 µg mL-1), and
ampicillin (100 µg mL-1) were added to the medium.

2. PCR assays

2.1. Analytical PCR
2.1.1. Detection of IS element upstream of scl1 in GAS strains – The presence of
IS1548 upstream of scl1 was determined by PCR with primers IS1548F and Scl1R
(Figure 1) using Qiagen Taq DNA polymerase (Qiagen, Germantown, MD) as follows:
95°C, 5 min-[95°C 1 min, 62°C 1 min, 72°C 1 min] x30 cycles- 72°C, 10 min. Sequences
of primers used in all PCR assays are listed in Table S1.
2.1.2. PCR amplification of scl1.3 and scl2.3 alleles – PCR was performed on genomic
DNA isolated from M3 strains with primer pairs 232 Up/ 232 Rev for scl1.3 amplification
and sequencing, and Scl2.3 F/R and SclUp/ SclRev for length polymorphism analysis and
sequencing of scl2.3, respectively. Amplification was performed using Qiagen Taq DNA
polymerase as follows: scl1.3: 95°C, 5 min-[95°C 1 min, 55°C 1 min, 72°C 1 min] x30
cycles- 72°C, 10 min; scl2.3: 95°C, 5 min-[95°C 1 min, 51°C 1 min, 72°C 1 min 45 sec]
x30 cycles- 72°C, 10 min. All PCR products were analyzed in a 1% agarose gel with 1 kb
Plus DNA ladder as a molecular size marker (Life Technologies, Grand Island, NY).

2.2. Quantitative reverse transcription PCR (qRT-PCR)
2.2.1. RNA isolation – Total RNA was isolated from the logarithmic phase (OD600 0.5)
GAS cultures using RNeasy Protect Bacteria Mini kit (Qiagen), employing an additional
pretreatment step with 250 µg lysozyme, 100 µg proteinase K, and 12.5 U mutanolysin
per sample to augment cell wall disruption. Trace genomic DNA was removed by
incubation with TurboDNase enzyme (Ambion). RNA quality was assessed in 1% agarose
gel and spectrophotometrically; A260/280 and A260/230 ratios of >1.8 were considered

158

acceptable. RNA was used immediately in cDNA synthesis or stored at -80°C for no more
than 1 week.
2.2.2. Determination of transcription by qRT-PCR – Synthesis of cDNA was performed
using iScript Select cDNA synthesis kit (Bio-Rad) with 1 µg of RNA per reaction and
random primer mix. For each sample, a no reverse transcriptase control was performed,
containing only RNA, reaction buffer, and random primer mix, to ensure the absence of
genomic DNA. Incubations were carried out on a Bio-Rad C1000 Touch Thermal cycler:
25°C 5 min, 42°C 30 min, 85°C 5 min, and cDNA was stored at -20°C until used in qRTPCR. qRT-PCR reactions were performed with 250 nM primers using SsoAdvanced
SYBR Green Universal Supermix (Bio-Rad). For each qRT-PCR reaction, template
cDNA, diluted 1:20, control genomic DNA, or no reverse transcriptase control were used.
PCR was performed using the following conditions on a Bio-Rad CFX96 Thermal cycler:
95°C 2 min- [95°C 5 sec, 60°C 30 sec]x30- [65°C- 95°C, 5 sec, 0.5°C/ step]. Standard
curves were generated for each primer set using cDNA from MGAS315 to determine the
linear range and estimate reaction efficiency. Gene expression of scl1, scl2, emm, and
mga was normalized against the expression of tufA gene, which has previously been
identified and validated as an appropriate endogenous control (46). The ∆∆Ct method
was utilized to compare gene expression between MGAS315 and other M3 strains, as
well as M1, M28, and M41-type strains. Data was averaged from three independent
experiments, each containing three technical replicates. Statistical significance was
determined using an unpaired t-test.

3. Recombinant Scl (rScl) proteins
3.1. Cloning, expression, and purification of M3-derived rScl proteins – The rScl
proteins were generated using the Strep-tag II cloning, expression and purification system
(IBA-GmbH, Gottingen, Germany). Proteins were expressed with a C-terminal affinity tag
and purified on Strep-Tactin sepharose, as described (47). rScl proteins rScl1.3V and
rScl1.3FL are derived from MGAS315, whereas rScl2.3 protein is derived from the M3
strain MGAS3375. The recombinant Scl2.3V protein has been described previously (42).
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Construct containing the recombinant full-length Scl1.3FL (rScl1.3FL) protein was
previously described (40). Briefly, the scl1.3 coding region from MGAS315 was cloned
into the E. coli/GAS shuttle vector pJRS525 (48), generating plasmid pSL501. PCR
mutagenesis was used to convert the internal TAA stop codon into a GAA glutamate
codon, resulting in plasmid pSL502 with continuous full-length scl1.3FL allele. This
sequence was subsequently cloned into the pASK-IBA2 expression vector for
recombinant Scl1.3FL protein production; each clone was verified by sequencing. Protein
expression constructs are listed in Table 1.
Protein expression was induced by the addition of anhydrotetracycline at 0.2 µg
mL-1 for 3 hours. Cells were centrifuged and resuspended in high sucrose buffer (100 mM
Tris-HCl, 1 mM EDTA, pH 8.0, 500 mM sucrose) or Cell Lytic B Buffer (Sigma), for
separation of the periplasmic fraction and subsequent affinity purification. Proteins were
dialyzed against 25 mM HEPES, pH 8.0, and analyzed by SDS-PAGE stained with
RAPIDstainTM

(G-Biosciences). Protein

sequence

was

confirmed

using

mass

spectrometry (University of Nebraska Medical Center) and N-terminal Edman
Degradation sequencing (Iowa State University).
3.2. Electron microscopy of rotary shadowed rScl proteins – Electron microscopy
visualization of the rotary shadowed preparations of rScl1.3FL and rScl2.3 was used to
assess the domain organization of rScl proteins, as employed previously (49). The rScl
proteins were dialyzed against 0.1 M ammonium bicarbonate and mixed with glycerol to
a final concentration of 70% (vol:vol). Samples were nebulized onto mica chips with an
airbrush and rotary-shadowed with carbon/platinum using an electron beam gun.
Photomicrograph images were acquired using a transmission electron microscope FEI
G2 operated at 80KV.
3.3. Mass spectrometry analysis – Samples from in-gel trypsin digested proteins were
cleaned using a Millipore µC18 ZipTip, then resuspended in 0.1% formic acid. Samples
were fractionated on a Eksigent cHiPLC column (75 µm x 15 cm ChromXP C18-CL 3 µm
120 Å), and resulting peptides were sequenced using 5600 TripleTOF (typical gradient 260% ACN in 60 minutes). Peptides identified were searched against the NCBI protein
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database with Protein Pilot software employing the following settings: search effort,
thorough; taxonomy, none. Positive identification was considered as the identification of
two or more unique peptides at high confidence ≥95%, FDR=0.05, 0.01, or 0.001, which
matched the same protein entry in the database searched.

3.4. Binding of rScl proteins to extracellular matrix proteins and synthetic peptide
3.4.1. ELISA binding assays – Binding of rScl proteins to extracellular matrix proteins,
cellular fibronectin (cFn) and laminin (Lm), was tested by ELISA (35). rScl proteins were
immobilized onto Strep-Tactin® coated microplate wells (IBA GmbH) at 0.5 µM at room
temperature for 1.5 hours, then blocked with Tris-buffered saline (TBS) containing 1%
bovine serum albumin (BSA) overnight at 4°C. The cellular fibronectin from human
foreskin fibroblasts (Sigma) and murine laminin (Invitrogen) were added to the wells at 1
µg per well and incubated at room temperature for 1 hour. Bound ECM proteins were
detected with rabbit anti-laminin at 1:100 (Sigma) and anti- human fibronectin at 1:4,000
(Sigma) polyclonal antibodies. Secondary antibody goat anti-rabbit IgG (H+L) HRP
conjugate (Bio-Rad) was next used with 1-step ABTS substrate (2,2'-Azinobis [3ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) (ThermoScientific). Absorption
was measured using Spectramax 190 at a wavelength of 415 nm. Statistical analysis is
based on three independent experiments each containing three technical replicates,
using an unpaired t-test.
In antibody inhibition assay, the IST-9 mAb targeting the C-C’ loop of EDA domain
was utilized (37). cFn was either untreated or pre-treated with increasing concentrations
of IST-9 blocking mAb (0.1 µg- 1.0 µg), and added to Strep-Tactin®-coated microplate
wells immobilized with rScl proteins, then incubated for 1 hour. Bound ECM proteins were
detected as above.
3.4.2. Design and synthesis of the C-C’ cyclic peptide – The C-C’ cyclic peptide was
designed based on the crystal structure of the EDA domain of cFn (PDB code 1J8K). In
particular, the region, which was reported to be involved in Scl1 binding, connecting to
two β-strands C and C’ of EDA was elongated to the whole C-C’ β-hairpin by allowing the
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formation the electrostatic interaction between Arg33 and Glu45. The terminal Tyr32 and
Pro48 were mutated to Cys to stabilize the β-hairpin by introducing a disulfide bond
(Figure S4). The obtained sequence, CRVTYSSPEDGIHELFC (molecular weight:
1997.1 Da), endowed with a cyclic structure to mimic the structure of this region in EDA,
was acetylated and amidated at the N- and C-terminus, respectively. Synthesis of the
designed peptide was performed employing the solid phase method on a 50 μmol scale
initially following standard Fmoc strategies (50). Due to aspartimide formation during
traditional acylation reactions, peptide synthesis was carried out employing microwave
technology (51). Cyclization was achieved by treating the peptide at 0.1 mg/mL (to avoid
intermolecular disulphide formation) with buffer carbonate 50 mM, pH=9, overnight. The
peptide was purified by RP-HPLC and the identity and purity (> 97%) was assessed by
LC-MS (data not shown).
3.4.3. Surface plasmon resonance (SPR) experiments – Real time binding assays
were performed at 25 °C on a Biacore 3000 Surface Plasmon Resonance (SPR)
instrument (GE Healthcare). For immobilization, rScl1.3FL protein containing the Cterminal Strep-tag II was injected at a concentration of 40 µM on streptavidin-coated
sensor chip, SA Biacore, until the desired level of immobilization was achieved
(averaged value of 100 RU). Binding assays were carried out by injecting the C-C’ cyclic
peptide at concentrations ranging between 10-500 µM. Experiments were carried out in
HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4). The association
phase (kon) was followed for 270 s, whereas the dissociation phase (koff) was followed
for 300 s. The reference chip sensorgrams were subtracted from sample sensorgrams.
Experiments were carried out in duplicates. Kinetic parameters were estimated
assuming a 1:1 Langmuir binding model and using version 4.1 Evaluation Software (GE
Healthcare).
3.4.4. Fluorescence binding analysis – rScl1.3FL protein, at a concentration of 30 μM,
was incubated with increasing concentrations of C-C’ cyclic peptide (0 - 300 μM) at 25.0
°C, using an excitation wavelength of 298.0 nm and a fluorescence emission wavelength
ranging from 300 to 400 nm. The acquisition parameters were set as follows: excitation
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and emission slits at 5 nm; 120 nm/min scan rate; 1.00 nm data interval averaging time
at 0.500 s, PMT voltage at “high”. Fluorescence values were recorded at 333 nm, and
subtracted from the fluorescence intensity of the ligand-free protein, generating ∆fluorescence.

The

-∆fluorescence

values

were

plotted

against

the

peptide

concentration. (52). Experiments were carried out in duplicates. A control assay was
carried out employing the buffer as titrant to assess that the dilution effect was under 3%,
not affecting the results.
4. Complementation of GAS strains with full-length Scl1.3FL – For transcomplementation experiments, plasmid pSL502, encoding full-length cell-associated
Scl1.3FL protein, was electroporated into MGAS315 WT and MGAS6183Δscl1
electrocompetent cells. The pJRS525 vector was electroporated as a control.
Transformants were selected on BHI agar containing 100 µg mL -1 spectinomycin, and
plasmids were re-sequenced. For MGAS10870∆scl1, which contains a spectinomycin
resistance cassette in place of the scl1.3 allele, the spectinomycin resistance marker in
pSL502 was replaced with a kanamycin resistance, generating the plasmid pSL518 and
colonies were selected on BHI agar containing 150 µg mL-1 kanamycin.

4.1. Determination of Scl1.3- and Scl2.3-protein expression in wild-type and
complemented GAS strains
4.1.1. Western blot analysis – Expression of the Scl1.3 and Scl2.3 proteins was
determined by western immunoblotting of the bacterial cell wall and culture supernatant
protein fractions, as described before (29,30). Briefly, bacterial cultures were grown to an
OD600 of 0.5 and cells were harvested by centrifugation. Culture supernatant proteins
were precipitated with trichloroacetic acid (Sigma) to a final concentration of 10% (vol:vol).
The cell wall protein fraction was obtained after cell digestion with lysozyme and
mutanolysin in a high sucrose buffer. A total of 10 µg of protein samples were separated
by SDS-PAGE and transferred to a nitrocellulose membrane. Detection of Scl1.3, Scl2.3,
and M3 proteins was performed using the same sample preparations with rabbit
polyclonal antibodies generated against the truncated rScl1.3WT protein (anti-Scl1
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1:15,000 dilution, reported in (40)) and the rScl2.3V region (anti-rScl2.3V 1:2,500;
generated by Proteintech (43)). Horseradish peroxidase-conjugated goat anti-rabbit IgG
(H+L) secondary antibody (Bio-Rad), combined with PierceTM ECL western blotting
substrate (Thermo Scientific) was used for detection. Images were acquired using a
ChemiDoc Touch Imaging System (Bio-Rad).
4.1.2. Flow cytometry analysis – Surface detection of Scl1.3 and Scl2.3 proteins was
determined by flow cytometry. Bacteria grown to an OD600 of 0.5 were harvested by
centrifugation, and washed with flow cytometry buffer (sterile phosphate-buffered saline
containing 10% Todd-Hewitt broth supplemented with 0.2% yeast extract). Cells were
incubated with polyclonal antibodies against Scl1.3 and Scl2.3 described above at a
dilution of 1:100 for 30 minutes on ice, then washed and incubated with Allophycocyanin
(APC)-conjugated donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch) for 30
minutes on ice. Cells were washed and fixed in 0.4% paraformaldehyde, and stored at
4°C until analysis. Before analysis, cells were washed twice and resuspended in flow
cytometry buffer. Cells were analyzed using a BD LSRFortessa, and 50,000 events were
collected per sample. Data was analyzed using the FCS Express Flow 5 software.

5. Assessment of biofilm formation
5.1. Crystal violet staining assay – Wild-type, mutant, and complemented strains were
grown to OD600 of 0.5 and seeded into 24-well culture plates coated with ECM at 2 µg per
well, then incubated at 37°C with 5% CO2 for 24 hours. Wells were washed with PBS
followed by the addition of 0.5 mL 1% crystal violet solution (Fisher Scientific) diluted in
PBS and incubation at room temperature for 30 minutes. Wells were rinsed twice with
PBS and stain was solubilized with 0.5 mL of 75% ethanol. Spectrophotometric readings
were taken for each sample at OD600. Statistical analysis is shown based on three
independent experiments, each containing three technical replicates, using an unpaired
t-test.
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5.2. Confocal laser scanning microscopy (CLSM) – To visualize GAS by CLSM,
bacterial cells were transformed with a GFP-encoding plasmid pSB027 (53), as before
(36). 15-mm glass cover slips were placed into 24-well tissue culture plate wells and
coated with 2 µg of cFn or Lm per well. Bacterial cultures grown to logarithmic-phase
were added to the wells and allowed to form biofilms for 24 hours. Wells were rinsed with
PBS and bacterial cells were fixed with 3% paraformaldehyde at room temperature for 30
min. Wells were washed again and coverslips were mounted onto slides using ProLong
Gold Antifade Mountant (Thermo Scientific). Confocal images were acquired using a
63×/1.40 Plan-Apochromat objective and a Zeiss LSM 510 laser scanning confocal
microscope.

6. In vitro and in vivo GAS infection models
6.1. GAS infection of in vitro cultured human skin equivalents – Wounded fullthickness skin equivalents, EpiDerm-FT (MatTek, Boston, MA) were used. The tissues
are discs 8 mm in diameter, which are provided in transwells. A 3-mm wound is generated
by performing a punch biopsy to remove the keratinocyte layer. Immediately upon arrival,
tissues were equilibrated in antibiotic-free manufacturer’s medium overnight at 37°C in
atmosphere with 5% CO2. Wounds were infected with 10 µL of GFP-expressing log-phase
group A streptococcal inocula and incubated in a humid environment at 37°C with 5%
CO2 in daily-fresh media; a total of 4 experiments were performed and variables included
the inoculum size of 3 x 106 -1.8 x 107 CFU and collection time points between 1-5 days.
Tissues designated for histopathological evaluation were fixed in 10% formalin, whereas
tissues for two-photon fluorescence (TPF) microscopy imaging were fixed in 4%
paraformaldehyde for several hours and then transferred to petri dishes containing PBS.
For visualization of glycocalyx produced by GAS strains, tissues were permeabilized with
0.1% Triton X-100 in 1 x PBS and blocked with 0.05% Triton X-100 in 1x PBS with 1%
BSA before staining with concanavalin A- tetramethylrhodamine (Molecular Probes).
Tissues were then rinsed and stored in PBS at 4°C until TPF imaging was performed. For
TPF analysis, an Olympus 60x/ 1.2NA water dipping objective was used. Fixed tissues
were imaged by two-photon microscopy with the Ti:sapphire laser (Mira, Coherent)
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intensity at 60 mW and input wavelength of 850 nm. Laser scanning images were
collected at 0.5- 1 µm incremental depths using ScanImage (Janelia Farms, HHMI).
Images were saved in a single TIFF file with 16 bit depth. Deconvolution of the images
was performed using AutoQuant x3 and 3D models of z-stacks were generated using
Imaris software.
6.2. Mouse model of soft tissue infection – Animal experiments were conducted in
compliance with the regulations and standards under the Animal Welfare Act, the Public
Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide
for the Care and Use of Laboratory Animals. The protocol was approved by the West
Virginia University Institutional Animal Care and Use Committee (IACUC).
Subcutaneous infections of mice were carried out as described previously (54).
Briefly, 5-week-old male, immunocompetent, hairless mice (strain Crl:SKH1-hrBR) were
used (Charles River, Wilmington, MA). Groups of 10-15 mice anesthetized with isoflurane
were infected subcutaneously at the right flank with ~109 GAS CFU of WT or scl1-mutant
strains, and mice were observed for 14 days. The weight and abscess dimensions (length
[L] and width [W]) of each mouse were recorded daily during the first week and every
other day thereafter. To analyze differences between mice infected with WT and scl1mutant GAS, the area of each abscess was calculated with the equation for the area (A)
of an spherical ellipsoid: A=(L/2)x(W/2); statistical differences were calculated using the
student’s t-test. At the conclusion of the experiments, mice were anesthetized and
sacrificed by cervical dislocation.
RESULTS
M3-type GAS contain unique insertion of IS1548 element and nonsense mutation
within the scl1.3 locus – Since the resurgence of invasive GAS infections in the 1980s
and an advent of molecular epidemiology fostered by large-scale sequencing, significant
efforts have been made to define the molecular basis for the invasive phenotype of M3type strains. In parallel to these advances, we identified two unique genomic traits in the
scl1.3 locus, encoding streptococcal collagen-like protein 1: (i) the presence of an
insertional sequence element, IS1548, in the promoter region and (ii) the presence of a
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nonsense mutation within the coding sequence of scl1.3 allele that was absent in other
M-types.
Studies employing mga-inactivated mutants have indicated that Scl1 expression
was positively regulated by the GAS-global transcriptional regulator, Mga (30,32). Two
putative Mga binding sites were identified upstream of the scl1 coding sequence in the
M1-type strain SF370 and experiments demonstrated that the Mga binding site distal to
scl1 was responsible for transcription activation (34). Identical Mga binding sites I and II
were also identified upstream of scl1.3 in the sequenced M3-type strain MGAS315 with
IS1548 element inserted 38 bp upstream of the distal Mga I-binding site (Figure 1A). To
determine if the IS1548 insertion was specific to M3 strains, we BLAST-searched this
element in 45 completed GAS genomes representing 21 different M-types. We observed
the presence of IS1548 in all strains searched with varying locations and occurrences
from one to twelve per genome (Figure 1B). However, the IS1548 insertion upstream of
the scl1.3 allele was only found in the sequenced genomes of M3-type strains MGAS315,
SSI-1, and M3-b. Interestingly, a complete IS1548 element was not present upstream of
scl1.3 in the recently reported genome of the M3 strain STAB902, which represents a
non-invasive isolate (55); instead, a 34-bp remnant of IS1548, including the inverted
repeat and additional 14 bp, was found. Based on this bioinformatics data, we examined
the presence of the IS1548 element upstream of scl1 by PCR in a panel of 40 M3-type
strains, using primers located in the IS1548 and scl1.3 sequences (IS1548F and Scl1R,
Table S1). All M3-type strains examined were positive for the IS1548-scl1.3 amplicon,
while M1, M41, and M28-type controls were negative (Figure 1C), demonstrating a broad
and conserved presence of the IS1548 insertion in this location among M3-type GAS.
The nonsense mutation in the 11th Gly-X-Y repeat in the Scl1.3-CL collagenous
region (Figure 1A, red box), presumably results in a truncated secreted variant, which
consists of the Scl1-V variable region and 10 Gly-X-Y repeats but lacks the cell wall
anchor. This polymorphism was originally identified in five M3-type invasive GAS strains
but was absent in 45 other strains analyzed, representing 20 different M-types (29). It was
later shown in 98.7% of 479 sequenced invasive M3-type isolates (40). We performed
targeted PCR amplification of scl1.3 from 46 additional M3-type strains and observed
identical amplicon sizes in all of them (Figure S1A). Sequencing showed that all tested
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strains harbored an identical scl1.3 allele, containing 25 Gly-X-Y repeats in the
collagenous domain with the null mutation in the 11 th repeat (Data Set S1). A complete
lack of genetic variation within scl1.3 is surprising and differs from the length variation
that is commonly observed among scl alleles from other M-types (29,32,33). These
results demonstrate that the IS1548 insertion and null mutation we identified in the scl1.3
locus are unique to and conserved among M3-type GAS. Based on these results, we
hypothesized M3 strains produce a truncated, but potentially biologically active Scl1.3
variant, which is secreted instead of being cell-attached.
scl1.3 expression is diminished in M3-type GAS – Original reports showed scl1
transcripts in northern blots, as well as full-length Scl1 proteins (both cell-associated and
cell-free fractions) in western blots for strains of emm types 1, 28, 52, and 41
(29,30,32,45). To analyze the expression of the truncated Scl1.3 protein in M3-type GAS,
western blot analysis was performed on cell-wall (CW samples) and culture-supernatant
(Sup samples) protein fractions of several M3-type strains grown to exponential phase
(Figure 2A). The expected truncated Scl1.3 protein was not detected by anti-Scl1
antibodies, whereas the rScl1.3V positive control, corresponding to the V region of Scl1.3
variant, produced the expected immunoreactive band of ~8.3 kDa. In an additional control
experiment, the same panel of M3 strains was tested for Scl1.3 on the cell surface using
flow cytometry (Figure 2B). No shift in median fluorescence intensity was observed in M3
strains incubated with anti-Scl1 antibody compared to a secondary-only antibody control,
indicating a lack of Scl1 on the cell surface among M3 strains.
Given the unique IS1548-scl1.3 location and the lack of truncated Scl1.3 products
in culture supernatants, we investigated scl1.3 expression by qRT-PCR. Total RNA was
isolated from exponential phase cultures of 5 M3-type strains, as well as from previously
characterized control strains of emm types 1, 28, and 41 (29,30,32,45). Expression of
scl1 from each strain was compared to scl1.3 transcription in M3 strain MGAS315 (Figure
2C). Each non-M3-type strain tested had significantly higher transcription level of
respective scl1 allele compared to MGAS315. The M1 strain had the most increased
expression by 21-fold, while M28 and M41 strains exhibited 6-fold and 8-fold higher scl1
expression, respectively. Interestingly, the scl1.3 transcripts examined in four additional
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M3-type MGAS strains 158, 335, 1313, and 10870 were significantly reduced as
compared to MGAS315, with a range of 25-45-fold decrease. Overall, we observed that
M3-type GAS harboring the IS element upstream of scl1.3 have drastically decreased
scl1.3 transcript levels and lack the Scl1 protein product, as assessed by western blot
and flow cytometry.
Since scl1 is regulated by the transcriptional activator Mga, we investigated
whether the decreased scl1.3 transcripts in M3 strains were due to lack of mga gene
expression in these strains. In parallel, we assessed transcript levels of the emm gene
encoding the M surface protein, a key virulence factor regulated by Mga. For comparison,
we included the M1 strain, which had significantly increased scl1 expression compared
to the M3 strains. With the exception of MGAS335, which had significantly downregulated
mga and emm expression, we found no significant differences in either mga or emm gene
expression between MGAS315 and the other M3 strains or M1 strain (Figure 2D).
Furthermore, M3 protein was highly expressed, as it was found in both cell wall and
supernatant fractions, except for the MGAS335 strain, consistent with transcription data
(Figure 2E). These results demonstrate that the striking downregulation of scl1.3 in M3type GAS is not due to decreased mga expression or non-functional Mga protein, as emm
is normally expressed in these strains.
scl2.3 is expressed in M3-type GAS – Scl2 shares a similar structure with Scl1 but its
biological function is poorly understood. One study demonstrated in a different M-type
background that isogenic mutant devoid of Scl2.55 variant had lower adhesion to human
skin fibroblasts (Rasmussen and Bjӧrck, 2001); however, the Scl2.3 variant present in
M3-type GAS has not been investigated for expression and ECM binding. Therefore, we
next assessed scl2.3/Scl2.3 expression in M3 strains. PCR amplification and sequencing
showed that the majority of M3 strains contained in-frame scl2.3 allele (Figure S1B, Table
S2).
Western blot analysis of cell wall (CW samples) and supernatant (Sup) protein
fractions found Scl2.3 protein was expressed by M3 strains MGAS315, 10870, 158, 9517
and 1313, whereas samples obtained from strain MGAS335, which contains an out-offrame scl2.3 allele, generated no immunoreactive band; rScl2.3V control produced the
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expected 10.1-kDa band (Figure 3A). Mass spectrometry confirmed the identity of the
presumed immunoreactive Scl2.3-protein band from MGAS315 (Table S3). Consistently,
Scl2.3 was detected on the surface of all five M3 strains containing in-frame scl2.3 alleles
by flow cytometry, with a positive shift in median fluorescence intensity ranging in 67-131fold change, as compared to the secondary-only antibody control (Figure 3B). We next
compared the scl2-transcription level in M3 strain MGAS315 with scl2-transcription levels
in M1-, M28-, and M41-type strains. In striking contrast to the pattern of scl1.3
transcription, scl2 transcripts were significantly decreased in the M1-type strain by 13fold, as well as in the M28 (6-fold) and M41 (3-fold) strains (Figure 3C). Additionally, there
was no significant difference between scl2 expression in MGAS315 and the M3 strains
MGAS158, 335, 1313, and 10870 (Table S4). These results confirm that the M3 scl2.3
allele is transcribed at high levels, resulting in considerable expression of the Scl2.3
protein. These results suggested that Scl2 has an important biological function in M3
strains and warranted subsequent experiments assessing Scl2.3 function.
GAS infection disseminates through human tissue and inhibits wound healing – A
wounded human skin equivalent, devoid of an inflammatory component, was utilized as
a “mechanistic model” of GAS tissue colonization. The epidermal wound of each skin
equivalent was infected with GFP-expressing M3-type invasive strain MGAS315 or M41type non-invasive strain MGAS6183, and analyzed after 1-5 days by standard
histopathology (H&E and Gram’s stain) and using two-photon fluorescence (TPF)
microscopy. H&E of uninfected tissue controls harvested at day 0 showed the absence
of a keratinocyte layer where the punch biopsy was performed (Figure 4A). Complete
healing of the wound was observed after 5 days, with a newly-generated intact
keratinocyte layer covering the punch biopsy site (Figure 4B). In contrast, tissue infected
with either GAS strain exhibited delayed wound closure as late as day 5 post-infection
(Figure 4E, H). H&E staining of skin equivalents infected with either M3 or M41 after 24
hours revealed bacterial colonization of the exposed dermal surface, as well as bacterial
invasion into puncture-associated defects extending deep into the dermal layer, largely
located at the wound edges (Figure 4D, G). Notably, extensive bacterial growth and
spread was largely confined to tissue crevices in the dermis, whereas the presence of
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large bacterial colonies directly below the wound bed was rarely seen on microscopic
examination. By day 5 of infection, bacterial invasion via these dermal defects extended
to the bottom of the dermis for both strains, presenting both vertical and lateral spread of
bacteria (Figure 4E, H). Gram stain of infected tissues showed the formation of superficial
colonies near dermal surfaces, as well as biofilm formation on the surface of exposed
dermis (Figure 4J-L). Additionally, epidermal tissue neighboring the wound bed exhibited
~60% decreased thickness of the viable keratinocyte layer in tissues infected with
MGAS315 and MGAS6183 by day 5, relative to uninfected tissues (Figure 4C, F, I). This
suggests bacterial infection of the wound affects epidermal cells distant from the site of
infection in this model.
TPF analysis was then performed on whole infected skin equivalents on day 5
post-infection in order to assess bacterial spread directly below the wound bed. This
method allowed us to visualize bacterial structures within tissue that were not apparent in
H&E or Gram-stained sections. Tissue microcolonies were observed in samples infected
with M41 GAS (Figure 4N), whereas M3 cells had a scattered appearance (Figure 4P).
TRITC-concanavalin A (TRITC-conA) was utilized to visualize glycocalyx associated with
bacteria. TRITC-conA stain colocalized with bacterial microcolonies formed by the M41
GAS (Figure 4O, Figure S3), indicating microcolonies were encased in a glycocalyx,
much like a classic biofilm. In contrast, TRITC-conA stain was associated with scattered
M3-GAS chains located at the bottom cell layer in MGAS315-infected skin equivalents
(Figure 4Q). These results indicate that M41 GAS, but not the M3 GAS, forms
microcolonies in the tissue during a human skin infection that are encased in a glycocalyx,
consistent with the observation that M41, but not M3, GAS forms robust biofilm in vitro on
ECM coatings. In addition, M3 GAS disseminates in a form of scattered chains or single
cells through the tissue.
M3-type GAS strains form poor biofilms on extracellular matrix coatings – It was
previously reported that M3-type strains have no substantial biofilm formation in vitro on
an inanimate surface (36). Here, we tested biofilm formation on cellular fibronectin (cFn)
and laminin (Lm) coatings by a panel of representative M3 strains isolated from invasive
cases of GAS disease, as compared to the non-invasive biofilm-capable M41-type model
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strain MGAS6183. As expected, wells coated with either cFn or Lm supported robust
biofilm formation by the M41 strain, whereas significantly less bacterial biomass was
measured for all M3-type GAS on both ECM coatings (Figure 5A). There was also no
correlation between Scl2 expression and biofilm formation. We hypothesized that M3type GAS, devoid of Scl1 adhesin, have decreased binding to cFn and Lm ECM
components, thus, preventing the formation of tissue microcolonies, and that restoration
of full-length Scl1.3 (Scl1.3FL) on the GAS cell surface will confer binding to host ECM,
as well as biofilm capacity in vivo (Figure 5B).
Full-length recombinant Scl1.3 binds cellular fibronectin and laminin – To test this
hypothesis, we: (i) constructed Scl1.3- and Scl2.3-derived recombinant proteins, (ii)
characterized their structural organization, and (iii) assessed their ECM-binding
capacities.
First, rScl1.3FL and rScl2.3 proteins were assessed for purity and integrity by SDSPAGE (Figure 6A). The expected 20.6-kDa rScl1.3FL migrated at ~34 kDa, which is
consistent with previous reports of aberrant migration of rScl proteins (29,30), whereas
the rScl2.3 protein migrated according to the expected molecular mass of 16.2 kDa; both
proteins were verified by mass spectrometry (Table S3). Rotary shadowed rScl1.3FL and
rScl2.3 constructs, exhibited the characteristic lollipop-like structural organization (Figure
S2), as observed for previously characterized rScl proteins (47,49). Interestingly,
rScl1.3FL formed aggregates that were mediated by the intermolecular interactions
between the globular domains; such interactions, however, were not observed between
rScl2.3 molecules. The appearance of Scl1-Scl1 aggregates implies an attractive
hypothesis that V-to-V-region interactions between the Scl1 molecules, but not between
the Scl2 molecules, on the surface of neighboring GAS chains may support biofilm
structure, as proposed in our model (Figure 5B).
It has been established that Scl1 proteins selectively bind cellular, but not plasma,
fibronectin and laminin (35), and that selective cFn binding is achieved by a unique
binding mechanism involving the C-C’ loop of the extra domain A in cFn (EDA-cFn) (37).
Here, we pre-incubated cFn with increasing concentrations of EDA-blocking IST-9 mAb
(0.1, 1.0 µg), then added to wells containing immobilized rScl proteins and allowed for
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binding. We observed significant dose-dependent inhibition of cFn binding to rScl1.3FL,
with a 36% inhibition at 0.1 µg and a 60% inhibition at 1.0 µg of IST-9 (Figure 6B). In
addition, the rScl2.3 protein did not bind cFn, which is consistent with our previous data
employing several different rScl2 proteins (35). Surface plasmon resonance (SPR)
measurements of binding affinity between rScl1.3FL and EDA-derived C-C’ cyclic peptide
provided a dissociation constant of KD= 63.3 µM (Figure 6C). To corroborate the
rScl1.3FL-EDA binding affinity, an in-solution fluorescence binding assay was performed,
in which the variation in tryptophan fluorescence of rScl1.3FL was recorded as a measure
of positive binding to the C-C’ cyclic peptide. Tryptophan fluorescence emission at 333
nm showed a dose-response quenching upon addition of the C-C’ cyclic peptide and -
fluorescence intensity was plotted against peptide concentration (Figure 6D). Data were
fitted with a 1:1 model of interaction, providing a KD = 44.54 ±9 μM, in agreement with
SPR data (56).
We next assessed binding of rScl1.3FL and rScl2.3 proteins to laminin (Lm) by
ELISA. We determined rScl1.3FL had significant Lm binding, whereas rScl2.3 had not
(Figure 6E), consistent with previous findings that Scl1-derived recombinant proteins, but
not the Scl2-derived, bind ECM proteins (35). Collectively, these results demonstrate
specific binding of Scl1.3FL to the EDA domain of cFn and to Lm and its capacity of being
surface adhesin.

Homologous complementation of M3 strains with full-length surface-exposed
Scl1.3 adhesin confers biofilm formation on ECM – To assess the effect of cell-surface
Scl1.3FL expression on the capacity to form biofilm, an in-trans complementation of two
representative invasive M3 strains was performed, MGAS315 wild-type (WT) strain,
naturally lacking Scl1.3 expression, and a previously generated scl1-inactivated mutant
of MGAS10870 (10870Δscl1), with plasmids pSL502 (SpR) and pSL518 (KmR),
respectively, both encoding the full-length Scl1.3FL protein. As a control, MGAS315 was
complemented with a shuttle vector pJRS525. The cell wall-associated expression of
Scl1.3FL in complemented M3-type GAS was first tested by western blot analysis of the
cell wall protein fractions and on the GAS-cell surface by flow cytometry. An expected
~35-kDa immunoreactive band in complemented strains was observed, which was absent
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in the parent strains (Figure 7A). Mass spectrometry analysis of the corresponding bands
extracted from the gel confirmed they represented the Scl1.3FL protein, with five unique
peptides identified with 17% sequence coverage for complemented MGAS315 and four
unique peptides identified with 11% sequence coverage for complemented MGAS10870
(Table S3). A 6.8-fold increase in median fluorescence intensity of Scl1.3FLcomplemented MGAS315 cells was measured by flow cytometry, as compared to the
vector-complemented and WT control strains (Figure 7B). The Scl1.3FL-complemented
10870Δscl1 exhibited a 2.2 -fold increase in median fluorescence intensity, as compared
to the mutant control (Figure 7B). These results indicate the Scl1.3FL is indeed expressed
and surface-exposed in the complemented M3-type strains.
Biofilm formation by the complemented and parent strains was then assessed after
24 hours following crystal violet staining and using confocal laser scanning microscopy
(CLSM). Scl1.3FL-expressing MGAS315 showed significantly increased biomass on both
cFn and Lm coatings compared to the WT parent organism, as well as vectorcomplemented control; 3.6 or 2.5- and 2.5 or 2.1-fold OD600 increases on cFn and Lm,
respectively, were measured compared to MGAS315 WT or to vector-complemented
MGAS315 (Figure 7C). Significantly thicker biofilm formed by Scl1.3FL-complemented
MGAS315 was imaged by CLSM. We observed on average a 2.8-fold (P= 0.0002) and
2.6-fold (P= 0.0002) increased biofilm thickness on cFn and Lm, respectively, compared
to MGAS315 WT, and a 2.0-fold (P= 0.0036) and 4.8-fold (P= 2.1x10-5) increased biofilm
thickness on cFn and Lm, respectively, compared to vector-complemented MGAS315
(Figure 7D and E, representative images). Similar results were obtained for the
complemented 10870Δscl1 mutant, which had 1.7-fold increase in biomass staining on
both cFn and Lm compared to the MGAS10870 WT strain, and 2.2- and 2.6-fold increase
in biomass staining on cFn and Lm, respectively, compared to the 10870Δscl1 mutant
strain (Figure 7C). CLSM data, however, could not be rendered for MGAS10870 strains
due to poor GFP expression for unknown reasons. Altogether, it was demonstrated that
null mutation in the scl1 gene, which ablates surface Scl1.3 protein and is unique to M3type GAS, is responsible for the decreased biofilm capacity since restoration of the fulllength surface-exposed Scl1.3 adhesin significantly fosters stable biofilm formation.
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Heterologous complementation of M41 Δscl1 mutant strain with full-length surfaceexposed Scl1.3 restores biofilm formation on ECM – In a previous study we showed
that scl1.41-inactivation in a non-invasive biofilm-rich M41 strain MGAS6183 resulted in
significantly decreased biofilm capacity, which was restored to wild-type level by
complementation with surface Scl1.41 (37). Notably, this M41 strain expresses at least
one additional major Fn-binding protein, protein F2 (45), which binds both plasma and
cellular fibronectin by a mechanism different from Scl1 (57). Here, we hypothesized that
expression of rScl1.3FL in the heterologous M41 GAS will confer biofilm formation.
Western immunoblotting of the cell wall protein fractions detected the ~35-kDa
immunoreactive band, corresponding to full-length Scl1.3, associated with complemented
cells, while the M41Δscl1 mutant and WT cells were signal-negative (Figure 8A). Mass
spectrometry of the corresponding band extracted from the gel confirmed Scl1.3FL
expression, with 3 unique peptides identified, covering 13% of the amino acid sequence
(Table S3). In addition, we showed the expression of the larger Scl1.41 variant in the cell
wall of M41 WT, but not in the ∆scl1 mutant, by re-probing a portion of the blot with antirScl1.41 antibody, using rScl1.41 protein as a positive control.
Similarly to complementation with homologous Scl1.41 protein, the heterologous
complementation of the M41Δscl1 mutant with Scl1.3FL also restored biofilm to M41 WT
levels on cFn and Lm (Figure 8B-D). Crystal violet staining showed increased bacterial
biomass (Figure 8B) and confocal microscopy revealed significantly thicker biofilms, on
average 3-fold increased, as compared to the parental M41Δscl1 mutant strain on both
cFn (Figure 8C) and Lm (Figure 8D) coatings (cFn, P= 0.0105; Lm, P= 0.0011).
Expression of Scl1 adhesin attenuates GAS during subcutaneous infection – We
have previously shown that an M3 strain harboring a carrier scl1.3 allele, producing a
shorter cell-attached Scl1.3 variant, had an attenuated phenotype in a murine model of
necrotizing fasciitis (40). Here, we tested our hypothesis that Scl1 adhesin in biofilm-rich
M28 and M41 background promotes stable colonization and localized infection, using a
murine
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infection

model.

Hairless,

immunocompetent

SKH1

mice

were

subcutaneously infected with ~109 GAS CFU of the M28 and M41 wild-type (WT) or their
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isogenic scl1-inactivated mutant (scl1) strains (44,45), and mice were assessed for
changes in gross pathology of the skin.
Skin lesions caused by both the WT and scl1 strains were observed as early as 48
hours post-infection, and the lesions began to regress after day 7 with complete resolution
of the lesion by the completion of the experiment. The areas of the skin lesions calculated
for mice infected with the scl1 mutant strains were significantly larger than those of WTinfected mice (Figure 9A; 96 hour time-point is shown); images of lesions of
representative mice demonstrate differences in lesion severity between WT- and scl1GAS infected mice for both the M28- and M41-infected groups (Figure 9B). Thus, the in
vivo data, using GAS strains expressing surface Scl1 proteins and producing rich biofilms,
support our hypothesis that decreased adhesion and biofilm formation, due to the
absence of Scl1.3 on the surface of M3 strains, bears an inverse correlation to the
invasive potential of the infecting GAS strain.
DISCUSSION
Since the resurgence of invasive GAS disease in the 1980’s, and emergence of invasive
M3-type isolates, significant efforts have been made to determine the molecular basis for
the invasive phenotype of M3-type strains. Numerous whole-genome sequencing
projects have identified specific genomic features of M3 strains that were correlated with
their potential to cause invasive infections. In this study, we show that Scl1-negative M3type GAS have reduced adhesion and biofilm formation within host tissue, and therefore
are predisposed to invasive spread over superficial infection (Figure 10).
Unique topography and expression patterns of scl loci – First, the insertion of IS1548
element in the promoter region of scl1 exclusively found in the M3-type strains is an
intriguing observation, given the abundance of IS1548 insertions across GAS genomes
representing a variety of M-types. IS elements are known to cause genomic
rearrangements and affect the expression of important genes that contribute to bacterial
virulence (58). For example, the insertion of IS1548 element (59) into the scpB-lmb
intergenic region in group B Streptococcus has been shown to upregulate lmb-gene
transcription and Lmb-adhesin surface expression, resulting in enhanced laminin binding
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(60). The IS1548 insertion in the scl1.3 promoter was conserved in the genomes of
sequenced M3 strains MGAS315, SSI-1, and M3-b, as well as in 40 additional M3 strains
tested by PCR. However, the recently sequenced STAB902 M3 strain (55), which
represents a non-invasive isolate, contained a 34-bp IS1548 remnant, suggesting that M3
circulating strains exist with this polymorphism. We hypothesize that the proximity of the
IS1548 insertion to the Mga I binding site in M3 strains affects scl1.3 transcription.
Comparative qRT-PCR analysis showed significantly higher levels of scl1 transcription,
particularly in M1, as well as in M28 and M41 strains, relative to M3-type strains analyzed.
Variation in the Mga coding sequence and autoregulated mga promoter has been
reported to significantly affect Mga-dependent gene expression and virulence properties
in GAS (26,27,61). For example, a 12-bp deletion of a single repeat in the VNTR region
of the mga promoter is present in M3 carrier strains and absent in the invasive M3 strains,
causing a downregulation of Mga expression and Mga-regulated genes in the carrier
strains (27). We identified an analogous 12-bp deletion in the VNTR of the mga promoter
of the M1-type MGAS5005 and in M3 strains, MGAS335 and MGAS1313, but not in
MGAS315, MGAS158 and MGAS10870. It is likely that the variation observed in the
VNTR region impacts Mga expression but could not, alone, explain differences in scl1
transcription patterns observed in this work. Consequently, qRT-PCR analyses showed
mga and emm transcripts (emm is second downstream target of Mga within the Mga
regulon) were expressed at similar levels in MGAS5005 and M3 strains, except for the
MGAS335, indicating a mechanism of scl1 downregulation in M3 strains, which is
independent from the level of Mga transcription. The presence of emm transcripts and
M3-protein products indicate that Mga is present and functional in the majority of M3
strains tested, and therefore the polymorphism we observed in the mga promoter did not
affect Mga expression or activity of Mga-controlled scl1.3 promoter. Altogether, our data
hint at the insertion of the IS1548 in the downregulation of scl1.3 expression, specifically
in M3-type GAS, although additional studies are required to firmly establish whether the
IS element insertion is responsible.
It is intriguing that scl1 and scl2 expression patterns were drastically different
between M1 and M3-type GAS, both associated with invasive infections. The scl1.3
transcript was decreased by 21-fold in MGAS315, and even further in the remaining M3
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strains studied (additional 20-45 fold), as compared to the M1-type strain MGAS5005.
The upregulation of scl1 in M1-type GAS has previously been shown in invasive M1
isolates, including MGAS5005, as compared to pharyngeal M1 isolates (62). Studies
comparing wild-type and isogenic scl1.1 mutants in M1-type GAS reported that Scl1.1
contributed to immune evasion by inhibiting neutrophil extracellular trap production and
by protecting bacteria from the cathelicidin LL-37 (63). We conclude the differences we
observed in scl1 expression are related to different pathogenicity requirements for Scl1
protein in M1- versus M3-type strains. In contrast, Scl2 expression is highly upregulated
in M3-type strains, as compared to invasive M1-type GAS. While the majority of M3-type
strains contain in-frame scl2.3 alleles, all 21 M1 strains we analyzed contained out-offrame scl2.1 alleles (unpublished data). Although the Scl2.3 human ligands are not
known, it may have an unidentified biological function, which is important for pathogenesis
of M3, but not M1, strains. Hence, we are reporting striking differences in the expression
and features of the Scl1 and Scl2 proteins that evolved in the invasive M1 and M3 strains.
Scl1-mediated adhesion and biofilm formation in vitro – Scl1 mediates binding to
human extracellular matrix components, cellular fibronectin and laminin, as well as biofilm
formation (35-37). Previous work identified that Scl1 binds specifically to the C-C’ loop of
the type III-repeat EDA domain of cellular fibronectin (37). This represents a novel
mechanism of fibronectin binding, which is distinct from the mechanism employed by
other GAS fibronectin-binding proteins that bind to the N-terminal type I repeats of
fibronectin (64). Here, we determined that rScl1.3FL binds to cellular fibronectin via the
same C-C’ loop-dependent mechanism. It is important for our overall model to
acknowledge that the EDA-cFn isoform is specifically produced during embryogenesis
and during wound healing in adult tissue (65-67), which indicates Scl1 evolved with a
unique function for targeting wounded tissue, a presumed pathogen portal of entry. We
also demonstrate significant binding of rScl1.3FL to laminin, a major basement membrane
protein at the epidermal-dermal junction; none of those ECM ligands were bound by
rScl2.3, consistent with previous knowledge that Scl1, but not Scl2, variants exhibit
binding to cFn and Lm (35). These studies show that full-length Scl1.3, if expressed on
the M3-GAS cell surface, would bind ECM, contributing to tissue colonization.
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The diminished Scl1.3 expression and poor biofilm formation, led us to hypothesize
that lack of surface-expressed Scl1 in M3-type GAS reduces host ECM binding and stable
microcolony formation in tissue, thus, shifting the balance towards invasive spread,
augmented by other virulence factors expressed by these strains. Recombinant rScl1.3FL
formed aggregates that were mediated by the V-to-V region interactions, which could
represent a mechanism of biofilm and microcolony stabilization by Scl1 molecules on
adjacent GAS cells. Two representative invasive M3 isolates, MGAS315 and
MGAS10870, acquired biofilm formation on cFn and Lm when homologous
complementation was performed with surface-attached Scl1.3FL. MGAS315 has been
shown to contain a missense mutation in the covS gene, causing upregulation of CovRSregulated virulence genes and enhanced virulence during subcutaneous infection of mice,
compared to an isogenic strain containing the WT covS allele (68). Additionally,
MGAS315 contains a mutation in the regulator of protein B allele, ropB, which produces
a nonfunctional RopB variant, while MGAS10870 contains a wild-type covR/S and ropB
alleles (28), allowing us to demonstrate the effect of Scl1.3FL function in the presence of
differing regulatory networks. Similarly, heterologous complementation with surface
Scl1.3FL in a scl1.41-mutant of the non-invasive biofilm-capable strain M41-type
MGAS6183, restored its biofilm capacity to the wild-type level. These results indicate that
M3-derived Scl1.3FL variant has the full capacity to support biofilm formation to a similar
degree as Scl1 from a divergent M-type. The robust biofilm observed in vitro on ECM
coatings validates the concept that biofilm capacity combined with adherence to the
surrounding host ECM would reinforce the formation of stable tissue microcolonies in
vivo.
In vitro skin equivalent model of wound colonization and microcolony formation –
We observed inhibition of wound re-epithelization by GAS infection of wounded skin
equivalents, as well as the thinning of the viable epidermal layer at sites distant from the
infected wound. In addition to our study, others have reported changes in skin
histopathology and wound healing, resulting from bacterial infections. An in vivo study
has reported epidermal defects as a result of GAS infection in a humanized mouse model
with human skin graft (69). Previous study of M3-type GAS infection using a skin
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equivalent model showed that hyaluronic acid capsule interactions with CD44 receptor
on keratinocytes induced intracellular signaling, resulting in cytoskeletal rearrangement
and monolayer disruption (70). Infection of an in vitro skin model containing a burn wound
with Pseudomonas aeruginosa caused a loss of the keratinocyte layer and basement
membrane, while intact epidermis was observed in burned but uninfected tissue (71).
Impairment of wound healing has also been demonstrated by staphylococcal infections.
Infection of dermal wounds in rabbit ears with Staphylococcus aureus showed the
formation of biofilm, production of a persistent, low grade inflammatory response, and
significantly delayed wound healing (72). Similarly, delayed wound healing by both S.
aureus and S. epidermidis biofilms was observed in a mouse model of cutaneous wounds
(73). The inhibition of wound healing we describe here is by and large consistent with
reports by other laboratories generated using in vivo animal and in vitro human skin
infection models.
Microcolonies have been identified within human streptococcal impetigo lesions
(39) and in tonsils from patients with recurrent GAS pharyngeal tonsillitis (74), and likely
represent a superficial or persistent state of GAS colonization. However, streptococcal
infections can result in invasive disease due to biofilm disruption and bacterial
dissemination (75,76). We observed large rounded microcolonies formed in tissue during
infection with M41 strain, while M3 GAS remained scattered throughout the tissue as
single cells and chains. Microcolony formation has been previously observed with S.
aureus infection in organotypic skin model (77). Moreover, wound infection in rabbit ears
with S. aureus produced mature biofilms encased in exopolysaccharide, as revealed by
concanavalin A staining (72). Similarly, we also demonstrated that microcolonies in M41infected tissue were encapsulated in bacterial-associated glycocalyx. However, a lack of
glycocalyx-encapsulated microcolonies was associated with infection by M3-type GAS.
These results support our hypothesis that biofilm-poor M3 strains are abolished in
stable microcolony formation in vivo, in part due to a lack of the ECM-binding Scl1 protein
and an overall lack of surface adhesins, although they likely express the FbaB protein,
identified in M3 GAS to be involved in the adherence and invasion into epithelial and
endothelial cells (78-80).
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In vivo mouse model of skin infection – Recent study reported that a small proportion
of non-invasive M3-type strains (~1.3%) were found to harbor the scl1.3 “carrier allele”,
which resulted from an in-frame deletion in the collagenous region, encompassing the
null mutation, producing a shorter cell-attached Scl1.3 variant. This MGAS10870 strain
containing the scl1.3 carrier allele was attenuated following intramuscular infection (40).
In this study, we utilized the M28- and M41-type strains, representing biofilm-rich
producers, for subcutaneous inoculation. We observed that scl1.28- and scl1.41inactivated isogenic mutants produced significantly larger skin lesions as compared to the
wild-type parent strains. These results, again, support the hypothesis that lack of Scl1
surface adhesin destabilizes focused nidus of infection, resulting in a shift towards
increased tissue spread. However, previous studies performed in a M1 GAS background,
utilizing scl1.1-mutants for subcutaneous infection, reported smaller skin lesions in the
mutant groups, which likely reflects a differing predominant function of Scl1.1 in M1-type
GAS (29,63). Investigations using intranasal and intraperitoneal mouse infection models
of Streptococcus pneumoniae have shown that culture-grown bacteria disseminated to
the ear and lungs, while biofilm-grown bacteria stably colonized the nasopharynx (81,82).
A similar study on Streptococcus pyogenes showed that bacteria grown in biofilms have
downregulated virulence genes and tend to colonize the nasal associated lymphoid tissue
of mice, while culture-grown bacteria had significantly increased dissemination and were
more virulent in a septicemia model (83). Previous studies reported that inactivation of
some GAS genes resulted in increased skin pathology produced by the mutants
compared to their wild-type organisms, and these genes often encoded surface proteins,
including SpyCEP (84), Mrp (85), protein F1 (86), and Spy0128, encoding a major pilus
subunit (87). Similarly, the covS mutant of group A streptococcal M1T1 strain with
upregulated SpeB-protease activity was hypervirulent and had reduced capacity to bind
human epithelial cells and fibronectin, and also to form biofilm due to increased cleavage
of surface proteins (88). Altogether, the concept that expression of a surface adhesin,
such as Scl1, involved in biofilm formation and host tissue attachment, is inversely related
to strain invasiveness has gained support from several studies, including this study.
We show the invasive M1- and M3-type GAS evolved scl1 and scl2 alleles with
opposite expression patterns, with scl1 downregulated and scl2 upregulated in M3
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compared to M1 GAS. We show M3-type GAS, devoid of surface-expressed Scl1.3,
lacked biofilm formation on ECM coatings and microcolony formation during infection of
in vitro wounded skin equivalent. Complementation with surface Scl1.3FL restored biofilm
capacity of M3-type GAS on ECM coatings. Mouse infection with the isogenic scl1
mutants of biofilm-rich M28- and M41-type GAS produced larger lesions, supporting the
role of Scl1 in a localized tissue infection. Lastly we developed a model for Scl1-mediated
microcolony formation (Figure 10), whereby Scl1 expressed on the GAS surface
strengthens host colonization by attachment to cFn and Lm expressed within wounded
tissue, as well as biofilm formation via Scl1-Scl1 interactions, resulting in a local,
stabilized microcolony. Conversely, when Scl1 is absent on the GAS cell surface, as is
the case for M3-type GAS, bacteria lack stable anchoring in the surrounding host ECM,
as well as structural strength within microcolony, promoting cells to disperse more freely.
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FIGURES

Figure 1

Figure 1: M3-type GAS strains harbor unique polymorphisms in the scl1.3 locus. (A) Schematic
representation and nucleotide sequence are based on the scl1.3 locus in the M3-type strain MGAS315
genome. The scl1.3 promoter region contains two putative Mga binding sites, Pscl1-I with Mga I and Pscl1II with Mga II. IS1548 is inserted 38 bp upstream of the preferred *Pscl1-I/Mga I promoter, which was shown
to be necessary for scl1 transcription. Transcriptional start site (solid dot), -10 and -35 boxes are shown
upstream of scl1.3 coding sequence. Scl1 regions are designated as follows: SS, signal sequence; V,
variable region; CL, collagen-like region; L, linker region; WM, wall-membrane region; LPATG, cell-wall
anchor. The null mutation in the 11th Gly-X-Y repeat of the CL region is depicted by the red box, presumably
resulting in a truncated secreted Scl1.3 protein. Relative location of primers, IS1548F and Scl1R, used to
generate amplicons in (C) are shown. (B) IS1548 insertion upstream of scl1.3 is unique to M3 genomes.
BLAST search in the NCBI nucleotide (nr/nt) database using IS1548 (1,317 bp) sequence as query
identified insertions in 45 GAS genomes representing 21 different M-types. Only genomes of M3-type
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strains harbored IS1548 element upstream of the scl1 allele (bold text). (C) IS1548 insertion upstream of
scl1.3 is conserved among M3 strains. Genomic DNA was isolated from a collection of 40 M3-type strains
and analyzed by PCR for the presence of IS1548 upstream of scl1 using primers IS1548F and Scl1R
(located in conserved scl1 signal sequence). Additional M1-, M41-, and M28-type control strains, and a no
template control (NTC) are included. Expected amplicon size, 963 bp; M, 1 kb Plus DNA Ladder. MGAS
designation applies to all strain numbers shown above gel wells, with the exception of strain AM3.
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Figure 2

Figure 2: Assessment of Scl1.3 expression. (A) Assessment of Scl1.3 production by M3-type GAS. Cell
wall (CW) and culture supernatant (Sup) protein fractions prepared from exponential phase cultures of
several M3-type strains were analyzed by western immunoblotting, using anti-Scl1 rabbit polyclonal
antibody. Recombinant protein rScl1.3V, corresponding to the variable region of Scl1.3, was used as a
positive control. Expected molecular masses: Scl1.3, 11.4 kDa; rScl1.3V, 8.3 kDa. M, PageRuler TM Plus
Prestained Protein Ladder. (B) Detection of Scl1.3 on the surface of M3-type GAS. Flow cytometry analysis
of several M3-type strains is shown using anti-Scl1 antibody described in part (A) (color-shaded histograms)
or a secondary only control (2o sample, black outlined histogram). Median fluorescence intensities (MFI)
are shown in parentheses for each strain. (C) Assessment of scl1 transcription. Fold-change of scl1
transcript levels are shown compared to scl1.3 transcription in M3-type strain MGAS315. qRT-PCR was
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performed on RNA obtained from exponential phase cultures. Results are shown from three independent
experiments, each performed in triplicate wells. Standard errors and statistical analysis were computed
from averaged ΔCt values for each biological replicate prior to normalization against the endogenous
reference gene tufA; *P≤0.05, **P≤0.01, ***P≤0.001 (student’s t-test). (D) Assessment of mga and emm
transcription. Relative expression levels of mga and emm genes were compared between MGAS315 and
four additional M3 strains or the M1 strain MGAS5005. Results are shown from three independent
experiments, each performed in triplicate wells. Standard errors and statistical analysis were computed
from averaged ΔCt values for each biological replicate prior to normalization against the endogenous
reference gene tufA; **P≤0.01. (E) Assessment of M3-protein production by M3-type GAS. The same cell
wall (CW) and culture supernatant (Sup) protein samples prepared from exponential phase cultures of M3type strains (used in panel A) were analyzed by western immunoblotting, using anti-M3 protein rabbit
polyclonal antibody. Expected molecular mass: 65 kDa. M, PageRuler TM Plus Prestained Protein Ladder.
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Figure 3:

Figure 3: Characterization of the scl2.3 locus in M3-type GAS. (A) Assessment of Scl2.3 production by
M3-type GAS. The same cell wall (CW) and culture supernatant (Sup) protein samples prepared from
exponential phase cultures of several M3-type strains (used in Fig. 2A, E) were analyzed by western
immunoblotting, using anti-rScl2.3V rabbit polyclonal antibody. Recombinant protein rScl2.3V,
corresponding to the variable region of Scl2.3 protein, was used as a positive control. Expected molecular
masses based on MGAS315: Scl2.3, 52.5 kDa; rScl2.3V, 10.1 kDa. Aberrant migration of detected Scl2.3
variants is characteristic of Scl proteins. M, PageRuler TM Plus Prestained Protein Ladder. (B) Detection of
Scl2.3 on the surface of M3-type GAS. Flow cytometry analysis of several M3-type strains is shown using
anti-rScl2.3V rabbit polyclonal antibody (color-shaded histograms) or a secondary-only control (2o sample,
black outlined histogram). Median fluorescence intensities (MFI) are shown in parentheses for each strain.
(C) Assessment of scl2 transcription. Fold-change of scl2 transcription levels are shown compared to scl2.3
transcription in M3-type MGAS315. qRT-PCR was performed on reverse-transcribed RNA obtained from
exponential phase cultures. Results are shown from three independent experiments, each performed in
triplicate wells. Standard errors and statistical analysis were computed from averaged ΔCt values for each
biological replicate prior to normalization against the endogenous reference gene tufA; *P≤0.05, **P≤0.01
(student’s t-test).
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Figure 4

Figure 4: In vitro skin equivalent model of GAS infection. (A-I) H&E stained sections of uninfected (AC) or infected (D-I) wounded skin equivalents at 40x magnification; scale bar: 1000 µm. Uninfected wound
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at day 0 (A) shows a lack of the epidermal layer where biopsy punch was performed, which healed by day
5 (B). At day 1, infection of wounded skin equivalents with M3 and M41 GAS revealed superficial
colonization of the wound bed, as well as invasion into the defects formed at the wound edge (D, G, arrows).
By day 5, bacteria had disseminated throughout tissue laterally and vertically (arrows), reaching the bottom
of the dermis layer (E, H). (C, F, I) H&E stained sections of the keratinocyte layer of intact skin surrounding
the biopsy punch; scale bar: 100 µm. The thickness of the viable keratinocyte layer outside the wound (C,
double arrow) was significantly reduced in tissues infected with M3 (F) and M41 (I) by day 5. (J, L) Gram
stained sections of wounded tissue, corresponding to boxed areas in panels D and H, show tissue
microcolonies (arrows) and superficial bacterial colonization (arrowheads). (J, scale bar: 400 µm; L, scale
bar: 200 µm). (K, M) 1000x magnification micrographs of surface biofilms shown in J and L (scale bar: 10
µm). (N-Q) Two-photon fluorescence microscopy analysis of infected skin equivalents. Vertical
dissemination through the wound bed and glycocalyx formation by the GFP-expressing M41- (N-O) and
M3-type (P-Q) GAS at day 5. 3D projections of z-stacks are shown from the top view of the z-stack (top
panels) or the side view (bottom panels). Multi-channel images show GFP fluorescence of GAS cells (N,
P) and TRITC-conA stain of glycocalyx (O, Q). All images were acquired at 600x magnification.
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Figure 5
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Figure 5: In vitro biofilm formation and hypothetical model of microcolony formation by invasive
M3-type GAS. (A) Limited in vitro biofilm formation by invasive M3 strains on coatings with cellular
fibronectin and laminin. A panel of invasive M3-type strains was compared to a non-invasive biofilm-capable
M41-type strain MGAS 6183. Crystal violet staining was used to assess biomass formed after 24 hours of
growth in wells coated with cellular fibronectin (cFn) and laminin (Lm); results represent averaged values
from at least 3 independent experiments performed in triplicate wells. **P≤0.01 (student’s t-test). (B)
Hypothesis model. Top: Infection of wounded skin with wild-type M3-type GAS. Inherent lack of surfaceexpressed Scl1.3 causes decreased binding to cFn and Lm expressed in wounded tissue, and reduces
biofilm and tissue microcolony formation by M3-type bacteria (red circles). Bottom: In-trans
complementation of M3-type GAS with full-length cell-associated Scl1.3, Scl1.3FL, restores binding to cFn
and Lm in tissue, which confers biofilm and tissue microcolony formation during infection.
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Figure 6

Figure 6: Construction and binding characterization of recombinant full-length Scl1.3FL and Scl2.3
proteins. (A) Affinity purified rScl1.3FL and rScl2.3 proteins were analyzed by 4-20% gradient SDS-PAGE;
expected molecular masses: rScl1.3FL, 20.6 kDa and rScl2.3, 16.2 kDa. (B-D-) Binding of rScl1.3FL to
extra domain A (EDA) of cellular fibronectin. (B) IST-9 antibody inhibition identifies rScl1.3FL binding to the
C-C’ loop of EDA-cFN. Inhibition of rScl1.3FL binding to EDA-cFn was tested by ELISA following preincubation of cFn with blocking IST-9 mAb specific to the C-C’ loop. Significance of inhibition by 0.1 and
1.0 µg of IST-9 mAb was determined by student’s t-test as compared to the untreated cFn. A lack of
significant cFn binding by rScl2.3 was evident, as compared to rScl1.3FL-cFn binding; student’s t-test. (C)
rScl1.3FL binding to a cyclic peptide mimicking the C-C’ loop of EDA using surface plasmon resonance.
Overlay of sensorgrams for the interaction between immobilized rScl1.3FL and EDA-derived C-C’ cyclic
peptide is shown. The experimental curves corresponding to different concentrations of peptide (10-500
μM) were fitted according to a single binding model with 1:1 stoichiometry. (D) rScl1.3FL binding to a C-C’
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cyclic peptide using tryptophan fluorescence assay. Tryptophan fluorescence quenching analysis shows
the dose-response curve of the fluorescence values of rScl1.3FL at 333 nm plotted against the
concentration values of C-C’ cyclic peptide. (E) Laminin binding to rScl1.3FL and rScl2.3 by ELISA.
Recombinant rScl proteins were immobilized onto Strep-Tactin-coated wells and incubated with laminin.
Bound laminin was detected with specific primary pAbs and HRP-conjugated secondary Abs. Laminin
binding was compared between rScl1.3FL and rSc2.3 and evaluated statistically using student’s t-test.
Results for panels C and F represent averaged values from at least 3 independent experiments performed
in triplicate wells. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001.
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Figure 7

Figure 7: Homologous complementation of M3-type GAS with full-length surface-expressed Scl1.3
protein confers biofilm formation. (A) Western blot detection of full-length Scl1.3 in cell wall fractions of
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MGAS315 and MGAS10870∆scl1 complemented in-trans with the scl1.3FL allele. Parent strains were
included as negative controls and rScl1.3FL was used as a positive control for detection. (B) Flow cytometry
detection of Scl1.3FL on the GAS cell surface. Left: Fluorescence intensity of Scl1.3FL-complemented
MGAS315 WT strain was compared to vector-complemented or WT parent strain. Right: Fluorescence
intensity of Scl1.3FL-complemented MGAS10870∆scl1 was compared to WT and ∆scl1 parent strains.
Median fluorescence intensities are shown in parentheses for each strain. (C) Crystal violet assessment of
bacterial biomass after 24 hours of growth in cFn- or Lm-coated wells. MGAS315 WT complemented intrans with pJRS525 (SpcR vector) or pSL502 (Table 1) harboring the scl1.3FL allele was compared to WT
parental strain. Spectinomycin resistant MGAS10870∆scl1 mutant was complemented in-trans with KanR
pSL518 (Table 1), harboring the scl1.3FL allele. Biofilm biomass of the complemented strain was compared
to MGAS10870 WT and scl1-inactivated parental strains. Results represent averaged values from at least
3 independent experiments performed in triplicate wells. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001; students t-test.
(D, E) Confocal laser scanning microscopy analysis of biofilm formation by GFP-expressing MGAS315
vector and scl1.3FL- complemented strains. Biofilms were grown for 24 hours on cFn-coated (D) or Lmcoated (E) coverslips. Maximum intensity projections of GAS biofilms with cross-sectional views (left
panels) are representative of z-stacks from ten fields within a single experiment. Average vertical thickness
is indicated in micrometers. 3D projections of z-stacks (right panels) are shown from the side view.
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Figure 8

Figure 8: Heterologous complementation of scl1-deficient mutant of M41-type GAS with full-length
Scl1.3 restores biofilm formation. (A) Left blot: western blot detection of full-length Scl1.3 protein in cell
wall fraction of M41∆scl1::scl1.3FL using anti-Scl1 polyclonal antibody. The M41∆scl1 and M41 WT strains
were included as negative controls, and rScl1.3FL was included as a positive control. Right blot: western
blot detection of Scl1.41 in M41∆scl1 and M41 WT strains using anti-rScl1.41 antibody and rScl1.41 as a
positive control. (B) Crystal violet assessment of biofilm biomass after 24 hours of growth in cFn- or Lm-
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coated wells. M41 scl1-inactivated (M41∆scl1) mutant was complemented in-trans with either homologous
scl1.41 allele harbored on pSL230 or with heterologous scl1.3FL allele harbored on pSL502 (Table 1). M41
WT, ∆scl1 mutant and two complemented mutant strains were assessed for biofilm formation and statistical
significance was assessed by students t-test as compared to M41∆scl1; *P≤ 0.05, **P≤ 0.01. (C, D)
Confocal laser scanning microscopy analysis of biofilm formation by GFP-expressing M41∆scl1 or
M41∆scl1:: scl1.3FL. Biofilms were grown for 24 hours on cFn-coated (C) or Lm-coated (D) coverslips.
Maximum intensity projections of GAS biofilms with cross-sectional views (top panels) are representative
of z-stacks from ten fields within a single experiment. Average vertical thickness is indicated in micrometers.
3D projections of z-stacks (bottom panels) are shown from the side view.
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Figure 9

Figure 9: Skin pathology of SKH1 hairless mice infected subcutaneously with wild-type and scl1inactivated mutants of M28- and M41-type GAS. (A) Mean area of skin lesions in mice infected with M28or M41-type isogenic GAS strains. The severity of skin lesions was compared following infection with wildtype (WT) or scl1-mutant (scl1) GAS; 96-hour time-point is shown. The mean lesion area and standard
deviation were calculated and compared between experimental groups. Data represents mean lesion size
from at least 10 mice per experimental group. Statistical differences were calculated using the student’s ttest; **P≤ 0.01, ***P≤ 0.001. (B) Gross pathology of the skin lesions. Digital images of the skin lesions of
representative animals infected with either WT or scl1-mutant GAS. The images show skin lesions
developed after 96 hours post-infection, and scale bar represents 10 mm.
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Figure 10

Figure 10: Model of Scl1-mediated GAS adhesion, biofilm formation, and host colonization. M28and M41-type GAS express full-length cell-attached Scl1, which mediates adherence to cFn and Lm. ECM
binding promotes biofilm formation in wounded tissue and allows the formation of superficial tissue
microcolonies resulting in non-invasive colonization. On the contrary, in M3-type GAS, naturally lacking fulllength cell-attached Scl1.3 adhesin, bacterial cells have reduced adherence to cFn and Lm and reduced
capacity for biofilm formation, thereby circumventing the formation of localized tissue microcolonies;
infection balance is shifted towards dissemination through tissue, promoting invasive spread.
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Supplemental Figure 1

Figure S1. Analytical PCR of scl1.3 and scl2.3 in M3-type GAS. (A) PCR of scl1.3 in 42 M3-type strains
was performed with primers 232Up and 232Rev flanking the scl1 locus (Table S1). Expected size based
on MGAS315: 1,010 bp. M, 1 kb Plus DNA Ladder. (B) PCR of scl2.3 in 42 M3-type strains was performed
with primers Scl2.3 F and Scl2.3 R flanking the scl2.3 collagen-like region (Table S1). Expected size based
on MGAS315 genome is 1,125 bp. M, 1 kb Plus DNA Ladder. MGAS designation applies to all strain
numbers shown above gel wells, with the exception of strain AM3.
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Supplemental Figure 2

Figure S2. Domain organization of rScl1.3FL and rScl2.3 proteins. Rotary shadowing of rScl proteins
demonstrates the conserved lollipop-like domain organization. Aggregates mediated by the interactions
between V regions of rScl1.3FL are seen in the top panels (depicted by arrows). No apparent aggregation
was observed in the rScl2.3 preparation (single lollipops are depicted by arrowheads). All scale bars reflect
100 nm.
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Supplementary Figure 3

Figure S3. Colocalization of glycocalyx staining with GFP-expressing M41-type GAS during in vitro
infection of skin equivalent. Representative TPF gallery image of z-stack layers from 3D projection
(Figure 5 of manuscript), showing colocalization of TRITC-concanavalin A staining of glycocalyx (red) with
GFP-expressing GAS microcolonies (green). Z-stack step size: 1 µm; 600x magnification.
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Supplementary Figure 4

Figure S4. Strategy for C-C’ loop peptide design. Cartoon model of the EDA domain of cFn (PDB code
1J8K) used for the C-C' peptide design. The designed peptide includes the C-C' beta-hairpin (orange). The
terminal residues of the beta-hairpin (magenta) were mutated to cysteine to induce a disulfide bond and
mimic the conformation of the peptide in the protein. The key residue for recognition, Asp41, is reported in
ball-and-stick along with the residues Arg33 and Glu45, which form a salt bridge, and the terminal residues
mutated to cysteine.
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TABLES

Table 1. Constructs used in this study
Plasmid

Description

Source

pJRS525

E. coli / S. pyogenes shuttle vector

McIver and Scott. 1997

pSL230

pJRS525 with scl1.41 allele

Caswell et al. 2007

pSL501

pJRS525 with scl1.3WT allele

Flores et al. 2015

pSL502

pSL501 with repaired allele scl1.3FL

Flores et al. 2015

pSL518

pSL502 with KanR in place of SpcR

This study

pASK-IBA2

E. coli expression vector

IBA, Göttingen

pSL154

pASK-IBA2 encoding rScl1.3V

This study

pSL503

pASK-IBA2 encoding rScl1.3FL

Flores et al. 2015

pSL514

pASK-IBA2 with rScl2.3

This study

pSB027

GFP-encoding plasmid

Cramer et al. 2003
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Supplementary Table 1: Primers used in this study
Primer name
Analytical PCR
IS1548F
Scl1 R
232 Up
232 Rev
Scl2.3 F
Scl2.3 R
Scl Up
Scl Rev
Cloning
Scl1.3 M3VF
Scl1.3 M3VR
232 Up
ME7
pJRS525F1
ME6a
Scl1.3 M3VF
Scl1.28WMR
Scl1.3 M3VF ext
Scl1.3 truncR2
Scl2 M3VF
Scl2.28_WMR

qRT-PCR analysis
tufA_F
tufA_R
Scl1_WMR_exp_F
Scl1_WMR_exp_R
Scl2_WMR_exp_F
Scl2_WMR_exp_R2
emm3_exp_F2
emm3_exp_R2
Mga_TMF
Mga_TMR
Mga_F1
Mga_R1

Sequence (5’-3’)

Use

GCCGTCTGCGTGCCCATTGCGTCTA
ACTAGATCTGAGATTATGGTGCTTTGATGTC
CTCCACAAAAGAGTGATCAGTC
TTAGTTGTTTTCTTTGCGTTT
AGGCATACAAGATCATGTCCTTGA
TTTGGTGTATGTGGTGCGGT
CTTTCAATGGATGACGATACC
ACTTTCCATCAGTTAGGTAGC

Detection of
IS1548
Amplification
of scl1.3
Amplification
of scl2.3
Amplification
of scl2.3

GAGATGGCCGAGACTCCTATGACATCAAAGG
CAGCGTCTCAGCGCTCTTTGTTGCACCTTTTTCAA
TCAG
CTCCACAAAAGAGTGATCAGTC
TCAGTGAATTCTCTTTAGAGGATTAG
GGGTTTTCCCAGTCACG
TCCAGCAGGACCTCGAGGTGAACGC
GAGATGGCCGAGACTCCTATGACATCAAAGG
GTCAAGCTTATTATTTTTCGAACTGCGGGTGGCTC
CAAGGTTTTTCTGGAGCTGGAGTTACC
GAGATGGCCGAGACTCCTATGACATCAAAGGAGA
GACAAG
GGTCTCAGCGCTACCTCGAGGTCCTGCTGGACCT
TG
GAGATGGCCGATGGTGAAGATGCCCAAAAAAG
GTCAAGCTTATTATTTTTCGAACTGCGGGTGGCTC
CAT

Cloning of
scl1.3V
region
Cloning of
scl1.3WT
Repair of
scl1.3 null
mutationof
Cloning
scl1.3FL

CAACTCGTCACTATGCGCACAT
GAGCGGCACCAGTGATCAT
TGCTGACAAAGAAGCTAACCAAAC
GTGGTTGTTGGCTACAGGTGTCT
TCCTAAAACACCAGAGGTCC
TGTGTGTGTCGTGAGCTGC
AACAAATCTCAGACGCAAGCCGTC
TTCAAGCTCTTTGTTWAGTTTTTCAAG
CAAGTCAACAGTGGAGAGAACTAAAATT
ATGGAGATGTTGAGAGCTTTGCT
ATCAGACAAAAACATTAAATTGCATG
TTGCATGTTAGTGAGACAAGTTTGC

Cloning of
scl1.3WT

Cloning of
scl2.3

qRT-PCR of
tufA
qRT-PCR of
scl1
qRT-PCR of
scl2
qRT-PCR of
emm
qRT-PCR of
mga
Sequencing
of mga
a Bolded GAA in primer ME6 indicates codon for glutamine in place of the original
promoter
TAA

stop codon.
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Supplementary Table 2: Variation in scl2.3 gene among M3 strains
Strain

No. of GXY
repeats

No. of bp in the
CL region

Amplicon size
(bp)a

MGAS274
~125
~1125
~1206
MGAS315
116
1044
1125
MGAS335
~135
~1215
~1296
MGAS1313
~119
~1071
~1152
AM3
~129
~1161
~1242
MGAS3375
17
153
234
MGAS9517
113
1017
1098
MGAS9622
111
999
1080
MGAS9631
113
1017
1098
MGAS9716
110
990
1071
MGAS9726
111
999
1080
MGAS9739
119
1071
1152
MGAS9760
113
1017
1098
MGAS9780
106
954
1035
MGAS9842
139
1251
1332
MGAS9852
103
927
1008
MGAS10080
117
1053
1134
MGAS10118
119
1071
1152
MGAS10220
110
990
1071
a
Amplicons were generated using primers Scl2.3 F/ R (Table S1)
b

GTG is scl2 start codon
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No. of
CAAAA
repeats
8
5
4
8
10
5
8
11
18
14
11
5
11
14
9
8
5
5
12

GTG in
frameb
yes
yes
no
yes
no
yes
yes
yes
no
yes
yes
yes
yes
yes
no
yes
yes
yes
no

Supplementary Table 3: Mass spectrometry identification of rScl and native Scl
proteinsa
Sample

rScl1.3V

No. of
peptides
>95%
confident
4

rScl2.3

2

MGAS315 WT
Scl2.3 in Sup 12

Scl2.3 in CW

7

Peptide

Confidence

Sequence
coverage

Confident
ID

EENSQEELK
EENSQEELKNFTEER
LKEILDLIEK
WYGTYFKEENSQEELK
GIQDHVLDGQDGDR
EELLSALIDGTSR

99%
99%
99%
99%
99%
98.13%

40%

yes

18%

yes

DVTPAPQNPSN
DVTPAPQNPSNR
EELLSALIDGTSR
GEAGPAGPR
GIQDHVLDGQDGDR
GIQDHVLDGQDGDRGEAGPA
GPR
GLNKPQTQGGNQL
GLNKPQTQGGNQLAK
NKPQTQGGNQLAK
REELLSALIDGTSR
TPEVPQKPDTAPHTPK
TPQIPGQSK
DVTPAPQNPSNR
EELLSALIDGTSR
GIQDHVLDGQDGDR
GIQDHVLDGQDGDRGEAGPA
GPR
GLNKPQTQGGNQLAK
REELLSALIDGTSR
TPEVPQKPDTAPHTPK

99%
99%
99%
99%
99%
99%

17%

yes

15%

yes

17%

yes

11%

yes

13%

yes

Scl1.3FL- complemented GAS
315WT ::
5
EENSQEELKNFTEER
scl1.3FL
EILDLIEK
GDKGETGLAGPVGPAGK
GETGLAGPVGPAGK
LKEILDLIEK
10870∆scl1 :: 4
EILDLIEK
scl1.3FL
GDKGETGLAGPVGPAGK
GETGLAGPVGPAGK
LKEILDLIEK
M41∆scl1 ::
3
EENSQEELKNFTEER
scl1.3FL
GDKGETGLAGPVGPAGK
GETGLAGPVGPAGK
a

99%
99%
99%
99%
99%
99%
99%
99%
99%
99%
99%
99%
99%

99%
99%
99%
99%
99%
99%
99%
99%
99%
99%
99%
99%

Protein identification is confident by the presence of at least two distinct peptides with

>95% confidence each. Sup, supernatant protein fractions; CW, cell-wall association
protein fractions.
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Supplementary Table 4: Summary table of fold-changes in scl1 and scl2
expressiona
Strain
M1

Gene
scl1
scl2
M28
scl1
scl2
M41
scl1
scl2
M3 MGAS:
10870 scl1
scl2
158
scl1
scl2
335
scl1
scl2
1313
scl1
scl2
aFold-changes

Fold change
21.05195084
-23.6920597
6.237987683
-7.25032516
7.787441864
-3.22615419

+SE
-2.33583
-1.97551
-1.1098
0.960352
-0.82018
0.376259

- SE
-2.62734
-1.82347
-1.34997
1.106978
-0.91673
0.425935

P value
0.001184755
0.01549836
0.01395444
0.034822349
0.004897482
0.141911016

Significance
**
*
*
*
**
N.S.

-25.2160816
-1.84753589
-45.8489636
1.077129939
-42.9309881
-2.44408041
-43.929358
-3.89390614

1.366976
-0.01174
-0.86051
0.059307
-4.03211
-1.65928
0.938527
-2.38312

1.445328
-0.01166
-0.84465
0.056212
-3.68593
-0.98832
0.959016
-1.47835

5.48581E-06
0.077646106
0.000121468
0.753558444
5.18378E-05
0.283398851
5.45812E-06
0.117229672

***
N.S.
***
N.S.
***
N.S.
***
N.S.

in scl1 and scl2 expression relative to M3 MGAS315 are shown for each

strain. Data is based on qRT-PCR analysis of RNA isolated during exponential growth
phase and expression is normalized to the expression of tufA gene. +SE, positive
standard error; -SE, negative standard error. Significance is calculated based on three
independent experiments, each performed in triplicate wells. *P<0.05, **P<0.01,
***P<0.001; student’s t-test.
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